Representative Walt Brooks proposes the following substitute bill:

	MEDICAL CANNABIS GOVERNANCE REVISIONS
	2023 GENERAL SESSION
	STATE OF UTAH
	Chief Sponsor: Walt Brooks
	Senate Sponsor: Evan J. Vickers
LONG T	ITLE
General l	Description:
Tł	is bill enacts provisions regarding medical cannabis governance.
Highlight	ed Provisions:
Th	ais bill:
•	defines terms;
►	moves most oversight and regulation of medical cannabis pharmacies and couriers
from the I	Department of Health and Human Services to the Department of
Agricultur	re and Food;
•	creates a transition period where the Department of Agriculture and Food may seek
assistance	from the Department of Health and Human Services;
►	authorizes the Department of Health and Human Services to revoke a pharmacy
medical p	rovider registration;
•	creates a Medical Cannabis Policy Advisory Board (board);
•	outlines the duties of board;
•	modifies the duties and membership of the medical cannabis governance working
group (wo	orking group);
•	extends a sunset date for the working group; and
•	makes technical changes.

	Money Appropriated in this Bill:
27	None
28	Other Special Clauses:
29	This bill provides a special effective date.
30	Utah Code Sections Affected:
31	AMENDS:
32	4-41a-102, as last amended by Laws of Utah 2022, Chapters 290, 452
33	4-41a-105, as enacted by Laws of Utah 2018, Third Special Session, Chapter 1
34	4-41a-201, as last amended by Laws of Utah 2022, Chapter 290
35	4-41a-404, as last amended by Laws of Utah 2020, Chapter 12
36	4-41a-802, as last amended by Laws of Utah 2022, Chapter 97
37	10-9a-528, as last amended by Laws of Utah 2021, Chapter 60
38	17-27a-525, as last amended by Laws of Utah 2021, Chapter 60
39	26-61-202 , as last amended by Laws of Utah 2022, Chapter 415
40	26-61a-102, as last amended by Laws of Utah 2022, Chapters 290, 452
41	26-61a-103, as last amended by Laws of Utah 2022, Chapters 290, 415
42	26-61a-105 , as last amended by Laws of Utah 2022, Chapter 452
43	26-61a-106, as last amended by Laws of Utah 2022, Chapters 415, 452
44	26-61a-109 , as last amended by Laws of Utah 2019, First Special Session, Chapter 5
45	26-61a-201 , as last amended by Laws of Utah 2022, Chapters 198, 290 and 452
46	26-61a-403, as last amended by Laws of Utah 2022, Chapters 415, 452
47	26-61a-601 , as last amended by Laws of Utah 2021, Chapter 337
48	26-61a-701 , as enacted by Laws of Utah 2018, Third Special Session, Chapter 1
49	26-61a-703 , as last amended by Laws of Utah 2022, Chapter 97
50	36-12-8.2, as enacted by Laws of Utah 2022, Chapter 97
51	58-17b-302, as last amended by Laws of Utah 2022, Chapter 353
52	58-17b-502, as last amended by Laws of Utah 2022, Chapter 465
53	58-37-3.8, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
54	631-2-204, as last amended by Laws of Utah 2022, Chapters 67, 68
55	631-2-236 , as last amended by Laws of Utah 2022, Chapters 97, 141, 363, 437, and 458
56	78A-2-231, as last amended by Laws of Utah 2022, Chapter 256

57	80-3-110, as last amended by Laws of Utah 2022, Chapter 256
58	80-4-109, as enacted by Laws of Utah 2021, Chapter 261
59	ENACTS:
60	4-41a-102.1, Utah Code Annotated 1953
61	4-41a-110, Utah Code Annotated 1953
62	4-41a-1201, Utah Code Annotated 1953
63	26-61a-206, Utah Code Annotated 1953
64	26-61a-801, Utah Code Annotated 1953
65	26-61a-802, Utah Code Annotated 1953
66	26-61a-803, Utah Code Annotated 1953
67	RENUMBERS AND AMENDS:
68	4-41a-108, (Renumbered from 26-61a-603, as last amended by Laws of Utah 2020,
69	Chapter 12)
70	4-41a-109, (Renumbered from 26-61a-116, as enacted by Laws of Utah 2022, Chapter
71	452)
72	4-41a-801.1, (Renumbered from 26-61a-702, as last amended by Laws of Utah 2022,
73	Chapter 452)
74	4-41a-1001, (Renumbered from 26-61a-301, as last amended by Laws of Utah 2022,
75	Chapter 290)
76	4-41a-1002, (Renumbered from 26-61a-302, as last amended by Laws of Utah 2019,
77	First Special Session, Chapter 5)
78	4-41a-1003, (Renumbered from 26-61a-303, as last amended by Laws of Utah 2022,
79	Chapters 290, 415)
80	4-41a-1004, (Renumbered from 26-61a-304, as last amended by Laws of Utah 2019,
81	First Special Session, Chapter 5)
82	4-41a-1005, (Renumbered from 26-61a-305, as last amended by Laws of Utah 2022,
83	Chapter 290)
84	4-41a-1101, (Renumbered from 26-61a-501, as last amended by Laws of Utah 2022,
85	Chapters 290, 415)
86	4-41a-1102, (Renumbered from 26-61a-502, as last amended by Laws of Utah 2022,
87	Chapter 290)

_

88	4-41a-1103, (Renumbered from 26-61a-504, as last amended by Laws of Utah 2021,
89	Chapter 350)
90	4-41a-1104, (Renumbered from 26-61a-505, as last amended by Laws of Utah 2022,
91	Chapter 452 and last amended by Coordination Clause, Laws of Utah 2022, Chapter
92	290)
93	4-41a-1105, (Renumbered from 26-61a-507, as last amended by Laws of Utah 2020,
94	Chapter 12)
95	4-41a-1106, (Renumbered from 26-61a-401, as last amended by Laws of Utah 2022,
96	Chapters 290, 415)
97	4-41a-1107, (Renumbered from 26-61a-402, as renumbered and amended by Laws of
98	Utah 2018, Third Special Session, Chapter 1)
99	4-41a-1202, (Renumbered from 26-61a-604, as last amended by Laws of Utah 2022,
100	Chapters 290, 452)
101	4-41a-1203, (Renumbered from 26-61a-605, as last amended by Laws of Utah 2022,
102	Chapter 415)
103	4-41a-1204, (Renumbered from 26-61a-606, as last amended by Laws of Utah 2022,
104	Chapters 290, 415)
105	4-41a-1205, (Renumbered from 26-61a-607, as last amended by Laws of Utah 2022,
106	Chapter 452)
107	26-61a-404 , (Renumbered from 26-61a-503, as last amended by Laws of Utah 2022,
108	Chapter 415)
109	REPEALS:
110	26-61a-108 , as enacted by Laws of Utah 2018, Third Special Session, Chapter 1
111 112	26-61a-506 , as last amended by Laws of Utah 2022, Chapter 415
112	Be it enacted by the Legislature of the state of Utah:
114	Section 1. Section 4-41a-102 is amended to read:
115	CHAPTER 41a. CANNABIS PRODUCTION ESTABLISHMENTS AND
116	PHARMACIES
117	4-41a-102. Definitions.
118	As used in this chapter:

119	(1) "Adulterant" means any poisonous or deleterious substance in a quantity that may
120	be injurious to health, including:
121	(a) pesticides;
122	(b) heavy metals;
123	(c) solvents;
124	(d) microbial life;
125	(e) toxins; or
126	(f) foreign matter.
127	(2) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
128	Section 26-61a-801.
129	[(2)] (3) "Cannabis Research Review Board" means the Cannabis Research Review
130	Board created in Section 26-61-201.
131	[(3)] (4) "Cannabis" means the same as that term is defined in Section 26-61a-102.
132	[(4)] (5) "Cannabis concentrate" means:
133	(a) the product of any chemical or physical process applied to naturally occurring
134	biomass that concentrates or isolates the cannabinoids contained in the biomass; and
135	(b) any amount of a natural, derivative, or synthetic cannabinoid in the synthetic
136	cannabinoid's purified state.
137	[(5)] (6) "Cannabis cultivation byproduct" means any portion of a cannabis plant that is
138	not intended to be sold as a cannabis plant product.
139	[(6)] (7) "Cannabis cultivation facility" means a person that:
140	(a) possesses cannabis;
141	(b) grows or intends to grow cannabis; and
142	(c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis
143	processing facility, or a medical cannabis research licensee.
144	[(7)] (8) "Cannabis cultivation facility agent" means an individual who:
145	(a) is an employee of a cannabis cultivation facility; and
146	(b) holds a valid cannabis production establishment agent registration card.
147	[(8)] (9) "Cannabis derivative product" means a product made using cannabis
148	concentrate.
149	[(9)] (10) "Cannabis plant product" means any portion of a cannabis plant intended to

150	be sold in a form that is recognizable as a portion of a cannabis plant.
151	[(10)] (11) "Cannabis processing facility" means a person that:
152	(a) acquires or intends to acquire cannabis from a cannabis production establishment;
153	(b) possesses cannabis with the intent to manufacture a cannabis product;
154	(c) manufactures or intends to manufacture a cannabis product from unprocessed
155	cannabis or a cannabis extract; and
156	(d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a
157	medical cannabis research licensee.
158	[(11)] (12) "Cannabis processing facility agent" means an individual who:
159	(a) is an employee of a cannabis processing facility; and
160	(b) holds a valid cannabis production establishment agent registration card.
161	[(12)] (13) "Cannabis product" means the same as that term is defined in Section
162	26-61a-102.
163	[(13)] (14) "Cannabis production establishment" means a cannabis cultivation facility,
164	a cannabis processing facility, or an independent cannabis testing laboratory.
165	[(14)] (15) "Cannabis production establishment agent" means a cannabis cultivation
166	facility agent, a cannabis processing facility agent, or an independent cannabis testing
167	laboratory agent.
168	[(15)] (16) "Cannabis production establishment agent registration card" means a
169	registration card that the department issues that:
170	(a) authorizes an individual to act as a cannabis production establishment agent; and
171	(b) designates the type of cannabis production establishment for which an individual is
172	authorized to act as an agent.
173	[(16)] (17) "Community location" means a public or private elementary or secondary
174	school, a church, a public library, a public playground, or a public park.
175	[(17)] (18) "Cultivation space" means, quantified in square feet, the horizontal area in
176	which a cannabis cultivation facility cultivates cannabis, including each level of horizontal area
177	if the cannabis cultivation facility hangs, suspends, stacks, or otherwise positions plants above
178	other plants in multiple levels.
179	(19) "Delivery address" means:
180	(a) for a medical cannabis cardholder who is not a facility, the medical cannabis

181	cardholder's home address; or
182	(b) for a medical cannabis cardholder that is a facility, the facility's address.
183	[(18)] (20) "Department" means the Department of Agriculture and Food.
184	[(19)] (21) "Derivative cannabinoid" means any cannabinoid that has been intentionally
185	created using a process to convert a naturally occurring cannabinoid into another cannabinoid.
186	[(20)] (22) "Family member" means a parent, step-parent, spouse, child, sibling,
187	step-sibling, uncle, aunt, nephew, niece, first cousin, mother-in-law, father-in-law,
188	brother-in-law, sister-in-law, son-in-law, daughter-in-law, grandparent, or grandchild.
189	(23) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy
190	that the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
191	shipments to a delivery address to fulfill electronic orders that the state central patient portal
192	facilitates.
193	[(21)] (24) (a) "Independent cannabis testing laboratory" means a person that:
194	(i) conducts a chemical or other analysis of cannabis or a cannabis product; or
195	(ii) acquires, possesses, and transports cannabis or a cannabis product with the intent to
196	conduct a chemical or other analysis of the cannabis or cannabis product.
197	(b) "Independent cannabis testing laboratory" includes a laboratory that the department
198	or a research university operates in accordance with Subsection 4-41a-201(14).
199	[(22)] (25) "Independent cannabis testing laboratory agent" means an individual who:
200	(a) is an employee of an independent cannabis testing laboratory; and
201	(b) holds a valid cannabis production establishment agent registration card.
202	[(23)] <u>(26)</u> "Industrial hemp waste" means:
203	(a) a cannabinoid concentrate; or
204	(b) industrial hemp biomass.
205	[(24)] (27) "Inventory control system" means a system described in Section 4-41a-103.
206	[(25)] (28) "Licensing board" or "board" means the Cannabis Production Establishment
207	Licensing Advisory Board created in Section 4-41a-201.1.
208	[(26)] (29) "Medical cannabis" means the same as that term is defined in Section
209	26-61a-102.
210	[(27)] (30) "Medical cannabis card" means the same as that term is defined in Section
211	26-61a-102.

211 26-61a-102.

212	(31) "Medical cannabis courier" means a courier that:
213	(a) the department licenses in accordance with Section 4-41a-1201; and
214	(b) contracts with a home delivery medical cannabis pharmacy to deliver medical
215	cannabis shipments to fulfill electronic orders that the state central patient portal facilitates.
216	(32) "Medical cannabis courier agent" means an individual who:
217	(a) is an employee of a medical cannabis courier; and
218	(b) who holds a valid medical cannabis courier agent registration card.
219	[(28)] (33) "Medical cannabis pharmacy" means the same as that term is defined in
220	Section 26-61a-102.
221	[(29)] (34) "Medical cannabis pharmacy agent" means the same as that term is defined
222	in Section 26-61a-102.
223	[(30)] (35) "Medical cannabis research license" means a license that the department
224	issues to a research university for the purpose of obtaining and possessing medical cannabis for
225	academic research.
226	[(31)] (36) "Medical cannabis research licensee" means a research university that the
227	department licenses to obtain and possess medical cannabis for academic research, in
228	accordance with Section 4-41a-901.
229	(37) "Medical cannabis shipment" means a shipment of medical cannabis or a medical
230	cannabis product that a home delivery medical cannabis pharmacy or a medical cannabis
231	courier delivers to a delivery address to fulfill an electronic medical cannabis order that the
232	state central patient portal facilitates.
233	[(32)] (38) "Medical cannabis treatment" means the same as that term is defined in
234	Section 26-61a-102.
235	[(33)] (39) "Medicinal dosage form" means the same as that term is defined in Section
236	26-61a-102.
237	(40) "Pharmacy medical provider" means the same as that term is defined in Section
238	<u>26-61a-102.</u>
239	[(34)] (41) "Qualified medical provider" means the same as that term is defined in
240	Section 26-61a-102.
241	[(35)] (42) "Qualified Production Enterprise Fund" means the fund created in Section
242	4-41a-104.

243	[(36)] (43) "Recommending medical provider" means the same as that term is defined
244	in Section 26-61a-102.
245	[(37)] (44) "Research university" means the same as that term is defined in Section
246	53B-7-702 and a private, nonprofit college or university in the state that:
247	(a) is accredited by the Northwest Commission on Colleges and Universities;
248	(b) grants doctoral degrees; and
249	(c) has a laboratory containing or a program researching a schedule I controlled
250	substance described in Section 58-37-4.
251	[(38)] (45) "State electronic verification system" means the system described in Section
252	26-61a-103.
253	[(39)] (46) "Synthetic cannabinoid" means any cannabinoid that:
254	(a) was chemically synthesized from starting materials other than a naturally occurring
255	cannabinoid; and
256	(b) is not a derivative cannabinoid.
257	[(40)] (47) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in
258	Section 4-41-102.
259	[(41)] (48) "THC analog" means the same as that term is defined in Section 4-41-102.
260	[(42)] (49) "Total composite tetrahydrocannabinol" means all detectable forms of
261	tetrahydrocannabinol.
262	[(43)] (50) "Total tetrahydrocannabinol" or "total THC" means the same as that term is
263	defined in Section 4-41-102.
264	Section 2. Section 4-41a-102.1 is enacted to read:
265	<u>4-41a-102.1.</u> Temporary governance over medical cannabis pharmacies.
266	(1) As used in this section:
267	(a) "Pharmacy provisions" means the provisions contained in the following parts:
268	(i) Part 10, Medical Cannabis Pharmacy License;
269	(ii) Part 11, Medical Cannabis Pharmacy Operation and Agents; and
270	(iii) Part 12, Medical Cannabis Home Delivery and Couriers.
271	(b) "Transition period" means the period of time beginning on July 1, 2023, and ending
272	<u>on January 1, 2024.</u>
272	(2) During the transition paris de

273 (2) During the transition period:

274	(a) the department may request:
275	(i) the Department of Health and Human Services to carry out the duties described in
276	the pharmacy provisions; and
277	(ii) technical assistance from the Department of Health and Human Services related to
278	carrying out the duties described in the pharmacy provisions;
279	(b) the department may terminate or limit the scope of the Department of Health and
280	Human Services' power to carry out duties described in the pharmacy provisions; and
281	(c) if the department requests the Department of Health and Human Services to carry
282	out duties described in the pharmacy provisions, the department may make personnel available
283	to the Department of Health and Human Services for carrying out the duties.
284	(3) Upon the request of the department under this section, the Department of Health
285	and Human Services has the authority to carry out any duties:
286	(a) within the scope of the request; and
287	(b) if related to the pharmacy provisions.
288	(4) Notwithstanding any other provision of law, the Department of Health and Human
289	Services may use funds from the Qualified Patient Enterprise Fund, created in Section
290	26-61a-109, to cover any costs of Department of Health and Human Services personnel related
291	to carrying out duties requested by the department under this section.
292	Section 3. Section 4-41a-105 is amended to read:
293	4-41a-105. Agreement with a tribe.
294	(1) As used in this section, "tribe" means a federally recognized Indian tribe or Indian
295	band.
296	(2) (a) In accordance with this section, the governor may enter into an agreement with a
297	tribe to allow for the operation of a cannabis production establishment or a medical cannabis
298	pharmacy on tribal land located within the state.
299	(b) An agreement described in Subsection (2)(a) may not exempt any person from the
300	requirements of this chapter.
301	(c) The governor shall ensure that an agreement described in Subsection (2)(a):
302	(i) is in writing;
303	(ii) is signed by:
304	(A) the governor; and

305	(B) the governing body of the tribe that the tribe designates and has the authority to
306	bind the tribe to the terms of the agreement;
307	(iii) states the effective date of the agreement;
308	(iv) provides that the governor shall renegotiate the agreement if the agreement is or
309	becomes inconsistent with a state statute; and
310	(v) includes any accommodation that the tribe makes:
311	(A) to which the tribe agrees; and
312	(B) that is reasonably related to the agreement.
313	(d) Before executing an agreement under this Subsection (2), the governor shall consult
314	with the department.
315	(e) At least 30 days before the execution of an agreement described in this Subsection
316	(2), the governor or the governor's designee shall provide a copy of the agreement in the form
317	in which the agreement will be executed to:
318	(i) the chairs of the Native American Legislative Liaison Committee; and
319	(ii) the Office of Legislative Research and General Counsel.
320	Section 4. Section 4-41a-108, which is renumbered from Section 26-61a-603 is
321	renumbered and amended to read:
322	[26-61a-603]. <u>4-41a-108.</u> Payment provider for electronic medical cannabis
323	transactions.
324	(1) A cannabis production establishment, a medical cannabis pharmacy, or a
325	prospective home delivery medical cannabis pharmacy seeking to use a payment provider shall
326	submit to the Division of Finance and the state treasurer information regarding the payment
327	provider the prospective licensee will use to conduct financial transactions related to medical
328	cannabis, including:
329	(a) the name and contact information of the payment provider;
330	(b) the nature of the relationship between the establishment, pharmacy, or prospective
331	pharmacy and the payment provider; and
332	(c) for a prospective home delivery medical cannabis pharmacy, the processes the
333	
333	prospective licensee and the payment provider have in place to safely and reliably conduct
333 334	prospective licensee and the payment provider have in place to safely and reliably conduct financial transactions for medical cannabis shipments.

336	(a) in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
337	make rules to establish standards for identifying payment providers that demonstrate the
338	functional and technical ability to safely conduct financial transactions related to medical
339	cannabis, including medical cannabis shipments;
340	(b) review submissions the Division of Finance and the state treasurer receive under
341	Subsection (1);
342	(c) approve a payment provider that meets the standards described in Subsection (2)(a);
343	and
344	(d) establish a list of approved payment providers.
345	(3) Any licensed cannabis production establishment, licensed medical cannabis
346	pharmacy, or medical cannabis courier may use a payment provider that the Division of
347	Finance approves, in consultation with the state treasurer, to conduct transactions related to the
348	establishment's, pharmacy's, or courier's respective medical cannabis business.
349	(4) If Congress passes legislation that allows a cannabis-related business to facilitate
350	payments through or deposit funds in a financial institution, a cannabis production
351	establishment or a medical cannabis pharmacy may facilitate payments through or deposit
352	funds in a financial institution in addition to or instead of a payment provider that the Division
353	of Finance approves, in consultation with the state treasurer, under this section.
354	Section 5. Section 4-41a-109, which is renumbered from Section 26-61a-116 is
355	renumbered and amended to read:
356	[26-61a-116]. <u>4-41a-109.</u> Advertising.
357	(1) Except as provided in this chapter, a person may not advertise regarding the
358	recommendation, sale, dispensing, or transportation of medical cannabis.
359	(2) Notwithstanding any authorization to advertise regarding medical cannabis under
360	this chapter, the person advertising may not advertise:
361	(a) using promotional discounts or incentives;
362	(b) a particular medical cannabis product, medical cannabis device, or medicinal
363	dosage form; or
364	(c) an assurance regarding an outcome related to medical cannabis treatment.
365	(3) Notwithstanding Subsection (1):
366	(a) a nonprofit organization that offers financial assistance for medical cannabis

02-10-23 4:58 PM

367 treatment to low-income patients may advertise the organization's assistance if the 368 advertisement does not relate to a specific medical cannabis pharmacy or a specific medical 369 cannabis product; and 370 (b) a medical cannabis pharmacy may provide information regarding subsidies for the 371 cost of medical cannabis treatment to patients who affirmatively accept receipt of the subsidy 372 information. 373 (4) To ensure that the name and logo of a licensee under this chapter have a medical 374 rather than a recreational disposition, the name and logo of the licensee: 375 (a) may include terms and images associated with: (i) a medical disposition, including "medical," "medicinal," "medicine," "pharmacy," 376 377 "apothecary," "wellness," "therapeutic," "health," "care," "cannabis," "clinic," "compassionate," 378 "relief," "treatment," and "patient;" or 379 (ii) the plant form of cannabis, including "leaf," "flower," and "bloom;"[;] and 380 (b) may not include: 381 (i) any term, statement, design representation, picture, or illustration that is associated 382 with a recreational disposition or that appeals to children; 383 (ii) an emphasis on a psychoactive ingredient; 384 (iii) a specific cannabis strain: or 385 (iv) terms related to recreational marijuana, including "weed," "pot," "reefer," "grass," "hash," "ganga," "Mary Jane," "high," "buzz," "haze," "stoned," "joint," "bud," "smoke," 386 "euphoria," "dank," "doobie," "kush," "frost," "cookies," "rec," "bake," "blunt," "combust." 387 "bong," "budtender," "dab," "blaze," "toke," or "420." 388 389 (5) The department shall define standards for advertising authorized under this chapter, 390 including names and logos in accordance with Subsection (4), to ensure a medical rather than 391 recreational disposition. 392 Section 6. Section **4-41a-110** is enacted to read: 393 4-41a-110. Department coordination with the advisory board. 394 The department shall: 395 (1) provide draft rules made under this chapter to the advisory board for the advisory 396 board's review; 397 (2) consult with the advisory board before issuing an additional:

398	(a) cultivation facility license under Section <u>4-41a-205; or</u>
399	(b) pharmacy license under Section <u>4-41a-1005;</u>
400	(3) consult with the advisory board regarding fees set by the department that pertain to
401	the medical cannabis program; and
402	(4) when appropriate, consult with the advisory board regarding issues that arise in the
403	medical cannabis program.
404	Section 7. Section 4-41a-201 is amended to read:
405	4-41a-201. Cannabis production establishment License.
406	(1) Except as provided in Subsection (14), a person may not operate a cannabis
407	production establishment without a license that the department issues under this chapter.
408	(2) (a) (i) Subject to Subsections (6), (7), (8), and (13) and to Section 4-41a-205, for a
409	licensing process that the department initiates after March 17, 2021, the department, through
410	the licensing board, shall issue licenses in accordance with Section 4-41a-201.1.
411	(ii) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
412	department shall make rules to specify a transparent and efficient process to:
413	(A) solicit applications for a license under this section;
414	(B) allow for comments and questions in the development of applications;
415	(C) timely and objectively evaluate applications;
416	(D) hold public hearings that the department deems appropriate; and
417	(E) select applicants to receive a license.
418	(iii) The department may not issue a license to operate a cannabis production
419	establishment to an applicant who is not eligible for a license under this section.
420	(b) An applicant is eligible for a license under this section if the applicant submits to
421	the licensing board:
422	(i) subject to Subsection (2)(c), a proposed name and address or, for a cannabis
423	cultivation facility, addresses of no more than two facility locations, located in a zone described
424	in Subsection 4-41a-406(2)(a) or (b), where the applicant will operate the cannabis production
425	establishment;
426	(ii) the name and address of any individual who has:
427	(A) for a publicly traded company, a financial or voting interest of 2% or greater in the
100	a are a second state s

428 proposed cannabis production establishment;

429 (B) for a privately held company, a financial or voting interest in the proposed cannabis 430 production establishment; or 431 (C) the power to direct or cause the management or control of a proposed cannabis 432 production establishment; 433 (iii) an operating plan that: 434 (A) complies with Section 4-41a-204; 435 (B) includes operating procedures that comply with this chapter and any law the 436 municipality or county in which the person is located adopts that is consistent with Section 437 4-41a-406; and 438 (C) the department or licensing board approves; 439 (iv) a statement that the applicant will obtain and maintain a performance bond that a 440 surety authorized to transact surety business in the state issues in an amount of at least: 441 (A) \$100,000 for each cannabis cultivation facility for which the applicant applies; or 442 (B) \$50,000 for each cannabis processing facility or independent cannabis testing 443 laboratory for which the applicant applies: 444 (v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the 445 department sets in accordance with Section 63J-1-504; and 446 (vi) a description of any investigation or adverse action taken by any licensing 447 jurisdiction, government agency, law enforcement agency, or court in any state for any 448 violation or detrimental conduct in relation to any of the applicant's cannabis-related operations 449 or businesses. 450 (c) (i) A person may not locate a cannabis production establishment: 451 (A) within 1,000 feet of a community location; or 452 (B) in or within 600 feet of a district that the relevant municipality or county has zoned 453 as primarily residential. 454 (ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured 455 from the nearest entrance to the cannabis production establishment by following the shortest 456 route of ordinary pedestrian travel to the property boundary of the community location or 457 residential area. 458 (iii) The licensing board may grant a waiver to reduce the proximity requirements in 459 Subsection (2)(c)(i) by up to 20% if the licensing board determines that it is not reasonably

460	feasible for the applicant to site the proposed cannabis production establishment without the
461	waiver.
462	(iv) An applicant for a license under this section shall provide evidence of compliance
463	with the proximity requirements described in Subsection (2)(c)(i).
464	(3) If the licensing board approves an application for a license under this section and
465	Section 4-41a-201.1:
466	(a) the applicant shall pay the department:
467	(i) an initial license fee in an amount that, subject to Subsection 4-41a-104(5), the
468	department sets in accordance with Section 63J-1-504; or
469	(ii) a fee for a 120-day limited license to operate as a cannabis processing facility
470	described in Subsection (3)(b) that is equal to 33% of the initial license fee described in
471	Subsection (3)(a)(i); and
472	(b) the department shall notify the Department of Public Safety of the license approval
473	and the names of each individual described in Subsection (2)(b)(ii).
474	(4) (a) Except as provided in Subsection (4)(b), a cannabis production establishment
475	shall obtain a separate license for each type of cannabis production establishment and each
476	location of a cannabis production establishment.
477	(b) The licensing board may issue a cannabis cultivation facility license and a cannabis
478	processing facility license to a person to operate at the same physical location or at separate
479	physical locations.
480	(5) If the licensing board receives more than one application for a cannabis production
481	establishment within the same city or town, the licensing board shall consult with the local land
482	use authority before approving any of the applications pertaining to that city or town.
483	(6) The licensing board may not issue a license to operate an independent cannabis
484	testing laboratory to a person who:
485	(a) holds a license or has an ownership interest in a medical cannabis pharmacy, a
486	cannabis processing facility, or a cannabis cultivation facility;
487	(b) has an owner, officer, director, or employee whose family member holds a license
488	or has an ownership interest in a medical cannabis pharmacy, a cannabis processing facility, or
489	a cannabis cultivation facility; or
490	(c) proposes to operate the independent cannabis testing laboratory at the same physical

491	location as a medical cannabis pharmacy, a cannabis processing facility, or a cannabis
492	cultivation facility.
493	(7) The licensing board may not issue a license to operate a cannabis production
494	establishment to an applicant if any individual described in Subsection (2)(b)(ii):
495	(a) has been convicted under state or federal law of:
496	(i) a felony; or
497	(ii) after December 3, 2018, a misdemeanor for drug distribution;
498	(b) is younger than 21 years old; or
499	(c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.
500	(8) (a) If an applicant for a cannabis production establishment license under this
501	section holds a license under Title 4, Chapter 41, Hemp and Cannabinoid Act, the licensing
502	board may not give preference to the applicant based on the applicant's status as a holder of the
503	license.
504	(b) If an applicant for a license to operate a cannabis cultivation facility under this
505	section holds a license to operate a medical cannabis pharmacy under [Title 26, Chapter 61a,
506	Utah Medical Cannabis Act] this title, the licensing board[:]
507	[(i) shall consult with the Department of Health regarding the applicant; and]
508	[(ii)] may give consideration to the applicant based on the applicant's status as a holder
509	of a medical cannabis pharmacy license if:
510	[(A)] (i) the applicant demonstrates that a decrease in costs to patients is more likely to
511	result from the applicant's vertical integration than from a more competitive marketplace; and
512	[(B)] (ii) the licensing board finds multiple other factors, in addition to the existing
513	license, that support granting the new license.
514	(9) The licensing board may revoke a license under this part:
515	(a) if the cannabis production establishment does not begin cannabis production
516	operations within one year after the day on which the licensing board issues the initial license;
517	(b) after the third of the same violation of this chapter in any of the licensee's licensed
518	cannabis production establishments or medical cannabis pharmacies;
519	(c) if any individual described in Subsection (2)(b) is convicted, while the license is
520	active, under state or federal law of:
521	(i) a felony; or

522 (ii) after December 3, 2018, a misdemeanor for drug distribution; 523 (d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at 524 the time of application, or fails to supplement the information described in Subsection 525 (2)(b)(vi) with any investigation or adverse action that occurs after the submission of the 526 application within 14 calendar days after the licensee receives notice of the investigation or 527 adverse action; 528 (e) if the cannabis production establishment demonstrates a willful or reckless 529 disregard for the requirements of this chapter or the rules the department makes in accordance 530 with this chapter; 531 (f) if, after a change of ownership described in Subsection (15)(b), the board 532 determines that the cannabis production establishment no longer meets the minimum standards 533 for licensure and operation of the cannabis production establishment described in this chapter; 534 or 535 (g) for an independent cannabis testing laboratory, if the independent cannabis testing 536 laboratory fails to substantially meet the performance standards described in Subsection 537 (14)(b). 538 (10) (a) A person who receives a cannabis production establishment license under this 539 chapter, if the municipality or county where the licensed cannabis production establishment 540 will be located requires a local land use permit, shall submit to the licensing board a copy of 541 the licensee's approved application for the land use permit within 120 days after the day on 542 which the licensing board issues the license. 543 (b) If a licensee fails to submit to the licensing board a copy of the licensee's approved 544 land use permit application in accordance with Subsection (10)(a), the licensing board may 545 revoke the licensee's license. 546 (11) The department shall deposit the proceeds of a fee that the department imposes 547 under this section into the Qualified Production Enterprise Fund. 548 (12) The department shall begin accepting applications under this part on or before 549 January 1, 2020. 550 (13) (a) The department's authority, and consequently the licensing board's authority, to 551 issue a license under this section is plenary and is not subject to review. 552 (b) Notwithstanding Subsection (2)(a)(ii)(A), the decision of the department to award a

553 license to an applicant is not subject to: 554 (i) Title 63G, Chapter 6a, Part 16, Protests; or 555 (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board. 556 (14) (a) Notwithstanding this section, the department: 557 (i) may not issue more than four licenses to operate an independent cannabis testing 558 laboratory; 559 (ii) may operate or partner with a research university to operate an independent cannabis testing laboratory; 560 561 (iii) if the department operates or partners with a research university to operate an 562 independent cannabis testing laboratory, may not cease operating or partnering with a research 563 university to operate the independent cannabis testing laboratory unless: 564 (A) the department issues at least two licenses to independent cannabis testing 565 laboratories: and 566 (B) the department has ensured that the licensed independent cannabis testing 567 laboratories have sufficient capacity to provide the testing necessary to support the state's 568 medical cannabis market; and 569 (iv) after ceasing department or research university operations under Subsection 570 (14)(a)(ii) shall resume independent cannabis testing laboratory operations at any time if: 571 (A) fewer than two licensed independent cannabis testing laboratories are operating; or 572 (B) the licensed independent cannabis testing laboratories become, in the department's 573 determination, unable to fully meet the market demand for testing. 574 (b) (i) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah 575 Administrative Rulemaking Act, to establish performance standards for the operation of an 576 independent cannabis testing laboratory, including deadlines for testing completion. 577 (ii) A license that the department issues to an independent cannabis testing laboratory 578 is contingent upon substantial satisfaction of the performance standards described in 579 Subsection (14)(b)(i), as determined by the board. 580 (15) (a) A cannabis production establishment license is not transferrable or assignable. 581 (b) If the ownership of a cannabis production establishment changes by 50% or more: 582 (i) the cannabis production establishment shall submit a new application described in 583 Subsection (2)(b), subject to Subsection (2)(c);

584	(ii) within 30 days of the submission of the application, the board shall:
585	(A) conduct the application review described in Section 4-41a-201.1; and
586	(B) award a license to the cannabis production establishment for the remainder of the
587	term of the cannabis production establishment's license before the ownership change if the
588	cannabis production establishment meets the minimum standards for licensure and operation of
589	the cannabis production establishment described in this chapter; and
590	(iii) if the board approves the license application, notwithstanding Subsection (3), the
591	cannabis production establishment shall pay a license fee that the department sets in
592	accordance with Section 63J-1-504 in an amount that covers the board's cost of conducting the
593	application review.
594	Section 8. Section 4-41a-404 is amended to read:
595	4-41a-404. Medical cannabis transportation.
596	(1) (a) [Only] Except as provided in Part 12, Medical Cannabis Home Delivery and
597	Couriers, the following individuals may transport cannabis or a cannabis product under this
598	chapter:
599	(i) a registered cannabis production establishment agent; [or]
600	(ii) a medical cannabis cardholder who is transporting a medical cannabis treatment
601	that the cardholder is authorized to possess under this chapter[-];
602	(iii) a registered medical cannabis pharmacy agent;
603	(iv) a registered medical cannabis courier agent; and
604	(v) a registered pharmacy medical provider.
605	(b) Only an agent of a cannabis cultivation facility, when the agent is transporting
606	cannabis plants to a cannabis processing facility or an independent cannabis testing laboratory,
607	may transport unprocessed cannabis outside of a medicinal dosage form.
608	(2) Except for an individual with a valid medical cannabis card under Title 26, Chapter
609	61a, Utah Medical Cannabis Act, who is transporting a medical cannabis treatment, an
610	individual transporting cannabis or a cannabis product shall possess a transportation manifest
611	that:
612	(a) includes a unique identifier that links the cannabis or cannabis product to a relevant
613	inventory control system;
614	(b) includes origin and destination information for any cannabis or cannabis product

615	that the individual is transporting; and
616	(c) identifies the departure and arrival times and locations of the individual
617	transporting the cannabis or cannabis product.
618	(3) (a) In addition to the requirements in Subsections (1) and (2), the department may
619	establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking
620	Act, requirements for transporting cannabis or cannabis product to ensure that the cannabis or
621	cannabis product remains safe for human consumption.
622	(b) The transportation described in Subsection (3)(a) is limited to transportation:
623	(i) between a cannabis production establishment and another cannabis production
624	establishment; [and]
625	(ii) between a cannabis processing facility and a medical cannabis pharmacy[-]; and
626	(iii) a medical cannabis pharmacy and:
627	(A) another medical cannabis pharmacy; or
628	(B) for a medical cannabis shipment, a delivery address.
629	(4) (a) It is unlawful for a registered cannabis production establishment agent to make a
630	transport described in this section with a manifest that does not meet the requirements of this
631	section.
632	(b) Except as provided in Subsection (4)(d), an agent who violates Subsection (4)(a) is:
633	(i) guilty of an infraction; and
634	(ii) subject to a \$100 fine.
635	(c) An individual who is guilty of a violation described in Subsection (4)(b) is not
636	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
637	underlying the violation described in Subsection (4)(b).
638	(d) If the agent described in Subsection (4)(a) is transporting more cannabis or
639	cannabis product than the manifest identifies, except for a de minimis administrative error:
640	(i) the penalty described in Subsection (4)(b) does not apply; and
641	(ii) the agent is subject to penalties under Title 58, Chapter 37, Utah Controlled
642	Substances Act.
643	(5) Nothing in this section prevents the department from taking administrative
644	enforcement action against a cannabis production establishment, medical cannabis pharmacy,
645	medical cannabis courier, or another person for failing to make a transport in compliance with

646	the requirements of this section.
647	(6) An individual other than an individual described in Subsection (1) may transport a
648	medical cannabis device within the state if the transport does not also contain medical
649	cannabis.
650	Section 9. Section 4-41a-801.1, which is renumbered from Section 26-61a-702 is
651	renumbered and amended to read:
652	[26-61a-702]. <u>4-41a-801.1.</u> Enforcement for medical cannabis pharmacies
653	and couriers Fine Citation.
654	(1) (a) The department may, for a medical cannabis pharmacy's or a medical cannabis
655	courier's violation of this chapter or an applicable administrative rule:
656	(i) revoke the medical cannabis pharmacy or medical cannabis courier license;
657	(ii) refuse to renew the medical cannabis pharmacy or medical cannabis courier
658	license; or
659	(iii) assess the medical cannabis pharmacy or medical cannabis courier an
660	administrative penalty.
661	(b) The department may, for a medical cannabis pharmacy agent's or medical cannabis
662	courier agent's violation of this chapter:
663	(i) revoke the medical cannabis pharmacy agent or medical cannabis courier agent
664	registration card;
665	(ii) refuse to renew the medical cannabis pharmacy agent or medical cannabis courier
666	agent registration card; or
667	(iii) assess the medical cannabis pharmacy agent or medical cannabis courier agent an
668	administrative penalty.
669	(2) The department shall deposit an administrative penalty imposed under this section
670	into the General Fund.
671	(3) For a person subject to an uncontested citation, a stipulated settlement, or a finding
672	of a violation in an adjudicative proceeding under this section, the department may:
673	(a) for a fine amount not already specified in law, assess the person a fine of up to
674	\$5,000 per violation, in accordance with a fine schedule that the department establishes by rule
675	in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act; or
676	(b) order the person to cease and desist from the action that creates a violation.

677	(4) The department may not revoke a medical cannabis pharmacy's license or a medical
678	cannabis courier's license without first directing the medical cannabis pharmacy or the medical
679	cannabis courier to appear before an adjudicative proceeding conducted under Title 63G,
680	Chapter 4, Administrative Procedures Act.
681	(5) If, within 20 calendar days after the day on which the department issues a citation
682	for a violation of this chapter, the person that is the subject of the citation fails to request a
683	hearing to contest the citation, the citation becomes the department's final order.
684	(6) The department may, for a person who fails to comply with a citation under this
685	section:
686	(a) refuse to issue or renew the person's license or agent registration card; or
687	(b) suspend, revoke, or place on probation the person's license or agent registration
688	card.
689	(7) (a) Except where a criminal penalty is expressly provided for a specific violation of
690	this chapter, if an individual violates a provision of this chapter, the individual is:
691	(i) guilty of an infraction; and
692	(ii) subject to a \$100 fine.
693	(b) An individual who is guilty of a violation described in Subsection (7)(a) is not
694	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
695	underlying the violation described in Subsection (7)(a).
696	Section 10. Section 4-41a-802 is amended to read:
697	4-41a-802. Report.
698	(1) At or before the November interim meeting each year, the department shall report
699	to the Health and Human Services Interim Committee on:
700	(a) the number of applications and renewal applications that the department receives
701	under this chapter;
702	(b) the number of each type of cannabis production facility that the department licenses
703	in each county;
704	(c) the amount of cannabis that licensees grow;
705	(d) the amount of cannabis that licensees manufacture into cannabis products;
706	(e) the number of licenses the department revokes under this chapter;
707	(f) the department's operation of an independent cannabis testing laboratory under

708	Section 4-41a-201, including:
709	(i) the cannabis and cannabis products the department tested; and
710	(ii) the results of the tests the department performed; and
711	(g) the expenses incurred and revenues generated under this chapter.
712	(2) The department may not include personally identifying information in the report
713	described in this section.
714	(3) [During the 2022 legislative interim, the] The department shall report to the
715	working group described in Section 36-12-8.2 as requested by the working group.
716	Section 11. Section 4-41a-1001, which is renumbered from Section 26-61a-301 is
717	renumbered and amended to read:
718	Part 10. Medical Cannabis Pharmacy License
719	[26-61a-301]. <u>4-41a-1001.</u> Medical cannabis pharmacy License
720	Eligibility.
721	(1) A person may not operate as a medical cannabis pharmacy without a license that
722	the department issues under this part.
723	(2) (a) (i) Subject to Subsections (4) and (5) and to Section $[26-61a-305]$ <u>4-41a-1005</u> ,
724	the department shall issue a license to operate a medical cannabis pharmacy in accordance with
725	Title 63G, Chapter 6a, Utah Procurement Code.
726	(ii) The department may not issue a license to operate a medical cannabis pharmacy to
727	an applicant who is not eligible for a license under this section.
728	(b) An applicant is eligible for a license under this section if the applicant submits to
729	the department:
730	(i) subject to Subsection (2)(c), a proposed name and address where the applicant will
731	operate the medical cannabis pharmacy;
732	(ii) the name and address of an individual who:
733	(A) for a publicly traded company, has a financial or voting interest of 2% or greater in
734	the proposed medical cannabis pharmacy;
735	(B) for a privately held company, a financial or voting interest in the proposed medical
736	cannabis pharmacy; or
737	(C) has the power to direct or cause the management or control of a proposed medical
738	cannabis pharmacy;

739	(iii) a statement that the applicant will obtain and maintain a performance bond that a
740	surety authorized to transact surety business in the state issues in an amount of at least
741	\$100,000 for each application that the applicant submits to the department;
742	(iv) an operating plan that:
743	(A) complies with Section $[\frac{26-61a-304}{4-41a-1004}]$
744	(B) includes operating procedures to comply with the operating requirements for a
745	medical cannabis pharmacy described in this chapter and with a relevant municipal or county
746	law that is consistent with Section $\left[\frac{26-61a-507}{4-41a-1106}\right]$ and
747	(C) the department approves;
748	(v) an application fee in an amount that, subject to Subsection $\left[\frac{26-61a-109(5)}{2}\right]$
749	4-41a-104(5), the department sets in accordance with Section 63J-1-504; and
750	(vi) a description of any investigation or adverse action taken by any licensing
751	jurisdiction, government agency, law enforcement agency, or court in any state for any
752	violation or detrimental conduct in relation to any of the applicant's cannabis-related operations
753	or businesses.
754	(c) (i) A person may not locate a medical cannabis pharmacy:
755	(A) within 200 feet of a community location; or
756	(B) in or within 600 feet of a district that the relevant municipality or county has zoned
757	as primarily residential.
758	(ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured
759	from the nearest entrance to the medical cannabis pharmacy establishment by following the
760	shortest route of ordinary pedestrian travel to the property boundary of the community location
761	or residential area.
762	(iii) The department may grant a waiver to reduce the proximity requirements in
763	Subsection (2)(c)(i) by up to 20% if the department determines that it is not reasonably feasible
764	for the applicant to site the proposed medical cannabis pharmacy without the waiver.
765	(iv) An applicant for a license under this section shall provide evidence of compliance
766	with the proximity requirements described in Subsection (2)(c)(i).
767	(d) The department may not issue a license to an eligible applicant that the department
768	has selected to receive a license until the selected eligible applicant obtains the performance
769	bond described in Subsection (2)(b)(iii).

770	(e) If the department receives more than one application for a medical cannabis
771	pharmacy within the same city or town, the department shall consult with the local land use
772	authority before approving any of the applications pertaining to that city or town.
773	(3) If the department selects an applicant for a medical cannabis pharmacy license
774	under this section, the department shall:
775	(a) charge the applicant an initial license fee in an amount that, subject to Subsection
776	$\left[\frac{26-61a-109(5)}{4-41a-104(5)}\right]$, the department sets in accordance with Section 63J-1-504;
777	(b) notify the Department of Public Safety of the license approval and the names of
778	each individual described in Subsection (2)(b)(ii); and
779	(c) charge the licensee a fee in an amount that, subject to Subsection $\left[\frac{26-61a-109(5)}{5}\right]$
780	<u>4-41a-104(5)</u> , the department sets in accordance with Section 63J-1-504, for any change in
781	location, ownership, or company structure.
782	(4) The department may not issue a license to operate a medical cannabis pharmacy to
783	an applicant if an individual described in Subsection (2)(b)(ii):
784	(a) has been convicted under state or federal law of:
785	(i) a felony; or
786	(ii) after December 3, 2018, a misdemeanor for drug distribution;
787	(b) is younger than 21 years old; or
788	(c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.
789	(5) (a) If an applicant for a medical cannabis pharmacy license under this section holds
790	[a] another license under [Title 4, Chapter 41, Hemp and Cannabinoid Act] this chapter, the
791	department may not give preference to the applicant based on the applicant's status as a holder
792	of the license.
793	(b) If an applicant for a medical cannabis pharmacy license under this section holds a
794	license to operate a cannabis cultivation facility under this section, the department may give
795	consideration to the applicant's status as a holder of the license if:
796	(i) the applicant demonstrates that a decrease in costs to patients is more likely to result
797	from the applicant's vertical integration than from a more competitive marketplace; and
798	(ii) the department finds multiple other factors, in addition to the existing license, that
799	support granting the new license.
800	[(b) If an applicant for a medical cannabis pharmacy license under this section holds a

801	license to operate a cannabis cultivation facility under Title 4, Chapter 41a, Cannabis
802	Production Establishments, the department:]
803	[(i) shall consult with the Department of Agriculture and Food regarding the applicant;
804	and]
805	[(ii) may give consideration to the applicant based on the applicant's status as a holder
806	of a license to operate a cannabis cultivation facility if:]
807	[(A) the applicant demonstrates that a decrease in costs to patients is more likely to
808	result from the applicant's vertical integration than from a more competitive marketplace; and]
809	[(B) the department finds multiple other factors, in addition to the existing license, that
810	support granting the new license.]
811	(6) (a) The department may revoke a license under this part:
812	(i) if the medical cannabis pharmacy does not begin operations within one year after
813	the day on which the department issues an announcement of the department's intent to award a
814	license to the medical cannabis pharmacy;
815	(ii) after the third the same violation of this chapter in any of the licensee's licensed
816	cannabis production establishments or medical cannabis pharmacies;
817	(iii) if an individual described in Subsection (2)(b)(ii) is convicted, while the license is
818	active, under state or federal law of:
819	(A) a felony; or
820	(B) after December 3, 2018, a misdemeanor for drug distribution;
821	(iv) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at
822	the time of application, or fails to supplement the information described in Subsection
823	(2)(b)(vi) with any investigation or adverse action that occurs after the submission of the
824	application within 14 calendar days after the licensee receives notice of the investigation or
825	adverse action;
826	(v) if the medical cannabis pharmacy demonstrates a willful or reckless disregard for
827	the requirements of this chapter or the rules the department makes in accordance with this
828	chapter; or
829	(vi) if, after a change of ownership described in Subsection (11)(c), the department
830	determines that the medical cannabis pharmacy no longer meets the minimum standards for
831	licensure and operation of the medical cannabis pharmacy described in this chapter.

832	(b) The department shall rescind a notice of an intent to issue a license under this part
833	to an applicant or revoke a license issued under this part if the associated medical cannabis
834	pharmacy does not begin operation on or before June 1, 2021.
835	(7) (a) A person who receives a medical cannabis pharmacy license under this chapter,
836	if the municipality or county where the licensed medical cannabis pharmacy will be located
837	requires a local land use permit, shall submit to the department a copy of the licensee's
838	approved application for the land use permit within 120 days after the day on which the
839	department issues the license.
840	(b) If a licensee fails to submit to the department a copy the licensee's approved land
841	use permit application in accordance with Subsection (7)(a), the department may revoke the
842	licensee's license.
843	(8) The department shall deposit the proceeds of a fee imposed by this section into the
844	Qualified [Patient] Production Enterprise Fund.
845	(9) The department shall begin accepting applications under this part on or before
846	March 1, 2020.
847	(10) (a) The department's authority to issue a license under this section is plenary and is
848	not subject to review.
849	(b) Notwithstanding Subsection (2), the decision of the department to award a license
850	to an applicant is not subject to:
851	(i) Title 63G, Chapter 6a, Part 16, Protests; or
852	(ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
853	(11) (a) A medical cannabis pharmacy license is not transferrable or assignable.
854	(b) A medical cannabis pharmacy shall report in writing to the department no later than
855	10 business days before the date of any change of ownership of the medical cannabis
856	pharmacy.
857	(c) If the ownership of a medical cannabis pharmacy changes by 50% or more:
858	(i) concurrent with the report described in Subsection (11)(b), the medical cannabis
859	pharmacy shall submit a new application described in Subsection (2)(b), subject to Subsection
860	(2)(c);
861	(ii) within 30 days of the submission of the application, the department shall:
862	(A) conduct an application review; and

3rd Sub. (Cherry) H.B. 72

863 (B) award a license to the medical cannabis pharmacy for the remainder of the term of 864 the medical cannabis pharmacy's license before the ownership change if the medical cannabis 865 pharmacy meets the minimum standards for licensure and operation of the medical cannabis 866 pharmacy described in this chapter; and 867 (iii) if the department approves the license application, notwithstanding Subsection (3), 868 the medical cannabis pharmacy shall pay a license fee that the department sets in accordance 869 with Section 63J-1-504 in an amount that covers the board's cost of conducting the application 870 review. 871 Section 12. Section 4-41a-1002, which is renumbered from Section 26-61a-302 is 872 renumbered and amended to read: 873 [26-61a-302]. 4-41a-1002. Medical cannabis pharmacy owners and 874 directors -- Criminal background checks. 875 (1) Each applicant to whom the department issues a notice of intent to award a license 876 to operate as a medical cannabis pharmacy shall submit, before the department may award the 877 license, from each individual who has a financial or voting interest of 2% or greater in the 878 applicant or who has the power to direct or cause the management or control of the applicant: 879 (a) a fingerprint card in a form acceptable to the Department of Public Safety; 880 (b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the 881 registration of the individual's fingerprints in the Federal Bureau of Investigation Next Generation Identification System's Rap Back Service; and 882 883 (c) consent to a fingerprint background check by: 884 (i) the Bureau of Criminal Identification; and 885 (ii) the Federal Bureau of Investigation. 886 (2) The Bureau of Criminal Identification shall: 887 (a) check the fingerprints the applicant submits under Subsection (1) against the 888 applicable state, regional, and national criminal records databases, including the Federal 889 Bureau of Investigation Next Generation Identification System; 890 (b) report the results of the background check to the department; 891 (c) maintain a separate file of fingerprints that applicants submit under Subsection (1) 892 for search by future submissions to the local and regional criminal records databases, including 893 latent prints;

894	(d) request that the fingerprints be retained in the Federal Bureau of Investigation Next
895	Generation Identification System's Rap Back Service for search by future submissions to
896	national criminal records databases, including the Next Generation Identification System and
897	latent prints; and
898	(e) establish a privacy risk mitigation strategy to ensure that the department only
899	receives notifications for an individual with whom the department maintains an authorizing
900	relationship.
901	(3) The department shall:
902	(a) assess an individual who submits fingerprints under Subsection (1) a fee in an
903	amount that the department sets in accordance with Section 63J-1-504 for the services that the
904	Bureau of Criminal Identification or another authorized agency provides under this section; and
905	(b) remit the fee described in Subsection (3)(a) to the Bureau of Criminal
906	Identification.
907	Section 13. Section 4-41a-1003, which is renumbered from Section 26-61a-303 is
908	renumbered and amended to read:
909	[26-61a-303]. <u>4-41a-1003.</u> Renewal.
910	(1) The department shall renew a license under this part every year if, at the time of
911	renewal:
912	(a) the licensee meets the requirements of Section [26-61a-301] 4-41a-1001;
913	(b) the licensee pays the department a license renewal fee in an amount that, subject to
914	Subsection $[26-61a-109(5)]$ $4-41a-1004(5)$, the department sets in accordance with Section
915	63J-1-504; and
916	(c) if the medical cannabis pharmacy changes the operating plan described in Section
917	[26-61a-304] <u>4-41a-1004</u> that the department approved under Subsection
918	$\left[\frac{26-61a-301(2)(b)(iv)}{4-41a-1001(2)(b)(iv)}\right]$, the department approves the new operating plan.
919	(2) (a) If a licensed medical cannabis pharmacy abandons the medical cannabis
920	pharmacy's license, the department shall publish notice of an available license:
921	(i) in a newspaper of general circulation for the geographic area in which the medical
922	cannabis pharmacy license is available; or
923	(ii) on the Utah Public Notice Website established in Section 63A-16-601.
924	(b) The department may establish criteria, in collaboration with the Division of

925	Professional Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter
926	3, Utah Administrative Rulemaking Act, to identify the medical cannabis pharmacy actions that
927	constitute abandonment of a medical cannabis pharmacy license.
928	(3) If the department has not completed the necessary processes to make a
929	determination on a license renewal under Subsections (1)(a) and (c) before the expiration of a
930	license, the department may issue a conditional medical cannabis pharmacy license to a
931	licensed medical cannabis pharmacy that has applied for license renewal under this section and
932	paid the fee described in Subsection (1)(b).
933	Section 14. Section 4-41a-1004, which is renumbered from Section 26-61a-304 is
934	renumbered and amended to read:
935	[26-61a-304]. <u>4-41a-1004.</u> Operating plan.
936	A person applying for a medical cannabis pharmacy license shall submit to the
937	department a proposed operation plan for the medical cannabis pharmacy [that complies with
938	this section and] that includes:
939	(1) a description of the physical characteristics of the proposed facility, including a
940	floor plan and an architectural elevation;
941	(2) a description of the credentials and experience of:
942	(a) each officer, director, or owner of the proposed medical cannabis pharmacy, and
943	(b) any highly skilled or experienced prospective employee;
944	(3) the medical cannabis pharmacy's employee training standards;
945	(4) a security plan;
946	(5) a description of the medical cannabis pharmacy's inventory control system,
947	including a plan to make the inventory control system compatible with the state electronic
948	verification system;
949	(6) storage protocols, both short- and long-term, to ensure that cannabis is stored in a
950	manner that is sanitary and preserves the integrity of the cannabis; and
951	(7) a description of the proposed medical cannabis pharmacy's strategic plan for
952	opening the medical cannabis pharmacy, including gauging appropriate timing based on:
953	(a) the supply of medical cannabis and medical cannabis products, in consultation with
954	the [Department of Agriculture and Food] department; and
955	(b) the quantity and condition of the population of medical cannabis cardholders, in

956	consultation with the [department] Department of Health and Human Services.
957	Section 15. Section 4-41a-1005, which is renumbered from Section 26-61a-305 is
958	renumbered and amended to read:
959	[26-61a-305]. <u>4-41a-1005.</u> Maximum number of licenses .
960	(1) (a) Except as provided in Subsections (1)(b) or (d), if a sufficient number of
961	applicants apply, the department shall issue up to 15 medical cannabis pharmacy licenses in
962	accordance with this section.
963	(b) If an insufficient number of qualified applicants apply for the available number of
964	medical cannabis pharmacy licenses, the department shall issue a medical cannabis pharmacy
965	license to each qualified applicant.
966	(c) The department may issue the licenses described in Subsection (1)(a) in accordance
967	with this Subsection (1)(c).
968	(i) Using one procurement process, the department may issue eight licenses to an initial
969	group of medical cannabis pharmacies and six licenses to a second group of medical cannabis
970	pharmacies.
971	(ii) If the department issues licenses in two phases in accordance with Subsection
972	(1)(c)(i), the department shall:
973	(A) divide the state into no less than four geographic regions;
974	(B) issue at least one license in each geographic region during each phase of issuing
975	licenses; and
976	(C) complete the process of issuing medical cannabis pharmacy licenses no later than
977	July 1, 2020.
978	(iii) In issuing a 15th license under Subsection (1), the department shall ensure that the
979	license recipient will locate the medical cannabis pharmacy within Dagget, Duchesne, Uintah,
980	Carbon, Sevier, Emery, Grand, or San Juan County.
981	(d) (i) The department may issue licenses to operate a medical cannabis pharmacy in
982	addition to the licenses described in Subsection (1)(a) if the department determines, in
983	consultation with the Department of [Agriculture and Food] Health and Human Services and
984	after an annual or more frequent analysis of the current and anticipated market for medical
985	cannabis, that each additional license is necessary to provide an adequate supply, quality, or
986	variety of medical cannabis to medical cannabis cardholders.

987 (ii) The department shall: 988 (A) in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, 989 make rules to establish criteria and processes for the consultation, analysis, and application for 990 a license described in Subsection (1)(d)(i); and 991 (B) report to the Executive Appropriations Committee of the Legislature before each 992 time the department issues an additional license under Subsection (1)(d)(i) regarding the results 993 of the consultation and analysis described in Subsection (1)(d)(i) and the application of the 994 criteria described in Subsection (1)(d)(ii)(A). 995 (2) (a) If there are more qualified applicants than there are available licenses for 996 medical cannabis pharmacies, the department shall: 997 (i) evaluate each applicant and award the license to the applicant that best 998 demonstrates: 999 (A) experience with establishing and successfully operating a business that involves 1000 complying with a regulatory environment, tracking inventory, and training, evaluating, and 1001 monitoring employees; 1002 (B) an operating plan that will best ensure the safety and security of patrons and the 1003 community; 1004 (C) positive connections to the local community; 1005 (D) the suitability of the proposed location and the location's accessibility for 1006 qualifying patients; 1007 (E) the extent to which the applicant can increase efficiency and reduce the cost of 1008 medical cannabis for patients; and 1009 (F) a strategic plan described in Subsection $\left[\frac{26-61a-304(7)}{26-61a-304(7)}\right]$ 4-41a-1004(7) that has a 1010 comparatively high likelihood of success; and 1011 (ii) ensure a geographic dispersal among licensees that is sufficient to reasonably 1012 maximize access to the largest number of medical cannabis cardholders. 1013 (b) In making the evaluation described in Subsection (2)(a), the department may give 1014 increased consideration to applicants who indicate a willingness to: 1015 (i) operate as a home delivery medical cannabis pharmacy that accepts electronic 1016 medical cannabis orders that the state central patient portal facilitates; and 1017 (ii) accept payments through:

1018	(A) a payment provider that the Division of Finance approves, in consultation with the
1019	state treasurer, in accordance with Section [26-61a-603] 4-41a-108; or
1020	(B) a financial institution in accordance with Subsection $[26-61a-603(4)]$
1021	<u>4-41a-108(4).</u>
1022	(3) The department may conduct a face-to-face interview with an applicant for a
1023	license that the department evaluates under Subsection (2).
1024	[(4) (a) The department may designate a medical cannabis pharmacy as a home
1025	delivery medical cannabis pharmacy if the department determines that the medical cannabis
1026	pharmacy's operating plan demonstrates the functional and technical ability to:]
1027	[(i) safely conduct transactions for medical cannabis shipments;]
1028	[(ii) accept electronic medical cannabis orders that the state central patient portal
1029	facilitates; and]
1030	[(iii) accept payments through:]
1031	[(A) a payment provider that the Division of Finance approves, in consultation with the
1032	state treasurer, in accordance with Section 26-61a-603; or]
1033	[(B) a financial institution in accordance with Subsection 26-61a-603(4).]
1034	[(b) An applicant seeking a designation as a home delivery medical cannabis pharmacy
1035	shall identify in the applicant's operating plan any information relevant to the department's
1036	evaluation described in Subsection (4)(a), including:]
1037	[(i) the name and contact information of the payment provider;]
1038	[(ii) the nature of the relationship between the prospective licensee and the payment
1039	provider;]
1040	[(iii) the processes of the following to safely and reliably conduct transactions for
1041	medical cannabis shipments:]
1042	[(A) the prospective licensee; and]
1043	[(B) the electronic payment provider or the financial institution described in Subsection
1044	(4)(a)(iii); and]
1045	[(iv) the ability of the licensee to comply with the department's rules regarding the
1046	secure transportation and delivery of medical cannabis or medical cannabis product to a
1047	medical cannabis cardholder.]
1048	[(c) Notwithstanding any county or municipal ordinance, a medical cannabis pharmacy

1049	that the department designates as a home delivery medical cannabis pharmacy may deliver
1050	medical cannabis shipments in accordance with this chapter.]
1051	Section 16. Section 4-41a-1101, which is renumbered from Section 26-61a-501 is
1052	renumbered and amended to read:
1053	Part 11. Medical Cannabis Pharmacy Operation and Agents
1054	[26-61a-501]. <u>4-41a-1101.</u> Operating requirements General.
1055	(1) (a) A medical cannabis pharmacy shall operate:
1056	(i) at the physical address provided to the department under Section $[26-61a-301]$
1057	<u>4-41a-1001;</u> and
1058	(ii) in accordance with the operating plan provided to the department under Section
1059	[26-61a-301] <u>4-41a-1001</u> and, if applicable, Section [26-61a-304] <u>4-41a-1004</u> .
1060	(b) A medical cannabis pharmacy shall notify the department before a change in the
1061	medical cannabis pharmacy's physical address or operating plan.
1062	(2) An individual may not enter a medical cannabis pharmacy unless the individual:
1063	(a) is at least 18 years old or is an emancipated minor under Section 80-7-105; and
1064	(b) except as provided in Subsection (4):
1065	(i) possesses a valid:
1066	(A) medical cannabis pharmacy agent registration card;
1067	(B) pharmacy medical provider registration card; or
1068	(C) medical cannabis card;
1069	(ii) is an employee of the department [or the Department of Agriculture and Food]
1070	performing an inspection under Section [26-61a-504] 4-41a-1103; or
1071	(iii) is another individual as the department provides.
1072	(3) A medical cannabis pharmacy may not employ an individual who is younger than
1073	21 years old.
1074	(4) Notwithstanding Subsection (2)(a), a medical cannabis pharmacy may authorize an
1075	individual who is not a medical cannabis pharmacy agent or pharmacy medical provider to
1076	access the medical cannabis pharmacy if the medical cannabis pharmacy tracks and monitors
1077	the individual at all times while the individual is at the medical cannabis pharmacy and
1078	maintains a record of the individual's access.
1079	(5) A medical cannabis pharmacy shall operate in a facility that has:

1080	(a) a single, secure public entrance;
1081	(b) a security system with a backup power source that:
1082	(i) detects and records entry into the medical cannabis pharmacy; and
1083	(ii) provides notice of an unauthorized entry to law enforcement when the medical
1084	cannabis pharmacy is closed; and
1085	(c) a lock on each area where the medical cannabis pharmacy stores cannabis or a
1086	cannabis product.
1087	(6) A medical cannabis pharmacy shall post, both clearly and conspicuously in the
1088	medical cannabis pharmacy, the limit on the purchase of cannabis described in Subsection
1089	$[\frac{26-61a-502(2)}{4-41a-1102(2)}.$
1090	(7) Except for an emergency situation described in Subsection 26-61a-201(3)(c), a
1091	medical cannabis pharmacy may not allow any individual to consume cannabis on the property
1092	or premises of the medical cannabis pharmacy.
1093	(8) A medical cannabis pharmacy may not sell cannabis or a cannabis product without
1094	first indicating on the cannabis or cannabis product label the name of the medical cannabis
1095	pharmacy.
1096	(9) (a) Each medical cannabis pharmacy shall retain in the pharmacy's records the
1097	following information regarding each recommendation underlying a transaction:
1098	(i) the recommending medical provider's name, address, and telephone number;
1099	(ii) the patient's name and address;
1100	(iii) the date of issuance;
1101	(iv) directions of use and dosing guidelines or an indication that the recommending
1102	medical provider did not recommend specific directions of use or dosing guidelines; and
1103	(v) if the patient did not complete the transaction, the name of the medical cannabis
1104	cardholder who completed the transaction.
1105	(b) (i) Except as provided in Subsection (9)(b)(iii), a medical cannabis pharmacy may
1106	not sell medical cannabis unless the medical cannabis has a label securely affixed to the
1107	container indicating the following minimum information:
1108	(A) the name, address, and telephone number of the medical cannabis pharmacy;
1109	(B) the unique identification number that the medical cannabis pharmacy assigns;
1110	(C) the date of the sale;


1111	(D) the name of the patient;
1112	(E) the name of the recommending medical provider who recommended the medical
1113	cannabis treatment;
1114	(F) directions for use and cautionary statements, if any;
1115	(G) the amount dispensed and the cannabinoid content;
1116	(H) the suggested use date;
1117	(I) for unprocessed cannabis flower, the legal use termination date; and
1118	(J) any other requirements that the department determines, in consultation with the
1119	Division of Professional Licensing and the Board of Pharmacy.
1120	(ii) A medical cannabis pharmacy is exempt from the requirement to provide the
1121	following information under Subsection (9)(b)(i) if the information is already provided on the
1122	product label that a cannabis production establishment affixes:
1123	(A) a unique identification number;
1124	(B) directions for use and cautionary statements;
1125	(C) amount and cannabinoid content; and
1126	(D) a suggested use date.
1127	(iii) If the size of a medical cannabis container does not allow sufficient space to
1128	include the labeling requirements described in Subsection (9)(b)(i), the medical cannabis
1129	pharmacy may provide the following information described in Subsection (9)(b)(i) on a
1130	supplemental label attached to the container or an informational enclosure that accompanies the
1131	container:
1132	(A) the cannabinoid content;
1133	(B) the suggested use date; and
1134	(C) any other requirements that the department determines.
1135	(iv) A medical cannabis pharmacy may sell medical cannabis to another medical
1136	cannabis pharmacy without a label described in Subsection (9)(b)(i).
1137	(10) A pharmacy medical provider or medical cannabis pharmacy agent shall:
1138	(a) upon receipt of an order from a limited medical provider in accordance with
1139	Subsections 26-61a-106(1)(b) through (d):
1140	(i) for a written order or an electronic order under circumstances that the department
1141	determines, contact the limited medical provider or the limited medical provider's office to

02-10-23 4:58 PM

1142	verify the validity of the recommendation; and
1143	(ii) for an order that the pharmacy medical provider or medical cannabis pharmacy
1144	agent verifies under Subsection (10)(a)(i) or an electronic order that is not subject to
1145	verification under Subsection (10)(a)(i), enter the limited medical provider's recommendation
1146	or renewal, including any associated directions of use, dosing guidelines, or caregiver
1147	indication, in the state electronic verification system;
1148	(b) in processing an order for a holder of a conditional medical cannabis card described
1149	in Subsection 26-61a-201(1)(b) that appears irregular or suspicious in the judgment of the
1150	pharmacy medical provider or medical cannabis pharmacy agent, contact the recommending
1151	medical provider or the recommending medical provider's office to verify the validity of the
1152	recommendation before processing the cardholder's order;
1153	(c) unless the medical cannabis cardholder has had a consultation under Subsection
1154	$\left[\frac{26-61a-502(4) \text{ or } (5)}{26-61a-404(5)}\right]$, verbally offer to a medical cannabis cardholder at the
1155	time of a purchase of cannabis, a cannabis product, or a medical cannabis device, personal
1156	counseling with the pharmacy medical provider; and
1157	(d) provide a telephone number or website by which the cardholder may contact a
1158	pharmacy medical provider for counseling.
1159	(11) (a) A medical cannabis pharmacy may create a medical cannabis disposal program
1160	that allows an individual to deposit unused or excess medical cannabis, cannabis residue from a
1161	medical cannabis device, or medical cannabis product in a locked box or other secure
1162	receptacle within the medical cannabis pharmacy.
1163	(b) A medical cannabis pharmacy with a disposal program described in Subsection
1164	(11)(a) shall ensure that only a medical cannabis pharmacy agent or pharmacy medical provider
1165	can access deposited medical cannabis or medical cannabis products.
1166	(c) A medical cannabis pharmacy shall dispose of any deposited medical cannabis or
1167	medical cannabis products by:
1168	(i) rendering the deposited medical cannabis or medical cannabis products unusable
1169	and unrecognizable before transporting deposited medical cannabis or medical cannabis
1170	products from the medical cannabis pharmacy; and
1171	(ii) disposing of the deposited medical cannabis or medical cannabis products in

(ii) disposing of the deposited medical cannabis or medical cannabis products inaccordance with:

- 38 -



1173	(A) federal and state law, rules, and regulations related to hazardous waste;
1174	(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
1175	(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
1176	(D) other regulations that the department makes in accordance with Title 63G, Chapter
1177	3, Utah Administrative Rulemaking Act.
1178	(12) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
1179	Utah Administrative Rulemaking Act, protocols for a recall of cannabis and cannabis products
1180	by a medical cannabis pharmacy.
1181	Section 17. Section 4-41a-1102, which is renumbered from Section 26-61a-502 is
1182	renumbered and amended to read:
1183	[26-61a-502]. <u>4-41a-1102.</u> Dispensing Amount a medical cannabis
1184	pharmacy may dispense Reporting Form of cannabis or cannabis product.
1185	(1) (a) A medical cannabis pharmacy may not sell a product other than[, subject to this
1186	chapter]:
1187	(i) cannabis in a medicinal dosage form that the medical cannabis pharmacy acquired
1188	from another medical cannabis pharmacy or a cannabis processing facility that is licensed
1189	under Section 4-41a-201;
1190	(ii) a cannabis product in a medicinal dosage form that the medical cannabis pharmacy
1191	acquired from another medical cannabis pharmacy or a cannabis processing facility that is
1192	licensed under Section 4-41a-201;
1193	(iii) a medical cannabis device; or
1194	(iv) educational material related to the medical use of cannabis.
1195	(b) A medical cannabis pharmacy may only sell an item listed in Subsection (1)(a) to
1196	an individual with:
1197	(i) (A) a medical cannabis card; <u>or</u>
1198	(B) a department registration described in [Section 26-61a-201(10)] Subsection
1199	<u>26-61a-201(11);</u> and
1200	(ii) a corresponding valid form of photo identification.
1201	(c) Notwithstanding Subsection (1)(a), a medical cannabis pharmacy may not sell a
1202	cannabis-based drug that the United States Food and Drug Administration has approved.
1203	(d) Notwithstanding Subsection (1)(b), a medical cannabis pharmacy may not sell a

1204	medical cannabis device to an individual described in Subsection 26-61a-201(2)(a)(i)(B) or to a
1205	minor described in Subsection 26-61a-201(2)(c) unless the individual or minor has the
1206	approval of the Compassionate Use Board in accordance with Subsection 26-61a-105(5).
1207	(2) A medical cannabis pharmacy:
1208	(a) may dispense to a medical cannabis cardholder, in any one 28-day period, up to the
1209	legal dosage limit of:
1210	(i) unprocessed cannabis that:
1211	(A) is in a medicinal dosage form; and
1212	(B) carries a label clearly displaying the amount of tetrahydrocannabinol and
1213	cannabidiol in the cannabis; and
1214	(ii) a cannabis product that is in a medicinal dosage form; and
1215	(b) may not dispense:
1216	(i) more medical cannabis than described in Subsection (2)(a); or
1217	(ii) to an individual whose recommending medical provider did not recommend
1218	directions of use and dosing guidelines, until the individual consults with the pharmacy
1219	medical provider in accordance with Subsection [(4),] $26-61a-404(5)$ any medical cannabis.
1220	[(3) An individual with a medical cannabis card:]
1221	[(a) may purchase, in any one 28-day period, up to the legal dosage limit of:]
1222	[(i) unprocessed cannabis in a medicinal dosage form; and]
1223	[(ii) a cannabis product in a medicinal dosage form;]
1224	[(b) may not purchase:]
1225	[(i) more medical cannabis than described in Subsection (3)(a); or]
1226	[(ii) if the relevant recommending medical provider did not recommend directions of
1227	use and dosing guidelines, until the individual consults with the pharmacy medical provider in
1228	accordance with Subsection (4), any medical cannabis; and]
1229	[(c) may not use a route of administration that the relevant recommending medical
1230	provider or the pharmacy medical provider, in accordance with Subsection (4) or (5), has not
1231	recommended.]
1232	[(4) If a recommending medical provider recommends treatment with medical cannabis
1233	but wishes for the pharmacy medical provider to determine directions of use and dosing
1234	guidelines:]

1025	[(a) the recommon diag modical analysider shall analy ide to the abarman and issl
1235	[(a) the recommending medical provider shall provide to the pharmacy medical
1236	provider, either through the state electronic verification system or through a medical cannabis
1237	pharmacy's recording of a recommendation under the order of a limited medical provider, any
1238	of the following information that the recommending medical provider feels would be needed to
1239	provide appropriate directions of use and dosing guidelines:]
1240	[(i) information regarding the qualifying condition underlying the recommendation;]
1241	[(ii) information regarding prior treatment attempts with medical cannabis; and]
1242	[(iii) portions of the patient's current medication list; and]
1243	[(b) before the relevant medical cannabis cardholder may obtain medical cannabis, the
1244	pharmacy medical provider shall:]
1245	[(i) review pertinent medical records, including the recommending medical provider
1246	documentation described in Subsection (4)(a); and]
1247	[(ii) unless the pertinent medical records show directions of use and dosing guidelines
1248	from a state central patient portal medical provider in accordance with Subsection (5), after
1249	completing the review described in Subsection (4)(b)(i) and consulting with the recommending
1250	medical provider as needed, determine the best course of treatment through consultation with
1251	the cardholder regarding:]
1252	[(A) the patient's qualifying condition underlying the recommendation from the
1253	recommending medical provider;]
1254	[(B) indications for available treatments;]
1255	[(C) directions of use and dosing guidelines; and]
1256	[(D) potential adverse reactions.]
1257	[(5) (a) A state central patient portal medical provider may provide the consultation
1258	and make the determination described in Subsection (4)(b) for a medical cannabis patient
1259	cardholder regarding an electronic order that the state central patient portal facilitates.]
1260	[(b) The state central patient portal medical provider described in Subsection (5)(a)
1261	shall document the directions of use and dosing guidelines, determined under Subsection (5)(a)
1262	in the pertinent medical records.]
1263	[(6)] (3) (a) A medical cannabis pharmacy shall:
1264	(i) (A) access the state electronic verification system before dispensing cannabis or a
1265	cannabis product to a medical cannabis cardholder in order to determine if the cardholder or,

1266	where applicable, the associated patient has met the maximum amount of medical cannabis
1267	described in Subsection (2); and
1268	(B) if the verification in Subsection $\left[\frac{(6)(a)(i)}{(3)(a)(i)}\right]$ indicates that the individual has
1269	met the maximum amount described in Subsection (2), decline the sale, and notify the
1270	recommending medical provider who made the underlying recommendation;
1271	(ii) submit a record to the state electronic verification system each time the medical
1272	cannabis pharmacy dispenses medical cannabis to a medical cannabis cardholder;
1273	(iii) ensure that the pharmacy medical provider who is a licensed pharmacist reviews
1274	each medical cannabis transaction before dispensing the medical cannabis to the cardholder in
1275	accordance with pharmacy practice standards;
1276	(iv) package any medical cannabis that is in a container that:
1277	(A) complies with Subsection 4-41a-602(1)(b) or, if applicable, provisions related to a
1278	container for unprocessed cannabis flower in the definition of "medicinal dosage form" in
1279	Section 26-61a-102;
1280	(B) is tamper-resistant and tamper-evident; and
1281	(C) provides an opaque bag or box for the medical cannabis cardholder's use in
1282	transporting the container in public; and
1283	(v) for a product that is a cube that is designed for ingestion through chewing or
1284	holding in the mouth for slow dissolution, include a separate, off-label warning about the risks
1285	of over-consumption.
1286	(b) A medical cannabis cardholder transporting or possessing the container described
1287	in Subsection $[(6)(a)(iv)]$ (3)(a)(iv) in public shall keep the container within the opaque bag or
1288	box that the medical cannabis pharmacist provides.
1289	[(7)] (4) (a) Except as provided in Subsection $[(7)(b)]$ (4)(b), a medical cannabis
1290	pharmacy may not sell medical cannabis in the form of a cigarette or a medical cannabis device
1291	that is intentionally designed or constructed to resemble a cigarette.
1292	(b) A medical cannabis pharmacy may sell a medical cannabis device that warms
1293	cannabis material into a vapor without the use of a flame and that delivers cannabis to an
1294	individual's respiratory system.
1295	[(8)] (5) (a) A medical cannabis pharmacy may not give, at no cost, a product that the
1296	medical cannabis pharmacy is allowed to sell under Subsection (1)(a)(i), (ii), or (iii).

1297	(b) A medical cannabis pharmacy may give, at no cost, educational material related to
1298	the medical use of cannabis.
1299	[(9) The department may impose a uniform fee on each medical cannabis transaction in
1300	a medical cannabis pharmacy in an amount that, subject to Subsection 26-61a-109(5), the
1301	department sets in accordance with Section 63J-1-504.]
1302	[(10)] (6) A medical cannabis pharmacy may purchase and store medical cannabis
1303	devices regardless of whether the seller has a cannabis-related license under this [title or Title
1304	4, Chapter 41a, Cannabis Production Establishments] chapter or Title 26B, Utah Health and
1305	Human Services Code.
1306	Section 18. Section 4-41a-1103, which is renumbered from Section 26-61a-504 is
1307	renumbered and amended to read:
1308	[26-61a-504]. <u>4-41a-1103.</u> Inspections.
1309	(1) Each medical cannabis pharmacy shall maintain the pharmacy's medical cannabis
1310	treatment recommendation files and other records in accordance with this chapter, department
1311	rules, and the federal Health Insurance Portability and Accountability Act of 1996, Pub. L. No.
1312	104-191, 110 Stat. 1936, as amended.
1313	(2) (a) The department [or the Department of Agriculture and Food] may inspect the
1314	records, facility, and inventory of a medical cannabis pharmacy at any time during business
1315	hours in order to determine if the medical cannabis pharmacy complies with this chapter [and
1316	Title 4, Chapter 41a, Cannabis Production Establishments].
1317	(b) The Department of Health and Human Services may inspect patient records held by
1318	a medical cannabis pharmacy:
1319	(i) for compliance with the federal Health Insurance Portability and Accountability Act
1320	of 1996, Pub. L. No. 104-191, 110 Stat. 1936, as amended; or
1321	(ii) to ensure that a medical cannabis pharmacy is providing a cannabis product to a
1322	patient in accordance with the recommendations of the patient's recommending medical
1323	provider.
1324	(3) (a) An inspection conducted by the department under this section may include:
1325	[(a)] (i) [inspection of] inspecting a site, facility, vehicle, book, record, paper,
1326	document, data, or other physical or electronic information, or any combination of the above;
1327	[(b)] (ii) questioning of any relevant individual;

1328	[(c)] (iii) [inspection of] inspecting equipment, an instrument, a tool, or machinery,
1329	including a container or label;
1330	[(d)] (iv) random sampling of medical cannabis [by the Department of Agriculture and
1331	Food] in accordance with rules described in Section 4-41a-701; or
1332	$\left[\frac{(\mathbf{c})}{(\mathbf{v})}\right]$ seizure of medical cannabis, medical cannabis devices, or educational material
1333	as evidence in a department investigation or inspection or in instances of compliance failure.
1334	(b) An inspection conducted by the Department of Health and Human Services under
1335	Subsection (2)(b) may include:
1336	(i) inspecting a site, facility, vehicle, book, record, paper, document, data, or other
1337	physical or electronic information, or any combination of the above; or
1338	(ii) questioning of any relevant individual.
1339	(4) In making an inspection under this section[,]:
1340	(a) the department [or the Department of Agriculture and Food] may freely access any
1341	area and review and make copies of a book, record, paper, document, data, or other physical or
1342	electronic information, including financial data, sales data, shipping data, pricing data, and
1343	employee data[-]; and
1344	(b) the Department of Health and Human Services may freely access any area and
1345	review and make copies of a book, record, paper, document, data, or other physical or
1346	electronic information related to patient records.
1347	(5) Failure to provide the department, the [Department of Agriculture and Food]
1348	Department of Health and Human Services, or the authorized agents of the department or the
1349	[Department of Agriculture and Food] Department of Health and Human Services immediate
1350	access to records and facilities during business hours in accordance with this section may result
1351	in:
1352	(a) the imposition of a civil monetary penalty that the department sets in accordance
1353	with Title 63G, Chapter 3, Utah Administrative Rulemaking Act;
1354	(b) license or registration suspension or revocation; or
1355	(c) an immediate cessation of operations under a cease and desist order that the
1356	department issues.
1357	(6) Notwithstanding any other provision of law, the department may temporarily store
1358	in any department facility the items the department seizes under Subsection $\left[\frac{(3)(e)}{(3)(a)(v)}\right]$

1359	until the department:
1360	(a) determines that sufficient compliance justifies the return of the seized items; or
1361	(b) disposes of the items in the same manner as a cannabis production establishment in
1362	accordance with Section 4-41a-405.
1363	Section 19. Section 4-41a-1104, which is renumbered from Section 26-61a-505 is
1364	renumbered and amended to read:
1365	[26-61a-505]. <u>4-41a-1104.</u> Advertising.
1366	(1) Except as provided in this section, a person may not advertise in any medium
1367	regarding a medical cannabis pharmacy or the dispensing of medical cannabis within the state.
1368	(2) Subject to Section $[\frac{26-61a-116}{4-41a-109}]$, a medical cannabis pharmacy may:
1369	(a) advertise an employment opportunity at the medical cannabis pharmacy;
1370	(b) notwithstanding any municipal or county ordinance prohibiting signage, use
1371	signage on the outside of the medical cannabis pharmacy that:
1372	(i) includes only:
1373	(A) in accordance with Subsection $[26-61a-116(4)]$ <u>4-41a-109(4)</u> , the medical cannabis
1374	pharmacy's name, logo, and hours of operation; and
1375	(B) a green cross; and
1376	(ii) complies with local ordinances regulating signage;
1377	(c) advertise in any medium:
1378	(i) the pharmacy's name and logo;
1379	(ii) the location and hours of operation of the medical cannabis pharmacy;
1380	(iii) a service available at the medical cannabis pharmacy;
1381	(iv) personnel affiliated with the medical cannabis pharmacy;
1382	(v) whether the medical cannabis pharmacy is licensed as a home delivery medical
1383	cannabis pharmacy;
1384	(vi) best practices that the medical cannabis pharmacy upholds; and
1385	(vii) educational material related to the medical use of cannabis, as defined by the
1386	department;
1387	(d) hold an educational event for the public or medical providers in accordance with
1388	Subsection (3) and the rules described in Subsection (4); and
1389	(e) maintain on the medical cannabis pharmacy's website non-promotional information

1390	regarding the medical cannabis pharmacy's inventory.
1391	(3) A medical cannabis pharmacy may not include in an educational event described in
1392	Subsection (2)(d):
1393	(a) any topic that conflicts with this chapter or [Title 4, Chapter 41a, Cannabis
1394	Production Establishments] Title 26, Chapter 61a, Utah Medical Cannabis Act;
1395	(b) any gift items or merchandise other than educational materials, as those terms are
1396	defined by the department;
1397	(c) any marketing for a specific product from the medical cannabis pharmacy or any
1398	other statement, claim, or information that would violate the federal Food, Drug, and Cosmetic
1399	Act, 21 U.S.C. Sec. 301, et seq.; or
1400	(d) a presenter other than the following:
1401	(i) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
1402	(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
1403	Practice Act;
1404	(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
1405	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act;
1406	(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
1407	Assistant Act;
1408	(v) a medical practitioner, similar to [the practitioners] a practitioner described in [this
1409	Subsection $(3)(d)(v)$ Subsections $(3)(d)(i)$ through (iv), who is licensed in another state or
1410	country;
1411	(vi) a state employee; or
1412	(vii) if the presentation relates to a cannabis topic other than medical treatment or
1413	medical conditions, an individual whom the department approves based on the individual's
1414	background and credentials in the presented topic.
1415	(4) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1416	Administrative Rulemaking Act, to define:
1417	(a) the educational material described in Subsection (2)(c)(vii); and
1418	(b) the elements of and restrictions on the educational event described in Subsection
1419	(3), including:
1420	(i) a minimum age of 21 years old for attendees; and

1421	(ii) an exception to the minimum age for a medical cannabis patient cardholder who is
1422	at least 18 years old.
1423	Section 20. Section 4-41a-1105, which is renumbered from Section 26-61a-507 is
1424	renumbered and amended to read:
1425	[26-61a-507]. <u>4-41a-1105.</u> Local control.
1426	(1) The operation of a medical cannabis pharmacy:
1427	(a) shall be a permitted use:
1428	(i) in any zone, overlay, or district within the municipality or county except for a
1429	primarily residential zone; and
1430	(ii) on land that the municipality or county has not zoned; and
1431	(b) is subject to the land use regulations, as defined in Sections $10-9a-103$ and
1432	17-27a-103, that apply in the underlying zone.
1433	(2) A municipality or county may not:
1434	(a) on the sole basis that the applicant or medical cannabis pharmacy violates federal
1435	law regarding the legal status of cannabis, deny or revoke:
1436	(i) a land use permit, as that term is defined in Sections 10-9a-103 and 17-27a-103, to
1437	operate a medical cannabis pharmacy; or
1438	(ii) a business license to operate a medical cannabis pharmacy;
1439	(b) require a certain distance between a medical cannabis pharmacy and:
1440	(i) another medical cannabis pharmacy;
1441	(ii) a cannabis production establishment;
1442	(iii) a retail tobacco specialty business, as that term is defined in Section 26-62-103; or
1443	(iv) an outlet, as that term is defined in Section 32B-1-202; or
1444	(c) in accordance with Subsections 10-9a-509(1) and 17-27a-508(1), enforce a land use
1445	regulation against a medical cannabis pharmacy that was not in effect on the day on which the
1446	medical cannabis pharmacy submitted a complete land use application.
1447	(3) (a) A municipality or county may enact an ordinance that:
1448	(i) is not in conflict with this chapter; and
1449	(ii) governs the time, place, or manner of medical cannabis pharmacy operations in the
1450	municipality or county.
1451	(b) An ordinance that a municipality or county enacts under Subsection (3)(a) may not

1452	restrict the hours of operation from 7 a.m. to 10 p.m.
1453	(4) An applicant for a land use permit to operate a medical cannabis pharmacy shall
1454	comply with the land use requirements and application process described in:
1455	(a) Title 10, Chapter 9a, Municipal Land Use, Development, and Management Act,
1456	including Section 10-9a-528; and
1457	(b) Title 17, Chapter 27a, County Land Use, Development, and Management Act,
1458	including Section 17-27a-525.
1459	Section 21. Section 4-41a-1106, which is renumbered from Section 26-61a-401 is
1460	renumbered and amended to read:
1461	[26-61a-401]. <u>4-41a-1106.</u> Medical cannabis pharmacy agent
1462	Registration.
1463	(1) An individual may not serve as a medical cannabis pharmacy agent of a medical
1464	cannabis pharmacy unless the department registers the individual as a medical cannabis
1465	pharmacy agent.
1466	(2) A recommending medical provider may not act as a medical cannabis pharmacy
1467	agent, have a financial or voting interest of 2% or greater in a medical cannabis pharmacy, or
1468	have the power to direct or cause the management or control of a medical cannabis pharmacy.
1469	(3) (a) The department shall, within 15 days after the day on which the department
1470	receives a complete application from a medical cannabis pharmacy on behalf of a prospective
1471	medical cannabis pharmacy agent, register and issue a medical cannabis pharmacy agent
1472	registration card to the prospective agent if the medical cannabis pharmacy:
1473	(i) provides to the department:
1474	(A) the prospective agent's name and address;
1475	(B) the name and location of the licensed medical cannabis pharmacy where the
1476	prospective agent seeks to act as the medical cannabis pharmacy agent; and
1477	(C) the submission required under Subsection (3)(b); and
1478	(ii) pays a fee to the department in an amount that, subject to Subsection
1479	26-61a-109(5), the department sets in accordance with Section 63J-1-504.
1480	(b) Except for an applicant reapplying for a medical cannabis pharmacy agent
1481	registration card within less than one year after the expiration of the applicant's previous
1482	medical cannabis pharmacy agent registration card, each prospective agent described in

1483 Subsection (3)(a) shall: 1484 (i) submit to the department: 1485 (A) a fingerprint card in a form acceptable to the Department of Public Safety, and 1486 (B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the 1487 registration of the prospective agent's fingerprints in the Federal Bureau of Investigation Next 1488 Generation Identification System's Rap Back Service; and 1489 (ii) consent to a fingerprint background check by: 1490 (A) the Bureau of Criminal Identification: and (B) the Federal Bureau of Investigation. 1491 1492 (c) The Bureau of Criminal Identification shall: 1493 (i) check the fingerprints the prospective agent submits under Subsection (3)(b) against 1494 the applicable state, regional, and national criminal records databases, including the Federal 1495 Bureau of Investigation Next Generation Identification System: 1496 (ii) report the results of the background check to the department; 1497 (iii) maintain a separate file of fingerprints that prospective agents submit under 1498 Subsection (3)(b) for search by future submissions to the local and regional criminal records 1499 databases, including latent prints; 1500 (iv) request that the fingerprints be retained in the Federal Bureau of Investigation Next 1501 Generation Identification System's Rap Back Service for search by future submissions to 1502 national criminal records databases, including the Next Generation Identification System and 1503 latent prints; and 1504 (v) establish a privacy risk mitigation strategy to ensure that the department only 1505 receives notifications for an individual with whom the department maintains an authorizing 1506 relationship. 1507 (d) The department shall: 1508 (i) assess an individual who submits fingerprints under Subsection (3)(b) a fee in an 1509 amount that the department sets in accordance with Section 63J-1-504 for the services that the 1510 Bureau of Criminal Identification or another authorized agency provides under this section; and 1511 (ii) remit the fee described in Subsection (3)(d)(i) to the Bureau of Criminal 1512 Identification.

1513

(4) The department shall designate, on an individual's medical cannabis pharmacy

1514	agent registration card the name of the medical cannabis pharmacy where the individual is
1515	registered as an agent.
1516	(5) A medical cannabis pharmacy agent shall comply with a certification standard that
1517	the department develops in collaboration with the Division of Professional Licensing and the
1518	Board of Pharmacy, or a third-party certification standard that the department designates by
1519	rule, in collaboration with the Division of Professional Licensing and the Board of Pharmacy
1520	and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
1521	(6) The department shall ensure that the certification standard described in Subsection
1522	(5) includes training in:
1523	(a) Utah medical cannabis law; and
1524	(b) medical cannabis pharmacy best practices.
1525	(7) The department may revoke the medical cannabis pharmacy agent registration card
1526	of, or refuse to issue a medical cannabis pharmacy agent registration card to, an individual
1527	who:
1528	(a) violates the requirements of this chapter; or
1529	(b) is convicted under state or federal law of:
1530	(i) a felony within the preceding 10 years; or
1531	(ii) after December 3, 2018, a misdemeanor for drug distribution.
1532	(8) (a) A medical cannabis pharmacy agent registration card expires two years after the
1533	day on which the department issues or renews the card.
1534	(b) A medical cannabis pharmacy agent may renew the agent's registration card if the
1535	agent:
1536	(i) is eligible for a medical cannabis pharmacy agent registration card under this
1537	section;
1538	(ii) certifies to the department in a renewal application that the information in
1539	Subsection (3)(a) is accurate or updates the information; and
1540	(iii) pays to the department a renewal fee in an amount that:
1541	(A) subject to Subsection $26-61a-109(5)$, the department sets in accordance with
1542	Section 63J-1-504; and
1543	(B) may not exceed the cost of the relatively lower administrative burden of renewal in
1 - 4 4	· · · · · · · · · · · · ·

1544 comparison to the original application process.

1545	(9) (a) As a condition precedent to registration and renewal of a medical cannabis
1546	pharmacy agent registration card, a medical cannabis pharmacy agent shall:
1547	(i) complete at least one hour of continuing education regarding patient privacy and
1548	federal health information privacy laws that is offered by the department under Subsection
1549	(9)(b) or an accredited or approved continuing education provider that the department
1550	recognizes as offering continuing education appropriate for the medical cannabis pharmacy
1551	practice; and
1552	(ii) make a continuing education report to the department in accordance with a process
1553	that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah
1554	Administrative Rulemaking Act, and in collaboration with the Division of Professional
1555	Licensing and the Board of Pharmacy.
1556	(b) The department may, in consultation with the Division of Professional Licensing,
1557	develop the continuing education described in this Subsection (9).
1558	(c) The pharmacist-in-charge described in Section 26-61a-403 shall ensure that each
1559	medical cannabis pharmacy agent working in the medical cannabis pharmacy who has access to
1560	the state electronic verification system is in compliance with this Subsection (9).
1561	Section 22. Section 4-41a-1107, which is renumbered from Section 26-61a-402 is
1562	renumbered and amended to read:
1563	[26-61a-402]. <u>4-41a-1107.</u> Medical cannabis pharmacy agent registration
1564	card Rebuttable presumption.
1565	(1) A medical cannabis pharmacy agent shall carry the individual's medical cannabis
1566	pharmacy agent registration card with the individual at all times when:
1567	(a) the individual is on the premises of a medical cannabis pharmacy; and
1568	(b) the individual is transporting cannabis in a medicinal dosage form, a cannabis
1569	product in a medicinal dosage form, or a medical cannabis device between a cannabis
1570	production establishment and a medical cannabis pharmacy.
1571	(2) If an individual handling, at a medical cannabis pharmacy, cannabis in a medicinal
1572	dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device or
1573	transporting cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage
1574	form, or a medical cannabis device, possesses the cannabis, cannabis product, or medical
1575	cannabis device in compliance with Subsection (1):

1576	(a) there is a rebuttable presumption that the individual possesses the cannabis,
1577	cannabis product, or medical cannabis device legally; and
1578	(b) there is no probable cause, based solely on the individual's possession of the
1579	cannabis in medicinal dosage form, cannabis product in medicinal dosage form, or medical
1580	cannabis device in compliance with Subsection (1), that the individual is engaging in illegal
1581	activity.
1582	(3) (a) A medical cannabis pharmacy agent who fails to carry the agent's medical
1583	cannabis pharmacy agent registration card in accordance with Subsection (1) is:
1584	(i) for a first or second offense in a two-year period:
1585	(A) guilty of an infraction; and
1586	(B) is subject to a \$100 fine; or
1587	(ii) for a third or subsequent offense in a two-year period:
1588	(A) guilty of a class C misdemeanor; and
1589	(B) subject to a \$750 fine.
1590	(b) (i) The prosecuting entity shall notify the department and the relevant medical
1591	cannabis pharmacy of each conviction under Subsection (3)(a).
1592	(ii) For each violation described in Subsection (3)(a)(ii), the department may assess the
1593	relevant medical cannabis pharmacy a fine of up to \$5,000, in accordance with a fine schedule
1594	that the department establishes by rule in accordance with Title 63G, Chapter 3, Utah
1595	Administrative Rulemaking Act.
1596	(c) An individual who is guilty of a violation described in Subsection (3)(a) is not
1597	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
1598	underlying the violation described in Subsection (3)(a).
1599	Section 23. Section 4-41a-1201 is enacted to read:
1600	Part 12. Medical Cannabis Home Delivery and Couriers
1601	4-41a-1201. Medical cannabis home delivery designation.
1602	(1) The department may designate a medical cannabis pharmacy as a home delivery
1603	medical cannabis pharmacy if the department determines that the medical cannabis pharmacy's
1604	operating plan demonstrates the functional and technical ability to:
1605	(a) safely conduct transactions for medical cannabis shipments;
1606	(b) accept electronic medical cannabis orders that the state central patient portal

1607	facilitates; and
1608	(c) accept payments through:
1609	(i) a payment provider that the Division of Finance approves, in consultation with the
1610	state treasurer, in accordance with Section 26-61a-603; or
1611	(ii) a financial institution in accordance with Subsection 26-61a-603(4).
1612	(2) An applicant seeking a designation as a home delivery medical cannabis pharmacy
1613	shall identify in the applicant's operating plan any information relevant to the department's
1614	evaluation described in Subsection (1), including:
1615	(a) the name and contact information of the payment provider;
1616	(b) the nature of the relationship between the prospective licensee and the payment
1617	provider;
1618	(c) the processes of the following to safely and reliably conduct transactions for
1619	medical cannabis shipments:
1620	(i) the prospective licensee; and
1621	(ii) the electronic payment provider or the financial institution described in Subsection
1622	<u>(1)(c); and</u>
1623	(d) the ability of the licensee to comply with the department's rules regarding the secure
1624	transportation and delivery of medical cannabis or medical cannabis product to a medical
1625	cannabis cardholder.
1626	(3) Notwithstanding any county or municipal ordinance, a medical cannabis pharmacy
1627	that the department designates as a home delivery medical cannabis pharmacy may deliver
1628	medical cannabis shipments in accordance with this part.
1629	Section 24. Section 4-41a-1202, which is renumbered from Section 26-61a-604 is
1630	renumbered and amended to read:
1631	[26-61a-604]. <u>4-41a-1202.</u> Home delivery of medical cannabis shipments
1632	Medical cannabis couriers License.
1633	(1) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah
1634	Administrative Rulemaking Act, to ensure the safety, security, and efficiency of a home
1635	delivery medical cannabis pharmacy's fulfillment of electronic medical cannabis orders that the
1636	state central patient portal facilitates, including rules regarding the safe and controlled delivery
1637	of medical cannabis shipments.

1638	(2) A person may not operate as a medical cannabis courier without a license that the
1639	department issues under this section.
1640	(3) (a) Subject to Subsections (5) and (6), the department shall issue a license to
1641	operate as a medical cannabis courier to an applicant who is eligible for a license under this
1642	section.
1643	(b) An applicant is eligible for a license under this section if the applicant submits to
1644	the department:
1645	(i) the name and address of an individual who:
1646	(A) has a financial or voting interest of 2% or greater in the proposed medical cannabis
1647	pharmacy; or
1648	(B) has the power to direct or cause the management or control of a proposed cannabis
1649	production establishment;
1650	(ii) an operating plan that includes operating procedures to comply with the operating
1651	requirements for a medical cannabis courier described in this chapter; and
1652	(iii) an application fee in an amount that, subject to Subsection [26-61a-109(5)]
1653	<u>4-41a-104(5)</u> , the department sets in accordance with Section 63J-1-504.
1654	(4) If the department determines that an applicant is eligible for a license under this
1655	section, the department shall:
1656	(a) charge the applicant an initial license fee in an amount that, subject to Subsection
1657	$\left[\frac{26-61a-109(5)}{4-41a-104(5)}\right]$, the department sets in accordance with Section 63J-1-504; and
1658	(b) notify the Department of Public Safety of the license approval and the names of
1659	each individual described in Subsection [(3)(b)(ii).] (3)(b)(i).
1660	(5) The department may not issue a license to operate as a medical cannabis courier to
1661	an applicant if an individual described in Subsection [(3)(b)(ii)] (3)(b)(i):
1662	(a) has been convicted under state or federal law of:
1663	(i) a felony; or
1664	(ii) after September 23, 2019, a misdemeanor for drug distribution; or
1665	(b) is younger than 21 years old.
1666	(6) The department may revoke a license under this part if:
1667	(a) the medical cannabis courier does not begin operations within one year after the day

1668 on which the department issues the initial license;

1669	(b) the medical cannabis courier makes the same violation of this chapter three times;
1670	(c) an individual described in Subsection $[(3)(b)(ii)]$ (3)(b)(i) is convicted, while the
1671	license is active, under state or federal law of:
1672	(i) a felony; or
1673	(ii) after September 23, 2019, a misdemeanor for drug distribution; or
1674	(d) after a change of ownership described in Subsection (15)(c), the department
1675	determines that the medical cannabis courier no longer meets the minimum standards for
1676	licensure and operation of the medical cannabis courier described in this chapter.
1677	(7) The department shall deposit the proceeds of a fee imposed by this section in the
1678	Qualified [Patient] Production Enterprise Fund.
1679	(8) The department shall begin accepting applications under this section on or before
1680	July 1, 2020.
1681	(9) The department's authority to issue a license under this section is plenary and is not
1682	subject to review.
1683	(10) Each applicant for a license as a medical cannabis courier shall submit, at the time
1684	of application, from each individual who has a financial or voting interest of 2% or greater in
1685	the applicant or who has the power to direct or cause the management or control of the
1686	applicant:
1687	(a) a fingerprint card in a form acceptable to the Department of Public Safety;
1688	(b) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
1689	registration of the individual's fingerprints in the Federal Bureau of Investigation Next
1690	Generation Identification System's Rap Back Service; and
1691	(c) consent to a fingerprint background check by:
1692	(i) the Bureau of Criminal Identification; and
1693	(ii) the Federal Bureau of Investigation.
1694	(11) The Bureau of Criminal Identification shall:
1695	(a) check the fingerprints the applicant submits under Subsection (10) against the
1696	applicable state, regional, and national criminal records databases, including the Federal
1697	Bureau of Investigation Next Generation Identification System;
1698	(b) report the results of the background check to the department;
1699	(c) maintain a separate file of fingerprints that applicants submit under Subsection (10)

1700	for search by future submissions to the local and regional criminal records databases, including
1701	latent prints;
1702	(d) request that the fingerprints be retained in the Federal Bureau of Investigation Next
1703	Generation Identification System's Rap Back Service for search by future submissions to
1704	national criminal records databases, including the Next Generation Identification System and
1705	latent prints; and
1706	(e) establish a privacy risk mitigation strategy to ensure that the department only
1707	receives notifications for an individual with whom the department maintains an authorizing
1708	relationship.
1709	(12) The department shall:
1710	(a) assess an individual who submits fingerprints under Subsection (10) a fee in an
1711	amount that the department sets in accordance with Section 63J-1-504 for the services that the
1712	Bureau of Criminal Identification or another authorized agency provides under this section; and
1713	(b) remit the fee described in Subsection (12)(a) to the Bureau of Criminal
1714	Identification.
1715	(13) The department shall renew a license under this section every year if, at the time
1716	of renewal:
1717	(a) the licensee meets the requirements of this section; and
1718	(b) the licensee pays the department a license renewal fee in an amount that, subject to
1719	Subsection 26-61a-109(5), the department sets in accordance with Section 63J-1-504.
1720	(14) A person applying for a medical cannabis courier license shall submit to the
1721	department a proposed operating plan that complies with this section and that includes:
1722	(a) a description of the physical characteristics of any proposed facilities, including a
1723	floor plan and an architectural elevation, and delivery vehicles;
1724	(b) a description of the credentials and experience of each officer, director, or owner of
1725	the proposed medical cannabis courier;
1726	(c) the medical cannabis courier's employee training standards;
1727	(d) a security plan; and
1728	(e) storage and delivery protocols, both short and long term, to ensure that medical
1729	cannabis shipments are stored and delivered in a manner that is sanitary and preserves the
1730	integrity of the cannabis.

1731	(15) (a) A medical cannabis courier license is not transferrable or assignable.
1732	(b) A medical cannabis courier shall report in writing to the department no later than
1733	10 business days before the date of any change of ownership of the medical cannabis courier.
1734	(c) If the ownership of a medical cannabis courier changes by 50% or more:
1735	(i) concurrent with the report described in Subsection (15)(b), the medical cannabis
1736	courier shall submit a new application described in Subsection (3)(b);
1737	(ii) within 30 days of the submission of the application, the department shall:
1738	(A) conduct an application review; and
1739	(B) award a license to the medical cannabis courier for the remainder of the term of the
1740	medical cannabis courier's license before the ownership change if the medical cannabis courier
1741	meets the minimum standards for licensure and operation of the medical cannabis courier
1742	described in this chapter; and
1743	(iii) if the department approves the license application, notwithstanding Subsection (4),
1744	the medical cannabis courier shall pay a license fee that the department sets in accordance with
1745	Section 63J-1-504 in an amount that covers the board's cost of conducting the application
1746	review.
1747	(16) (a) Except as provided in Subsection (15)(b), a person may not advertise regarding
1748	the transportation of medical cannabis.
1749	(b) Notwithstanding Subsection (15)(a) and subject to Section [26-61a-116] 4-41a-109,
1750	a licensed home delivery medical cannabis pharmacy or a licensed medical cannabis courier
1751	may advertise:
1752	(i) a green cross;
1753	(ii) the pharmacy's or courier's name and logo; and
1754	(iii) that the pharmacy or courier is licensed to transport medical cannabis shipments.
1755	Section 25. Section 4-41a-1203, which is renumbered from Section 26-61a-605 is
1756	renumbered and amended to read:
1757	[26-61a-605]. <u>4-41a-1203.</u> Medical cannabis shipment transportation.
1758	(1) The department shall ensure that each home delivery medical cannabis pharmacy is
1759	capable of delivering, directly or through a medical cannabis courier, medical cannabis
1760	shipments in a secure manner.
1761	(2) (a) A home delivery medical cannabis pharmacy may contract with a licensed

1762	medical cannabis courier to deliver medical cannabis shipments to fulfill electronic medical
1763	cannabis orders that the state central patient portal facilitates.
1764	(b) If a home delivery medical cannabis pharmacy enters into a contract described in
1765	Subsection (2)(a), the pharmacy shall:
1766	(i) impose security and personnel requirements on the medical cannabis courier
1767	sufficient to ensure the security and safety of medical cannabis shipments; and
1768	(ii) provide regular oversight of the medical cannabis courier.
1769	(3) [Except for an individual with a valid medical cannabis card who transports a
1770	shipment the individual receives, an] Notwithstanding Subsection 4-41a-404(1), an individual
1771	may [not] transport a medical cannabis shipment [unless] <u>if</u> the individual is:
1772	(a) a registered pharmacy medical provider;
1773	(b) a registered medical cannabis pharmacy agent; or
1774	(c) a registered agent of the medical cannabis courier described in Subsection (2).
1775	(4) An individual transporting a medical cannabis shipment under Subsection (3) shall
1776	[possess a physical or electronic transportation manifest that:] comply with the requirements of
1777	<u>Subsection 4-41a-404(3).</u>
1778	[(a) includes a unique identifier that links the medical cannabis shipment to a relevant
1779	inventory control system;]
1780	[(b) includes origin and destination information for the medical cannabis shipment the
1781	individual is transporting; and]
1782	[(c) indicates the departure and estimated arrival times and locations of the individual
1783	transporting the medical cannabis shipment.]
1784	(5) In addition to the requirements in Subsections (3) and (4), the department may
1785	establish by rule, in collaboration with the Division of Professional Licensing and the Board of
1786	Pharmacy and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
1787	requirements for transporting medical cannabis shipments that are related to safety for human
1788	consumption of cannabis or a cannabis product.
1789	(6) (a) It is unlawful for an individual to transport a medical cannabis shipment with a
1790	manifest that does not meet the requirements of Subsection (4).
1791	(b) Except as provided in Subsection (6)(d), an individual who violates Subsection
1792	(6)(a) is:

1793	(i) guilty of an infraction; and
1794	(ii) subject to a \$100 fine.
1795	(c) An individual who is guilty of a violation described in Subsection (6)(b) is not
1796	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
1797	underlying the violation described in Subsection (6)(b).
1798	(d) If the individual described in Subsection (6)(a) is transporting more cannabis,
1799	cannabis product, or medical cannabis devices than the manifest identifies, except for a de
1800	minimis administrative error:
1801	(i) this chapter does not apply; and
1802	(ii) the individual is subject to penalties under Title 58, Chapter 37, Utah Controlled
1803	Substances Act.
1804	Section 26. Section 4-41a-1204, which is renumbered from Section 26-61a-606 is
1805	renumbered and amended to read:
1806	[26-61a-606]. <u>4-41a-1204.</u> Medical cannabis courier agent Background
1807	check Registration card Rebuttable presumption.
1808	(1) An individual may not serve as a medical cannabis courier agent unless:
1809	(a) the individual is an employee of a licensed medical cannabis courier; and
1810	(b) the department registers the individual as a medical cannabis courier agent.
1811	(2) (a) The department shall, within 15 days after the day on which the department
1812	receives a complete application from a medical cannabis courier on behalf of a medical
1813	cannabis courier agent, register and issue a medical cannabis courier agent registration card to
1814	the prospective agent if the medical cannabis courier:
1815	(i) provides to the department:
1816	(A) the prospective agent's name and address;
1817	(B) the name and address of the medical cannabis courier;
1818	(C) the name and address of each home delivery medical cannabis pharmacy with
1819	which the medical cannabis courier contracts to deliver medical cannabis shipments; and
1820	(D) the submission required under Subsection (2)(b);
1821	(ii) as reported under Subsection (2)(c), has not been convicted under state or federal
1822	law of:
1822 1823	law of: (A) a felony; or

1824	(B) after December 3, 2018, a misdemeanor for drug distribution; and
1825	(iii) pays the department a fee in an amount that, subject to Subsection $[\frac{26-61a-109(5)}{5}]$
1826	4-41a-104(5), the department sets in accordance with Section 63J-1-504.
1827	(b) Except for an applicant reapplying for a medical cannabis courier agent registration
1828	card within less than one year after the expiration of the applicant's previous medical cannabis
1829	courier agent registration card, each prospective agent described in Subsection (2)(a) shall:
1830	(i) submit to the department:
1831	(A) a fingerprint card in a form acceptable to the Department of Public Safety; and
1832	(B) a signed waiver in accordance with Subsection 53-10-108(4) acknowledging the
1833	registration of the prospective agent's fingerprints in the Federal Bureau of Investigation Next
1834	Generation Identification System's Rap Back Service; and
1835	(ii) consent to a fingerprint background check by:
1836	(A) the Bureau of Criminal Identification; and
1837	(B) the Federal Bureau of Investigation.
1838	(c) The Bureau of Criminal Identification shall:
1839	(i) check the fingerprints the prospective agent submits under Subsection (2)(b) against
1840	the applicable state, regional, and national criminal records databases, including the Federal
1841	Bureau of Investigation Next Generation Identification System;
1842	(ii) report the results of the background check to the department;
1843	(iii) maintain a separate file of fingerprints that prospective agents submit under
1844	Subsection (2)(b) for search by future submissions to the local and regional criminal records
1845	databases, including latent prints;
1846	(iv) request that the fingerprints be retained in the Federal Bureau of Investigation Next
1847	Generation Identification System's Rap Back Service for search by future submissions to
1848	national criminal records databases, including the Next Generation Identification System and
1849	latent prints; and
1850	(v) establish a privacy risk mitigation strategy to ensure that the department only
1851	receives notifications for an individual with whom the department maintains an authorizing
1852	relationship.
1853	(d) The department shall:
1854	(i) assess an individual who submits fingerprints under Subsection (2)(b) a fee in an

1855	amount that the department sets in accordance with Section 63J-1-504 for the services that the
1856	Bureau of Criminal Identification or another authorized agency provides under this section; and
1857	(ii) remit the fee described in Subsection (2)(d)(i) to the Bureau of Criminal
1858	Identification.
1859	(3) The department shall designate on an individual's medical cannabis courier agent
1860	registration card the name of the medical cannabis pharmacy where the individual is registered
1861	as an agent and each home delivery medical cannabis courier for which the medical cannabis
1862	courier delivers medical cannabis shipments.
1863	(4) (a) A medical cannabis courier agent shall comply with a certification standard that
1864	the department develops, in collaboration with the Division of Professional Licensing and the
1865	Board of Pharmacy, or a third-party certification standard that the department designates by
1866	rule in collaboration with the Division of Professional Licensing and the Board of Pharmacy
1867	and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
1868	(b) The department shall ensure that the certification standard described in Subsection
1869	(4)(a) includes training in:
1870	(i) Utah medical cannabis law;
1871	(ii) the medical cannabis shipment process; and
1872	(iii) medical cannabis courier agent best practices.
1873	(5) (a) A medical cannabis courier agent registration card expires two years after the
1874	day on which the department issues or renews the card.
1875	(b) A medical cannabis courier agent may renew the agent's registration card if the
1876	agent:
1877	(i) is eligible for a medical cannabis courier agent registration card under this section;
1878	(ii) certifies to the department in a renewal application that the information in
1879	Subsection (2)(a) is accurate or updates the information; and
1880	(iii) pays to the department a renewal fee in an amount that:
1881	(A) subject to Subsection $\left[\frac{26-61a-109(5)}{2}\right] \frac{4-41a-104(5)}{2}$, the department sets in
1882	accordance with Section 63J-1-504; and
1883	(B) may not exceed the cost of the relatively lower administrative burden of renewal in
1884	comparison to the original application process.
1885	(6) The department may revoke or refuse to issue or renew the medical cannabis

1886	courier agent registration card of an individual who:
1887	(a) violates the requirements of this chapter; or
1888	(b) is convicted under state or federal law of:
1889	(i) a felony within the preceding 10 years; or
1890	(ii) after December 3, 2018, a misdemeanor for drug distribution.
1891	(7) A medical cannabis courier agent whom the department has registered under this
1892	section shall carry the agent's medical cannabis courier agent registration card with the agent at
1893	all times when:
1894	(a) the agent is on the premises of the medical cannabis courier, a medical cannabis
1895	pharmacy, or a medical cannabis cardholder's home address; and
1896	(b) the agent is handling a medical cannabis shipment.
1897	(8) If a medical cannabis courier agent handling a medical cannabis shipment possesses
1898	the shipment in compliance with Subsection (7):
1899	(a) there is a rebuttable presumption that the agent possesses the shipment legally; and
1900	(b) there is no probable cause, based solely on the agent's possession of the medical
1901	cannabis shipment that the agent is engaging in illegal activity.
1902	(9) (a) A medical cannabis courier agent who violates Subsection (7) is:
1903	(i) guilty of an infraction; and
1904	(ii) subject to a \$100 fine.
1905	(b) An individual who is guilty of a violation described in Subsection (9)(a) is not
1906	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
1907	underlying the violation described in Subsection (9)(a).
1908	Section 27. Section 4-41a-1205, which is renumbered from Section 26-61a-607 is
1909	renumbered and amended to read:
1910	[26-61a-607]. <u>4-41a-1205.</u> Home delivery of medical cannabis shipments.
1911	(1) An individual may not receive and a medical cannabis pharmacy agent or a medical
1912	cannabis courier agent may not deliver a medical cannabis shipment from a home delivery
1913	medical cannabis pharmacy unless:
1914	(a) the individual receiving the shipment presents:
1915	(i) a valid form of photo identification; and
1916	(ii) (A) a valid medical cannabis card under the same name that appears on the valid

1917	form of photo identification; or
1918	(B) for a facility that a medical cannabis cardholder has designated as a caregiver under
1919	Subsection 26-61a-202(1)(b), evidence of the facility caregiver designation; and
1920	(b) the delivery occurs at:
1921	(i) the medical cannabis cardholder's home address that is on file in the state electronic
1922	verification system; or
1923	(ii) the facility that the medical cannabis cardholder has designated as a caregiver under
1924	Subsection 26-61a-202(1)(b).
1925	(2) Before a medical cannabis pharmacy agent or a medical cannabis courier agent
1926	distributes a medical cannabis shipment to a medical cannabis cardholder, the agent shall:
1927	(a) verify the shipment information using the state electronic verification system;
1928	(b) ensure that the individual satisfies the identification requirements in Subsection (1);
1929	(c) verify that payment is complete; and
1930	(d) record the completion of the shipment transaction in a manner such that the
1931	delivery of the shipment will later be recorded within a reasonable period in the electronic
1932	verification system.
1933	(3) The medical cannabis courier shall:
1934	(a) (i) store each medical cannabis shipment in a secure manner until the recipient
1935	medical cannabis cardholder receives the shipment or the medical cannabis courier returns the
1936	shipment to the home delivery medical cannabis pharmacy in accordance with Subsection (4);
1937	and
1938	(ii) ensure that only a medical cannabis courier agent is able to access the medical
1939	cannabis shipment until the recipient medical cannabis cardholder receives the shipment;
1940	(b) return any undelivered medical cannabis shipment to the home delivery medical
1941	cannabis pharmacy, in accordance with Subsection (4), after the medical cannabis courier has
1942	possessed the shipment for 10 business days; and
1943	(c) return any medical cannabis shipment to the home delivery medical cannabis
1944	pharmacy, in accordance with Subsection (4), if a medical cannabis cardholder refuses to
1945	accept the shipment.
1946	(4) (a) If a medical cannabis courier or home delivery medical cannabis pharmacy
1947	agent returns an undelivered medical cannabis shipment that remains unopened, the home

1948	delivery medical cannabis pharmacy may repackage or otherwise reuse the shipment.
1949	(b) If a medical cannabis courier or home delivery medical cannabis pharmacy agent
1950	returns an undelivered or refused medical cannabis shipment under Subsection (3) that appears
1951	to be opened in any way, the home delivery medical cannabis pharmacy shall dispose of the
1952	shipment by:
1953	(i) rendering the shipment unusable and unrecognizable before transporting the
1954	shipment from the home delivery medical cannabis pharmacy; and
1955	(ii) disposing of the shipment in accordance with:
1956	(A) federal and state laws, rules, and regulations related to hazardous waste;
1957	(B) the Resource Conservation and Recovery Act, 42 U.S.C. Sec. 6991 et seq.;
1958	(C) Title 19, Chapter 6, Part 5, Solid Waste Management Act; and
1959	(D) other regulations that the department makes in accordance with Title 63G, Chapter
1960	3, Utah Administrative Rulemaking Act.
1961	Section 28. Section 10-9a-528 is amended to read:
1962	10-9a-528. Cannabis production establishments, medical cannabis pharmacies,
1963	and industrial hemp producer licensee.
1964	(1) As used in this section:
1965	(a) "Cannabis production establishment" means the same as that term is defined in
1966	Section 4-41a-102.
1967	(b) "Industrial hemp producer licensee" means the same as the term "licensee" is
1968	defined in Section 4-41-102.
1969	(c) "Medical cannabis pharmacy" means the same as that term is defined in Section
1970	26-61a-102.
1971	(2) (a) (i) A municipality may not regulate a cannabis production establishment or a
1972	medical cannabis pharmacy in conflict with:
1973	(A) Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies, and
1974	applicable jurisprudence; and
1975	(B) this chapter.
1976	[(ii) A municipality may not regulate a medical cannabis pharmacy in conflict with:]
1977	[(A) Title 26, Chapter 61a, Utah Medical Cannabis Act, and applicable jurisprudence;
1978	and]

1979	[(B) this chapter.]
1980	[(iii)] (ii) A municipality may not regulate an industrial hemp producer licensee in
1981	conflict with:
1982	(A) Title 4, Chapter 41, Hemp and Cannabinoid Act, and applicable jurisprudence; and
1983	(B) this chapter.
1984	(b) The Department of Agriculture and Food has plenary authority to license programs
1985	or entities that operate a cannabis production establishment or a medical cannabis pharmacy.
1986	[(c) The Department of Health has plenary authority to license programs or entities that
1987	operate a medical cannabis pharmacy.]
1988	(3) (a) Within the time period described in Subsection (3)(b), a municipality shall
1989	prepare and adopt a land use regulation, development agreement, or land use decision in
1990	accordance with this title and:
1991	(i) regarding a cannabis production establishment, Section 4-41a-406; or
1992	(ii) regarding a medical cannabis pharmacy, Section [26-61a-507] 4-41a-110.
1993	(b) A municipality shall take the action described in Subsection (3)(a):
1994	(i) before January 1, 2021, within 45 days after the day on which the municipality
1995	receives a petition for the action; and
1996	(ii) after January 1, 2021, in accordance with Subsection 10-9a-509.5(2).
1997	Section 29. Section 17-27a-525 is amended to read:
1998	17-27a-525. Cannabis production establishments and medical cannabis
1999	pharmacies.
2000	(1) As used in this section:
2001	(a) "Cannabis production establishment" means the same as that term is defined in
2002	Section 4-41a-102.
2003	(b) "Industrial hemp producer licensee" means the same as the term "licensee" is
2004	defined in Section 4-41-102.
2005	(c) "Medical cannabis pharmacy" means the same as that term is defined in Section
2006	26-61a-102.
2007	(2) (a) (i) A county may not regulate a cannabis production establishment or a medical
2008	cannabis pharmacy in conflict with:
2009	(A) Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies, and

2010	applicable jurisprudence; and
2011	(B) this chapter.
2012	[(ii) A county may not regulate a medical cannabis pharmacy in conflict with:]
2013	[(A) Title 26, Chapter 61a, Utah Medical Cannabis Act, and applicable jurisprudence;
2014	and]
2015	[(B) this chapter.]
2016	[(iii)] (ii) A county may not regulate an industrial hemp producer licensee in conflict
2017	with:
2018	(A) Title 4, Chapter 41, Hemp and Cannabinoid Act, and applicable jurisprudence; and
2019	(B) this chapter.
2020	(b) The Department of Agriculture and Food has plenary authority to license programs
2021	or entities that operate a cannabis production establishment or a medical cannabis pharmacy.
2022	[(c) The Department of Health has plenary authority to license programs or entities that
2023	operate a medical cannabis pharmacy.]
2024	(3) (a) Within the time period described in Subsection (3)(b), a county shall prepare
2025	and adopt a land use regulation, development agreement, or land use decision in accordance
2026	with this title and:
2027	(i) regarding a cannabis production establishment, Section 4-41a-406; or
2028	(ii) regarding a medical cannabis pharmacy, Section [26-61a-507] 4-41a-110.
2029	(b) A county shall take the action described in Subsection (3)(a):
2030	(i) before January 1, 2021, within 45 days after the day on which the county receives a
2031	petition for the action; and
2032	(ii) after January 1, 2021, in accordance with Subsection 17-27a-509.5(2).
2033	Section 30. Section 26-61-202 is amended to read:
2034	26-61-202. Duties.
2035	(1) The board shall review any available scientific research related to the human use of
2036	cannabis, a cannabinoid product, or an expanded cannabinoid product that:
2037	(a) was conducted under a study approved by an IRB;
2038	(b) was conducted or approved by the federal government; or
2039	(c) (i) was conducted in another country; and
2040	(ii) demonstrates, as determined by the board, a sufficient level of scientific reliability

2041 and significance to merit the board's review. 2042 (2) Based on the research described in Subsection (1), the board shall evaluate the 2043 safety and efficacy of cannabis, cannabinoid products, and expanded cannabinoid products. 2044 including: 2045 (a) medical conditions that respond to cannabis, cannabinoid products, and expanded 2046 cannabinoid products; 2047 (b) cannabis and cannabinoid dosage amounts and medical dosage forms; 2048 (c) interaction of cannabis, cannabinoid products, and expanded cannabinoid products 2049 with other treatments; and 2050 (d) contraindications, adverse reactions, and potential side effects from use of cannabis, 2051 cannabinoid products, and expanded cannabinoid products. 2052 (3) Based on the board's evaluation under Subsection (2), the board shall develop 2053 guidelines for treatment with cannabis, a cannabinoid product, and an expanded cannabinoid 2054 product that include: 2055 (a) a list of medical conditions, if any, that the board determines are appropriate for 2056 treatment with cannabis, a cannabis product, a cannabinoid product, or an expanded 2057 cannabinoid product; 2058 (b) a list of contraindications, side effects, and adverse reactions that are associated 2059 with use of cannabis, cannabinoid products, or expanded cannabinoid products; 2060 (c) a list of potential drug-drug interactions between medications that the United States 2061 Food and Drug Administration has approved and cannabis, cannabinoid products, and 2062 expanded cannabinoid products; and 2063 (d) any other guideline the board determines appropriate. 2064 (4) Based on the board's evaluation under Subsection (2), the board may provide 2065 recommendations to the Medical Cannabis Policy Advisory Board created in Section 2066 26-61a-801 regarding restrictions for a substance found in a medical cannabis product that: 2067 (a) is likely harmful to human health; or (b) is associated with a substance that is likely harmful to human health. 2068 2069 $\left[\frac{(4)}{(4)}\right]$ (5) The board shall submit the guidelines described in Subsection (3) to the 2070 director of the Division of Professional Licensing. 2071 $\left[\frac{(5)}{(5)}\right]$ (6) Guidelines that the board develops under this section may not limit the

2072	availability of cannabis, cannabinoid products, or expanded cannabinoid products permitted
2073	under Title 4, Chapter 41a, Cannabis Production Establishments, or Title 26, Chapter 61a, Utah
2074	Medical Cannabis Act.
2075	Section 31. Section 26-61a-102 is amended to read:
2076	26-61a-102. Definitions.
2077	As used in this chapter:
2078	(1) "Active tetrahydrocannabinol" means THC, any THC analog, and
2079	tetrahydrocannabinolic acid.
2080	(2) "Advisory board" means the Medical Cannabis Policy Advisory Board created in
2081	<u>Section 26-61a-117.</u>
2082	[(2)] (3) "Cannabis Research Review Board" means the Cannabis Research Review
2083	Board created in Section 26-61-201.
2084	[(3)] <u>(4)</u> "Cannabis" means marijuana.
2085	[(4)] (5) "Cannabis cultivation facility" means the same as that term is defined in
2086	Section 4-41a-102.
2087	[(5)] (6) "Cannabis processing facility" means the same as that term is defined in
2088	Section 4-41a-102.
2089	[(6)] (7) "Cannabis product" means a product that:
2090	(a) is intended for human use; and
2091	(b) contains cannabis or any tetrahydrocannabinol or THC analog in a total
2092	concentration of 0.3% or greater on a dry weight basis.
2093	[(7)] (8) "Cannabis production establishment" means the same as that term is defined
2094	in Section 4-41a-102.
2095	[(8)] (9) "Cannabis production establishment agent" means the same as that term is
2096	defined in Section 4-41a-102.
2097	[(9)] (10) "Cannabis production establishment agent registration card" means the same
2098	as that term is defined in Section 4-41a-102.
2099	[(10)] (11) "Community location" means a public or private elementary or secondary
2100	school, a church, a public library, a public playground, or a public park.
2101	[(11)] (12) "Conditional medical cannabis card" means an electronic medical cannabis
2102	card that the department issues in accordance with Subsection 26-61a-201(1)(b) to allow an

2103	applicant for a medical cannabis card to access medical cannabis during the department's
2104	review of the application.
2105	[(12)] (13) "Controlled substance database" means the controlled substance database
2106	created in Section 58-37f-201.
2107	[(13)] (14) "Department" means the Department of Health and Human Services.
2108	[(14)] (15) "Designated caregiver" means:
2109	(a) an individual:
2110	(i) whom an individual with a medical cannabis patient card or a medical cannabis
2111	guardian card designates as the patient's caregiver; and
2112	(ii) who registers with the department under Section 26-61a-202; or
2113	(b) (i) a facility that an individual designates as a designated caregiver in accordance
2114	with Subsection 26-61a-202(1)(b); or
2115	(ii) an assigned employee of the facility described in Subsection 26-61a-202(1)(b)(ii).
2116	[(15)] (16) "Directions of use" means recommended routes of administration for a
2117	medical cannabis treatment and suggested usage guidelines.
2118	[(16)] (17) "Dosing guidelines" means a quantity range and frequency of administration
2119	for a recommended treatment of medical cannabis.
2120	[(17)] (18) "Financial institution" means a bank, trust company, savings institution, or
2121	credit union, chartered and supervised under state or federal law.
2122	[(18)] (19) "Home delivery medical cannabis pharmacy" means a medical cannabis
2123	pharmacy that the department authorizes, as part of the pharmacy's license, to deliver medical
2124	cannabis shipments to a medical cannabis cardholder's home address to fulfill electronic orders
2125	that the state central patient portal facilitates.
2126	[(19)] (20) "Inventory control system" means the system described in Section
2127	4-41a-103.
2128	[(20)] (21) "Legal dosage limit" means an amount that:
2129	(a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the
2130	relevant recommending medical provider or the state central patient portal or pharmacy
2131	medical provider, in accordance with Subsection [26-61a-502(4) or (5)] 26-61a-404(5),
2132	recommends; and
2133	(b) may not exceed:

2134	(i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and
2135	(ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in total,
2136	greater than 20 grams of active tetrahydrocannabinol.
2137	[(21)] (22) "Legal use termination date" means a date on the label of a container of
2138	unprocessed cannabis flower:
2139	(a) that is 60 days after the date of purchase of the cannabis; and
2140	(b) after which, the cannabis is no longer in a medicinal dosage form outside of the
2141	primary residence of the relevant medical cannabis patient cardholder.
2142	[(22)] (23) "Limited medical provider" means an individual who:
2143	(a) meets the recommending qualifications; and
2144	(b) has no more than 15 patients with a valid medical cannabis patient card or
2145	provisional patient card as a result of the individual's recommendation, in accordance with
2146	Subsection 26-61a-106(1)(b).
2147	[(23)] (24) "Marijuana" means the same as that term is defined in Section 58-37-2.
2148	[(24)] (25) "Medical cannabis" means cannabis in a medicinal dosage form or a
2149	cannabis product in a medicinal dosage form.
2150	[(25)] (26) "Medical cannabis card" means a medical cannabis patient card, a medical
2151	cannabis guardian card, a medical cannabis caregiver card, or a conditional medical cannabis
2152	card.
2153	[(26)] (27) "Medical cannabis cardholder" means:
2154	(a) a holder of a medical cannabis card; or
2155	(b) a facility or assigned employee, described in Subsection[(14)(b),] (15)(b), only:
2156	(i) within the scope of the facility's or assigned employee's performance of the role of a
2157	medical cannabis patient cardholder's caregiver designation under Subsection
2158	26-61a-202(1)(b); and
2159	(ii) while in possession of documentation that establishes:
2160	(A) a caregiver designation described in Subsection 26-61a-202(1)(b);
2161	(B) the identity of the individual presenting the documentation; and
2162	(C) the relation of the individual presenting the documentation to the caregiver
2163	designation.
2164	[(27)] (28) "Medical cannabis caregiver card" means an electronic document that a

2165	cardholder may print or store on an electronic device or a physical card or document that:
2166	(a) the department issues to an individual whom a medical cannabis patient cardholder
2167	or a medical cannabis guardian cardholder designates as a designated caregiver; and
2168	(b) is connected to the electronic verification system.
2169	[(28)] (29) "Medical cannabis courier" means [a courier that:] the same as that term is
2170	defined in Section 4-41a-102.
2171	[(a) the department licenses in accordance with Section 26-61a-604; and]
2172	[(b) contracts with a home delivery medical cannabis pharmacy to deliver medical
2173	cannabis shipments to fulfill electronic orders that the state central patient portal facilitates.]
2174	[(29)] (30) "Medical cannabis courier agent" means [an individual who:] the same as
2175	that term is defined in Section 4-41a-102.
2176	[(a) is an employee of a medical cannabis courier; and]
2177	[(b) who holds a valid medical cannabis courier agent registration card.]
2178	[(30)] (31) (a) "Medical cannabis device" means a device that an individual uses to
2179	ingest or inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal
2180	dosage form.
2181	(b) "Medical cannabis device" does not include a device that:
2182	(i) facilitates cannabis combustion; or
2183	(ii) an individual uses to ingest substances other than cannabis.
2184	[(31)] (32) "Medical cannabis guardian card" means an electronic document that a
2185	cardholder may print or store on an electronic device or a physical card or document that:
2186	(a) the department issues to the parent or legal guardian of a minor with a qualifying
2187	condition; and
2188	(b) is connected to the electronic verification system.
2189	[(32)] (33) "Medical cannabis patient card" means an electronic document that a
2190	cardholder may print or store on an electronic device or a physical card or document that:
2191	(a) the department issues to an individual with a qualifying condition; and
2192	(b) is connected to the electronic verification system.
2193	[(33)] (34) "Medical cannabis pharmacy" means a person that:
2194	(a) (i) acquires or intends to acquire medical cannabis or a cannabis product in a
2195	medicinal dosage form from a cannabis processing facility or another medical cannabis

2196	pharmacy or a medical cannabis device; or
2197	(ii) possesses medical cannabis or a medical cannabis device; and
2198	(b) sells or intends to sell medical cannabis or a medical cannabis device to a medical
2199	cannabis cardholder.
2200	[(34)] (35) "Medical cannabis pharmacy agent" means an individual who:
2201	(a) is an employee of a medical cannabis pharmacy; and
2202	(b) who holds a valid medical cannabis pharmacy agent registration card.
2203	[(35)] (36) "Medical cannabis pharmacy agent registration card" means a registration
2204	card issued by the department that authorizes an individual to act as a medical cannabis
2205	pharmacy agent.
2206	[(36)] (37) "Medical cannabis shipment" means [a shipment of medical cannabis or a
2207	medical cannabis product that a home delivery medical cannabis pharmacy or a medical
2208	cannabis courier delivers to a medical cannabis cardholder's home address to fulfill an
2209	electronic medical cannabis order that the state central patient portal facilitates] the same as
2210	that term is defined in Section 4-41a-102.
2211	[(37)] (38) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a
2212	cannabis product in a medicinal dosage form, or a medical cannabis device.
2213	[(38)] (39) (a) "Medicinal dosage form" means:
2214	(i) for processed medical cannabis or a medical cannabis product, the following with a
2215	specific and consistent cannabinoid content:
2216	(A) a tablet;
2217	(B) a capsule;
2218	(C) a concentrated liquid or viscous oil;
2219	(D) a liquid suspension that, after December 1, 2022, does not exceed 30 ml;
2220	(E) a topical preparation;
2221	(F) a transdermal preparation;
2222	(G) a sublingual preparation;
2223	(H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or
2224	rectangular cuboid shape;
2225	(I) a resin or wax; or
2226	(J) an aerosol; or

2227	(ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:
2228	(A) contains cannabis flowers in a quantity that varies by no more than 10% from the
2229	stated weight at the time of packaging;
2230	(B) at any time the medical cannabis cardholder transports or possesses the container in
2231	public, is contained within an opaque bag or box that the medical cannabis pharmacy provides;
2232	and
2233	(C) is labeled with the container's content and weight, the date of purchase, the legal
2234	use termination date, and after December 31, 2020, a barcode that provides information
2235	connected to an inventory control system[; and].
2236	[(iii) a form measured in grams, milligrams, or milliliters.]
2237	(b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:
2238	(i) the medical cannabis cardholder has recently removed from the container described
2239	in Subsection [(38)] (39)(a)(ii) for use; and
2240	(ii) does not exceed the quantity described in Subsection $[(38)]$ (39)(a)(ii).
2241	(c) "Medicinal dosage form" does not include:
2242	(i) any unprocessed cannabis flower outside of the container described in Subsection
2243	[(38)] <u>(39)</u> (a)(ii), except as provided in Subsection [(38)(b);] <u>(39)(b);</u>
2244	(ii) $[any]$ unprocessed cannabis flower in a container described in Subsection $[(38)]$
2245	(39)(a)(ii) after the legal use termination date;
2246	(iii) a process of vaporizing and inhaling concentrated cannabis by placing the cannabis
2247	on a nail or other metal object that is heated by a flame, including a blowtorch; [or]
2248	(iv) a liquid suspension that is branded as a beverage[-]; or
2249	(v) a substance described in Subsection (39)(a)(i) or (ii) if the substance is not
2250	measured in grams, milligrams, or milliliters.
2251	[(39)] (40) "Nonresident patient" means an individual who:
2252	(a) is not a resident of Utah or has been a resident of Utah for less than 45 days;
2253	(b) has a currently valid medical cannabis card or the equivalent of a medical cannabis
2254	card under the laws of another state, district, territory, commonwealth, or insular possession of
2255	the United States; and
2256	(c) has been diagnosed with a qualifying condition as described in Section 26-61a-104.
2257	[(40)] (41) "Payment provider" means an entity that contracts with a cannabis

2258	production establishment or medical cannabis pharmacy to facilitate transfers of funds between
2259	the establishment or pharmacy and other businesses or individuals.
2260	[(41)] (42) "Pharmacy medical provider" means the medical provider required to be on
2261	site at a medical cannabis pharmacy under Section 26-61a-403.
2262	[(42)] (43) "Provisional patient card" means a card that:
2263	(a) the department issues to a minor with a qualifying condition for whom:
2264	(i) a recommending medical provider has recommended a medical cannabis treatment;
2265	and
2266	(ii) the department issues a medical cannabis guardian card to the minor's parent or
2267	legal guardian; and
2268	(b) is connected to the electronic verification system.
2269	[(43)] (44) "Qualified medical provider" means an individual:
2270	(a) who meets the recommending qualifications; and
2271	(b) whom the department registers to recommend treatment with cannabis in a
2272	medicinal dosage form under Section 26-61a-106.
2273	[(44)] (45) "Qualified Patient Enterprise Fund" means the enterprise fund created in
2274	Section 26-61a-109.
2275	[(45)] (46) "Qualifying condition" means a condition described in Section 26-61a-104.
2276	[(46)] (47) "Recommend" or "recommendation" means, for a recommending medical
2277	provider, the act of suggesting the use of medical cannabis treatment, which:
2278	(a) certifies the patient's eligibility for a medical cannabis card; and
2279	(b) may include, at the recommending medical provider's discretion, directions of use,
2280	with or without dosing guidelines.
2281	[(47)] (48) "Recommending medical provider" means a qualified medical provider or a
2282	limited medical provider.
2283	[(48)] (49) "Recommending qualifications" means that an individual:
2284	(a) (i) has the authority to write a prescription;
2285	(ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah
2286	Controlled Substances Act; and
2287	(iii) possesses the authority, in accordance with the individual's scope of practice, to
2288	prescribe a Schedule II controlled substance; and

(b) is licensed as:
(i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
(ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice
Act;
(iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,
Chapter 68, Utah Osteopathic Medical Practice Act; or
(iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.
[(49)] (50) "State central patient portal" means the website the department creates, in
accordance with Section 26-61a-601, to facilitate patient safety, education, and an electronic
medical cannabis order.
[(50)] (51) "State central patient portal medical provider" means a physician or
pharmacist that the department employs in relation to the state central patient portal to consult
with medical cannabis cardholders in accordance with Section 26-61a-602.
[(51)] (52) "State electronic verification system" means the system described in Section
26-61a-103.
[(52)] (53) "Tetrahydrocannabinol" or "THC" means a substance derived from
cannabis or a synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).
[(53)] (54) "THC analog" means the same as that term is defined in Section 4-41-102.
[(54)] (55) "Valid form of photo identification" means any of the following forms of
identification that is either current or has expired within the previous six months:
(a) a valid state-issued driver license or identification card;
(b) a valid United States federal-issued photo identification, including:
(i) a United States passport;
(ii) a United States passport card;
(iii) a United States military identification card; or
(iv) a permanent resident card or alien registration receipt card; or
(c) a passport that another country issued.
Section 32. Section 26-61a-103 is amended to read:
26-61a-103. Electronic verification system.
(1) The Department of Agriculture and Food, the department, the Department of Public
Safety, and the Division of Technology Services shall:

2320	(a) enter into a memorandum of understanding in order to determine the function and
2321	operation of the state electronic verification system in accordance with Subsection (2);
2322	(b) coordinate with the Division of Purchasing, under Title 63G, Chapter 6a, Utah
2323	Procurement Code, to develop a request for proposals for a third-party provider to develop and
2324	maintain the state electronic verification system in coordination with the Division of
2325	Technology Services; and
2326	(c) select a third-party provider who:
2327	(i) meets the requirements contained in the request for proposals issued under
2328	Subsection (1)(b); and
2329	(ii) may not have any commercial or ownership interest in a cannabis production
2330	establishment or a medical cannabis pharmacy.
2331	(2) The Department of Agriculture and Food, the department, the Department of Public
2332	Safety, and the Division of Technology Services shall ensure that[, on or before March 1,
2333	2020,] the state electronic verification system described in Subsection (1):
2334	(a) allows an individual to apply for a medical cannabis patient card or, if applicable, a
2335	medical cannabis guardian card, provided that the card may not become active until:
2336	(i) the relevant qualified medical provider completes the associated medical cannabis
2337	recommendation; or
2338	(ii) for a medical cannabis card related to a limited medical provider's
2339	recommendation, the medical cannabis pharmacy completes the recording described in
2340	Subsection (2)(d);
2341	(b) allows an individual to apply to renew a medical cannabis patient card or a medical
2342	cannabis guardian card in accordance with Section 26-61a-201;
2343	(c) allows a qualified medical provider, or an employee described in Subsection (3)
2344	acting on behalf of the qualified medical provider, to:
2345	(i) access dispensing and card status information regarding a patient:
2346	(A) with whom the qualified medical provider has a provider-patient relationship; and
2347	(B) for whom the qualified medical provider has recommended or is considering
2348	recommending a medical cannabis card;
2349	(ii) electronically recommend, after an initial face-to-face visit with a patient described
2350	in Subsection 26-61a-201(4)(a)(iii), treatment with cannabis in a medicinal dosage form or a

3rd Sub. (Cherry) H.B. 72

cannabis product in a medicinal dosage form and optionally recommend dosing guidelines; and

- (iii) electronically renew a recommendation to a medical cannabis patient cardholder ormedical cannabis guardian cardholder:
- (A) using telehealth services, for the qualified medical provider who originally
 recommended a medical cannabis treatment during a face-to-face visit with the patient; or
- (B) during a face-to-face visit with the patient, for a qualified medical provider who
 did not originally recommend the medical cannabis treatment during a face-to-face visit[-]
- (d) [beginning on the earlier of September 1, 2021, or the date on which the electronic
 verification system is functionally capable of facility medical cannabis pharmacy recording,]
 allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy agent, in
 accordance with Subsection [26-61a-501(10)(a),] 4-41a-1101(10)(a), to:
- (i) access the electronic verification system to review the history within the system of a
 patient with whom the provider or agent is interacting, limited to read-only access for medical
 cannabis pharmacy agents unless the medical cannabis pharmacy's pharmacist in charge
 authorizes add and edit access;
- (ii) record a patient's recommendation from a limited medical provider, including any
 directions of use, dosing guidelines, or caregiver indications from the limited medical provider;
 and

(iii) record a limited medical provider's renewal of the provider's previousrecommendation;

(e) connects with:

(i) an inventory control system that a medical cannabis pharmacy uses to track in real
time and archive purchases of any cannabis in a medicinal dosage form, cannabis product in a
medicinal dosage form, or a medical cannabis device, including:

- 2375 (A) the time and date of each purchase;
- (B) the quantity and type of cannabis, cannabis product, or medical cannabis devicepurchased;
- (C) any cannabis production establishment, any medical cannabis pharmacy, or any
 medical cannabis courier associated with the cannabis, cannabis product, or medical cannabis
 device; and
- 2381 (D) the personally identifiable information of the medical cannabis cardholder who

2382	made the purchase; and
2383	(ii) any commercially available inventory control system that a cannabis production
2384	establishment utilizes in accordance with Section 4-41a-103 to use data that the Department of
2385	Agriculture and Food requires by rule, in accordance with Title 63G, Chapter 3, Utah
2386	Administrative Rulemaking Act, from the inventory tracking system that a licensee uses to
2387	track and confirm compliance;
2388	(f) provides access to:
2389	(i) the department to the extent necessary to carry out the department's functions and
2390	responsibilities under this chapter;
2391	(ii) the Department of Agriculture and Food to the extent necessary to carry out the
2392	functions and responsibilities of the Department of Agriculture and Food under Title 4, Chapter
2393	41a, Cannabis Production Establishments; and
2394	(iii) the Division of Professional Licensing to the extent necessary to carry out the
2395	functions and responsibilities related to the participation of the following in the
2396	recommendation and dispensing of medical cannabis:
2397	(A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
2398	(B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;
2399	(C) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
2400	Practice Act;
2401	(D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
2402	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
2403	(E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant
2404	Act;
2405	(g) provides access to and interaction with the state central patient portal;
2406	(h) communicates dispensing information from a record that a medical cannabis
2407	pharmacy submits to the state electronic verification system under Subsection
2408	$\left[\frac{26-61a-502(6)(a)(ii)}{4-41a-1102(3)(a)(ii)}\right]$ to the controlled substance database;
2409	(i) provides access to state or local law enforcement:
2410	(i) during a law enforcement encounter, without a warrant, using the individual's driver
2411	license or state ID, only for the purpose of determining if the individual subject to the law
2412	enforcement encounter has a valid medical cannabis card; or

2413	(ii) after obtaining a warrant; and
2414	(j) creates a record each time a person accesses the system that identifies the person
2415	who accesses the system and the individual whose records the person accesses.
2416	(3) (a) [Beginning on the earlier of September 1, 2021, or the date on which the
2417	electronic verification system is functionally capable of allowing employee access under this
2418	Subsection (3), an] An employee of a qualified medical provider may access the electronic
2419	verification system for a purpose described in Subsection (2)(c) on behalf of the qualified
2420	medical provider if:
2421	(i) the qualified medical provider has designated the employee as an individual
2422	authorized to access the electronic verification system on behalf of the qualified medical
2423	provider;
2424	(ii) the qualified medical provider provides written notice to the department of the
2425	employee's identity and the designation described in Subsection (3)(a)(i); and
2426	(iii) the department grants to the employee access to the electronic verification system.
2427	(b) An employee of a business that employs a qualified medical provider may access
2428	the electronic verification system for a purpose described in Subsection (2)(c) on behalf of the
2429	qualified medical provider if:
2430	(i) the qualified medical provider has designated the employee as an individual
2431	authorized to access the electronic verification system on behalf of the qualified medical
2432	provider;
2433	(ii) the qualified medical provider and the employing business jointly provide written
2434	notice to the department of the employee's identity and the designation described in Subsection
2435	(3)(b)(i); and
2436	(iii) the department grants to the employee access to the electronic verification system.
2437	(4) (a) As used in this Subsection (4), "prescribing provider" means:
2438	(i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;
2439	(ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse
2440	Practice Act;
2441	(iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or
2442	Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or
2443	(iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician

02-10-23 4:58 PM

2444 Assistant Act. 2445 (b) Beginning on the earlier of September 1, 2021, or the date on which the electronic 2446 verification system is functionally capable of allowing provider access under this Subsection 2447 (4), a prescribing provider may access information in the electronic verification system 2448 regarding a patient the prescribing provider treats. 2449 (5) The department may release limited data that the system collects for the purpose of: 2450 (a) conducting medical and other department approved research; 2451 (b) providing the report required by Section 26-61a-703; and 2452 (c) other official department purposes. 2453 (6) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah 2454 Administrative Rulemaking Act, to establish: 2455 (a) the limitations on access to the data in the state electronic verification system as 2456 described in this section: and 2457 (b) standards and procedures to ensure accurate identification of an individual 2458 requesting information or receiving information in this section. 2459 (7) (a) Any person who knowingly and intentionally releases any information in the 2460 state electronic verification system in violation of this section is guilty of a third degree felony. 2461 (b) Any person who negligently or recklessly releases any information in the state 2462 electronic verification system in violation of this section is guilty of a class C misdemeanor. 2463 (8) (a) Any person who obtains or attempts to obtain information from the state 2464 electronic verification system by misrepresentation or fraud is guilty of a third degree felony. 2465 (b) Any person who obtains or attempts to obtain information from the state electronic 2466 verification system for a purpose other than a purpose this chapter authorizes is guilty of a third 2467 degree felony. 2468 (9) (a) Except as provided in Subsection (9)(e), a person may not knowingly and 2469 intentionally use, release, publish, or otherwise make available to any other person information 2470 obtained from the state electronic verification system for any purpose other than a purpose 2471 specified in this section. 2472 (b) Each separate violation of this Subsection (9) is: 2473 (i) a third degree felony; and 2474 (ii) subject to a civil penalty not to exceed \$5,000.

2475	(c) The department shall determine a civil violation of this Subsection (9) in
2476	accordance with Title 63G, Chapter 4, Administrative Procedures Act.
2477	(d) Civil penalties assessed under this Subsection (9) shall be deposited into the
2478	General Fund.
2479	(e) This Subsection (9) does not prohibit a person who obtains information from the
2480	state electronic verification system under Subsection (2)(a), (c), or (f) from:
2481	(i) including the information in the person's medical chart or file for access by a person
2482	authorized to review the medical chart or file;
2483	(ii) providing the information to a person in accordance with the requirements of the
2484	Health Insurance Portability and Accountability Act of 1996; or
2485	(iii) discussing or sharing that information about the patient with the patient.
2486	Section 33. Section 26-61a-105 is amended to read:
2487	26-61a-105. Compassionate Use Board.
2488	(1) (a) The department shall establish a Compassionate Use Board consisting of:
2489	(i) seven qualified medical providers that the executive director appoints and the
2490	Senate confirms:
2491	(A) who are knowledgeable about the medicinal use of cannabis;
2492	(B) who are physicians licensed under Title 58, Chapter 67, Utah Medical Practice Act,
2493	or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and
2494	(C) whom the appropriate board certifies in the specialty of neurology, pain medicine
2495	and pain management, medical oncology, psychiatry, infectious disease, internal medicine,
2496	pediatrics, or gastroenterology; and
2497	(ii) as a nonvoting member and the chair of the Compassionate Use Board, the
2498	executive director or the director's designee.
2499	(b) In appointing the seven qualified medical providers described in Subsection (1)(a),
2500	the executive director shall ensure that at least two have a board certification in pediatrics.
2501	(2) (a) Of the members of the Compassionate Use Board that the executive director
2502	first appoints:
2503	(i) three shall serve an initial term of two years; and
2504	(ii) the remaining members shall serve an initial term of four years.
2505	(b) After an initial term described in Subsection (2)(a) expires:

2506	(i) each term is four years; and
2507	(ii) each board member is eligible for reappointment.
2508	(c) A member of the Compassionate Use Board may serve until a successor is
2509	appointed.
2510	(3) Four members constitute a quorum of the Compassionate Use Board.
2511	(4) A member of the Compassionate Use Board may receive:
2512	(a) notwithstanding Section 63A-3-106, compensation or benefits for the member's
2513	service; and
2514	(b) travel expenses in accordance with Section 63A-3-107 and rules made by the
2515	Division of Finance in accordance with Section 63A-3-107.
2516	(5) The Compassionate Use Board shall:
2517	(a) review and recommend for department approval a petition to the board regarding an
2518	individual described in Subsection 26-61a-201(2)(a), a minor described in Subsection
2519	26-61a-201(2)(c), or an individual who is not otherwise qualified to receive a medical cannabis
2520	card to obtain a medical cannabis card for compassionate use, for the standard or a reduced
2521	period of validity, if:
2522	(i) for an individual who is not otherwise qualified to receive a medical cannabis card,
2523	the individual's qualified medical provider is actively treating the individual for an intractable
2524	condition that:
2525	(A) substantially impairs the individual's quality of life; and
2526	(B) has not, in the qualified medical provider's professional opinion, adequately
2527	responded to conventional treatments;
2528	(ii) the qualified medical provider:
2529	(A) recommends that the individual or minor be allowed to use medical cannabis; and
2530	(B) provides a letter, relevant treatment history, and notes or copies of progress notes
2531	describing relevant treatment history including rationale for considering the use of medical
2532	cannabis; and
2533	(iii) the Compassionate Use Board determines that:
2534	(A) the recommendation of the individual's qualified medical provider is justified; and
2535	(B) based on available information, it may be in the best interests of the individual to
2536	allow the use of medical cannabis;

2537	(b) review and approve or deny the use of a medical cannabis device for an individual
2538	described in Subsection 26-61a-201(2)(a)(i)(B) or a minor described in Subsection
2539	26-61a-201(2)(c) if the individual's or minor's qualified medical provider recommends that the
2540	individual or minor be allowed to use a medical cannabis device to vaporize the medical
2541	cannabis treatment;
2542	(c) unless no petitions are pending:
2543	(i) meet to receive or review compassionate use petitions at least quarterly; and
2544	(ii) if there are more petitions than the board can receive or review during the board's
2545	regular schedule, as often as necessary;
2546	(d) except as provided in Subsection (6), complete a review of each petition and
2547	recommend to the department approval or denial of the applicant for qualification for a medical
2548	cannabis card within 90 days after the day on which the board received the petition;
2549	(e) consult with the department regarding the criteria described in Subsection (6); and
2550	(f) report, before November 1 of each year, to the Health and Human Services Interim
2551	Committee:
2552	(i) the number of compassionate use recommendations the board issued during the past
2553	year; and
2554	(ii) the types of conditions for which the board recommended compassionate use.
2555	(6) The department shall make rules, in consultation with the Compassionate Use
2556	Board and in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to
2557	establish a process and criteria for a petition to the board to automatically qualify for expedited
2558	final review and approval or denial by the department in cases where, in the determination of
2559	the department and the board:
2560	(a) time is of the essence;
2561	(b) engaging the full review process would be unreasonable in light of the petitioner's
2562	physical condition; and
2563	(c) sufficient factors are present regarding the petitioner's safety.
2564	(7) (a) (i) The department shall review:
2565	(A) any compassionate use for which the Compassionate Use Board recommends
2566	approval under Subsection (5)(d) to determine whether the board properly exercised the board's
2567	discretion under this section; and

2568	(B) any expedited petitions the department receives under the process described in
2569	Subsection (6).
2570	(ii) If the department determines that the Compassionate Use Board properly exercised
2571	the board's discretion in recommending approval under Subsection (5)(d) or that the expedited
2572	petition merits approval based on the criteria established in accordance with Subsection (6), the
2573	department shall:
2574	(A) issue the relevant medical cannabis card; and
2575	(B) provide for the renewal of the medical cannabis card in accordance with the
2576	recommendation of the qualified medical provider described in Subsection (5)(a).
2577	(b) (i) If the Compassionate Use Board recommends denial under Subsection (5)(d),
2578	the individual seeking to obtain a medical cannabis card may petition the department to review
2579	the board's decision.
2580	(ii) If the department determines that the Compassionate Use Board's recommendation
2581	for denial under Subsection (5)(d) was arbitrary or capricious:
2582	(A) the department shall notify the Compassionate Use Board of the department's
2583	determination; and
2584	(B) the board shall reconsider the Compassionate Use Board's refusal to recommend
2585	approval under this section.
2586	(c) In reviewing the Compassionate Use Board's recommendation for approval or
2587	denial under Subsection (5)(d) in accordance with this Subsection (7), the department shall
2588	presume the board properly exercised the board's discretion unless the department determines
2589	that the board's recommendation was arbitrary or capricious.
2590	(8) Any individually identifiable health information contained in a petition that the
2591	Compassionate Use Board or department receives under this section is a protected record in
2592	accordance with Title 63G, Chapter 2, Government Records Access and Management Act.
2593	(9) The Compassionate Use Board shall annually report the board's activity to the
2594	Cannabis Research Review Board and the advisory board.
2595	Section 34. Section 26-61a-106 is amended to read:
2596	26-61a-106. Qualified medical provider registration Continuing education
2597	Treatment recommendation Limited medical provider.
2598	(1) (a) (i) Except as provided in Subsection (1)(b), an individual may not recommend a

2599 medical cannabis treatment unless the department registers the individual as a qualified
2600 medical provider in accordance with this section.
2601 (ii) Notwithstanding Subsection (1)(a)(i), a qualified medical provider who is podiatrist

2602 licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act, may not recommend a
2603 medical cannabis treatment except within the course and scope of a practice of podiatry, as that
2604 term is defined in Section 58-5a-102.

(b) Beginning on the earlier of September 1, 2021, or the date on which the department
gives notice that the electronic verification system is functionally capable as described in
Subsection 26-61a-103(2)(d), an individual who meets the recommending qualifications may
recommend a medical cannabis treatment as a limited medical provider without registering
under Subsection (1)(a) if:

(i) the individual recommends the use of medical cannabis to the patient through anorder described in Subsection (1)(c) after:

2612 (A) a face-to-face visit for an initial recommendation or the renewal of a
2613 recommendation for a patient for whom the limited medical provider did not make the patient's
2614 original recommendation; or

2615 (B) a visit using telehealth services for a renewal of a recommendation for a patient for 2616 whom the limited medical provider made the patient's original recommendation; and

(ii) the individual's recommendation or renewal would not cause the total number of
the individual's patients who have a valid medical cannabis patient card or provisional patient
card resulting from the individual's recommendation to exceed 15.

(c) The individual described in Subsection (1)(b) shall communicate the individual's
 recommendation through an order for the medical cannabis pharmacy to record the individual's
 recommendation or renewal in the state electronic verification system under the individual's
 recommendation that:

(i) (A) that the individual or the individual's employee sends electronically to a medicalcannabis pharmacy; or

2626 (B) that the individual gives to the patient in writing for the patient to deliver to a 2627 medical cannabis pharmacy; and

2628 (ii) may include:

2629 (A) directions of use or dosing guidelines; and

2630	(B) an indication of a need for a caregiver in accordance with Subsection
2631	26-61a-201(3)(c).
2632	(d) If the limited medical provider gives the patient a written recommendation to
2633	deliver to a medical cannabis pharmacy under Subsection (1)(c)(i)(B), the limited medical
2634	provider shall ensure that the document includes all of the information that is included on a
2635	prescription the provider would issue for a controlled substance, including:
2636	(i) the date of issuance;
2637	(ii) the provider's name, address and contact information, controlled substance license
2638	information, and signature; and
2639	(iii) the patient's name, address and contact information, age, and diagnosed qualifying
2640	condition.
2641	(e) In considering making a recommendation as a limited medical provider, an
2642	individual may consult information that the department makes available on the department's
2643	website for recommending providers.
2644	(2) (a) The department shall, within 15 days after the day on which the department
2645	receives an application from an individual, register and issue a qualified medical provider
2646	registration card to the individual if the individual:
2647	(i) provides to the department the individual's name and address;
2648	(ii) provides to the department a report detailing the individual's completion of the
2649	applicable continuing education requirement described in Subsection (3);
2650	(iii) provides to the department evidence that the individual meets the recommending
2651	qualifications;
2652	(iv) for an applicant on or after November 1, 2021, provides to the department the
2653	information described in Subsection (10)(a); and
2654	(v) pays the department a fee in an amount that:
2655	(A) the department sets, in accordance with Section 63J-1-504; and
2656	(B) does not exceed \$300 for an initial registration.
2657	(b) The department may not register an individual as a qualified medical provider if the
2658	individual is:
2659	(i) a pharmacy medical provider; or
2660	(ii) an owner, officer, director, board member, employee, or agent of a cannabis

2661	production establishment, a medical cannabis pharmacy, or a medical cannabis courier.
2662	(3) (a) An individual shall complete the continuing education described in this
2663	Subsection (3) in the following amounts:
2664	(i) for an individual as a condition precedent to registration, four hours; and
2665	(ii) for a qualified medical provider as a condition precedent to renewal, four hours
2666	every two years.
2667	(b) In accordance with Subsection (3)(a), a qualified medical provider shall:
2668	(i) complete continuing education:
2669	(A) regarding the topics described in Subsection (3)(d); and
2670	(B) offered by the department under Subsection (3)(c) or an accredited or approved
2671	continuing education provider that the department recognizes as offering continuing education
2672	appropriate for the recommendation of cannabis to patients; and
2673	(ii) make a continuing education report to the department in accordance with a process
2674	that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah
2675	Administrative Rulemaking Act, and in collaboration with the Division of Professional
2676	Licensing and:
2677	(A) for a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing
2678	Act, the Podiatric Physician Board;
2679	(B) for an advanced practice registered nurse licensed under Title 58, Chapter 31b,
2680	Nurse Practice Act, the Board of Nursing;
2681	(C) for a qualified medical provider licensed under Title 58, Chapter 67, Utah Medical
2682	Practice Act, the Physicians Licensing Board;
2683	(D) for a qualified medical provider licensed under Title 58, Chapter 68, Utah
2684	Osteopathic Medical Practice Act, the Osteopathic Physician and Surgeon's Licensing Board;
2685	and
2686	(E) for a physician assistant licensed under Title 58, Chapter 70a, Utah Physician
2687	Assistant Act, the Physician Assistant Licensing Board.
2688	(c) The department may, in consultation with the Division of Professional Licensing,
2689	develop the continuing education described in this Subsection (3).
2690	(d) The continuing education described in this Subsection (3) may discuss:
2691	(i) the provisions of this chapter;

02-10-23 4:58 PM

2692 (ii) general information about medical cannabis under federal and state law;

(iii) the latest scientific research on the endocannabinoid system and medical cannabis,including risks and benefits;

2695 (iv) recommendations for medical cannabis as it relates to the continuing care of a 2696 patient in pain management, risk management, potential addiction, or palliative care; and

(v) best practices for recommending the form and dosage of medical cannabis productsbased on the qualifying condition underlying a medical cannabis recommendation.

(4) (a) Except as provided in Subsection (4)(b), a qualified medical provider may not
recommend a medical cannabis treatment to more than 275 of the qualified medical provider's
patients at the same time, as determined by the number of medical cannabis cards under the
qualified medical provider's name in the state electronic verification system.

(b) A qualified medical provider may recommend a medical cannabis treatment to up
to 600 of the qualified medical provider's patients at any given time, as determined by the
number of medical cannabis cards under the qualified medical provider's name in the state
electronic verification system, if:

(i) the appropriate American medical board has certified the qualified medical provider
in the specialty of anesthesiology, gastroenterology, neurology, oncology, pain, hospice and
palliative medicine, physical medicine and rehabilitation, rheumatology, endocrinology, or
psychiatry; or

(ii) a licensed business employs or contracts with the qualified medical provider for thespecific purpose of providing hospice and palliative care.

(5) A recommending medical provider may recommend medical cannabis to an
individual under this chapter only in the course of a provider-patient relationship after the
recommending medical provider has completed and documented in the patient's medical record
a thorough assessment of the patient's condition and medical history based on the appropriate
standard of care for the patient's condition.

(6) (a) Except as provided in Subsection (6)(b), [an individual] a person may not
advertise that the [individual] person or the person's employee recommends a medical cannabis
treatment.

(b) Notwithstanding Subsection (6)(a) and [subject to] Section [26-61a-116]
 4-41a-109, a qualified medical provider or clinic or office that employs a qualified medical

2723	provider may advertise the following:
2724	(i) a green cross;
2725	(ii) the provider's or clinic's name and logo;
2726	(iii) a qualifying condition that the individual treats;
2727	(iv) that the individual is registered as a qualified medical provider and recommends
2728	medical cannabis; or
2729	(v) a scientific study regarding medical cannabis use.
2730	(7) (a) A qualified medical provider registration card expires two years after the day on
2731	which the department issues the card.
2732	(b) The department shall renew a qualified medical provider's registration card if the
2733	provider:
2734	(i) applies for renewal;
2735	(ii) is eligible for a qualified medical provider registration card under this section,
2736	including maintaining an unrestricted license under the recommending qualifications;
2737	(iii) certifies to the department in a renewal application that the information in
2738	Subsection (2)(a) is accurate or updates the information;
2739	(iv) submits a report detailing the completion of the continuing education requirement
2740	described in Subsection (3); and
2741	(v) pays the department a fee in an amount that:
2742	(A) the department sets, in accordance with Section 63J-1-504; and
2743	(B) does not exceed \$50 for a registration renewal.
2744	(8) The department may revoke the registration of a qualified medical provider who
2745	fails to maintain compliance with the requirements of this section.
2746	(9) A recommending medical provider may not receive any compensation or benefit for
2747	the qualified medical provider's medical cannabis treatment recommendation from:
2748	(a) a cannabis production establishment or an owner, officer, director, board member,
2749	employee, or agent of a cannabis production establishment;
2750	(b) a medical cannabis pharmacy or an owner, officer, director, board member,
2751	employee, or agent of a medical cannabis pharmacy; or
2752	(c) a recommending medical provider or pharmacy medical provider.
2753	(10) (a) On or before November 1, 2021, a qualified medical provider shall report to

2754	the department, in a manner designated by the department:
2755	(i) if applicable, that the qualified medical provider or the entity that employs the
2756	qualified medical provider represents online or on printed material that the qualified medical
2757	provider is a qualified medical provider or offers medical cannabis recommendations to
2758	patients; and
2759	(ii) the fee amount that the qualified medical provider or the entity that employs the
2760	qualified medical provider charges a patient for a medical cannabis recommendation, either as
2761	an actual cash rate or, if the provider or entity bills insurance, an average cash rate.
2762	(b) The department shall:
2763	(i) ensure that the following information related to qualified medical providers and
2764	entities described in Subsection (10)(a)(i) is available on the department's website or on the
2765	health care price transparency tool under Subsection (10)(b)(ii):
2766	(A) the name of the qualified medical provider and, if applicable, the name of the
2767	entity that employs the qualified medical provider;
2768	(B) the address of the qualified medical provider's office or, if applicable, the entity
2769	that employs the qualified medical provider; and
2770	(C) the fee amount described in Subsection (10)(a)(ii); and
2771	(ii) share data collected under this Subsection (10) with the state auditor for use in the
2772	health care price transparency tool described in Section 67-3-11.
2773	Section 35. Section 26-61a-109 is amended to read:
2774	26-61a-109. Qualified Patient Enterprise Fund Creation Revenue neutrality
2775	Uniform fee.
2776	(1) There is created an enterprise fund known as the "Qualified Patient Enterprise
2777	Fund."
2778	(2) The fund created in this section is funded from:
2779	(a) money the department deposits into the fund under this chapter;
2780	(b) appropriations the Legislature makes to the fund; and
2781	(c) the interest described in Subsection (3).
2782	(3) Interest earned on the fund shall be deposited into the fund.
2783	(4) The department may only use money in the fund to fund the department's
2784	responsibilities under this chapter.

2785	(5) The department shall set fees authorized under this chapter in amounts that the
2786	department anticipates are necessary, in total, to cover the department's cost to implement this
2787	chapter.
2788	(6) The department may impose a uniform fee on each medical cannabis transaction in
2789	a medical cannabis pharmacy in an amount that, subject to Subsection (5), the department sets
2790	in accordance with Section 63J-1-504.
2791	Section 36. Section 26-61a-201 is amended to read:
2792	26-61a-201. Medical cannabis patient card Medical cannabis guardian card
2793	Conditional medical cannabis card Application Fees Studies.
2794	(1) (a) The department shall, within 15 days after the day on which an individual who
2795	satisfies the eligibility criteria in this section or Section 26-61a-202 submits an application in
2796	accordance with this section or Section 26-61a-202:
2797	(i) issue a medical cannabis patient card to an individual described in Subsection
2798	(2)(a);
2799	(ii) issue a medical cannabis guardian card to an individual described in Subsection
2800	(2)(b);
2801	(iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
2802	(iv) issue a medical cannabis caregiver card to an individual described in Subsection
2803	26-61a-202(4).
2804	(b) (i) Beginning on the earlier of September 1, 2021, or the date on which the
2805	electronic verification system is functionally capable of facilitating a conditional medical
2806	cannabis card under this Subsection (1)(b), upon the entry of a recommending medical
2807	provider's medical cannabis recommendation for a patient in the state electronic verification
2808	system, either by the provider or the provider's employee or by a medical cannabis pharmacy
2809	medical provider or medical cannabis pharmacy in accordance with Subsection
2810	$\left[\frac{26-61a-501(10)(a)}{4-41a-1101(10)(a)}\right]$, the department shall issue to the patient an electronic
2811	conditional medical cannabis card, in accordance with this Subsection (1)(b).
2812	(ii) A conditional medical cannabis card is valid for the lesser of:
2813	(A) 60 days; or
2814	(B) the day on which the department completes the department's review and issues a
2815	medical cannabis card under Subsection (1)(a), denies the patient's medical cannabis card

2816	application, or revokes the conditional medical cannabis card under Subsection (8).
2817	(iii) The department may issue a conditional medical cannabis card to an individual
2818	applying for a medical cannabis patient card for which approval of the Compassionate Use
2819	Board is not required.
2820	(iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and
2821	obligations under law applicable to a holder of the medical cannabis card for which the
2822	individual applies and for which the department issues the conditional medical cannabis card.
2823	(2) (a) An individual is eligible for a medical cannabis patient card if:
2824	(i) (A) the individual is at least 21 years old; or
2825	(B) the individual is 18, 19, or 20 years old, the individual petitions the Compassionate
2826	Use Board under Section 26-61a-105, and the Compassionate Use Board recommends
2827	department approval of the petition;
2828	(ii) the individual is a Utah resident;
2829	(iii) the individual's recommending medical provider recommends treatment with
2830	medical cannabis in accordance with Subsection (4);
2831	(iv) the individual signs an acknowledgment stating that the individual received the
2832	information described in Subsection (9); and
2833	(v) the individual pays to the department a fee in an amount that, subject to Subsection
2834	26-61a-109(5), the department sets in accordance with Section 63J-1-504.
2835	(b) (i) An individual is eligible for a medical cannabis guardian card if the individual:
2836	(A) is at least 18 years old;
2837	(B) is a Utah resident;
2838	(C) is the parent or legal guardian of a minor for whom the minor's qualified medical
2839	provider recommends a medical cannabis treatment, the individual petitions the Compassionate
2840	Use Board under Section 26-61a-105, and the Compassionate Use Board recommends
2841	department approval of the petition;
2842	(D) the individual signs an acknowledgment stating that the individual received the
2843	information described in Subsection (9);
2844	(E) pays to the department a fee in an amount that, subject to Subsection
2845	26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the
2846	criminal background check described in Section 26-61a-203; and

3rd Sub. (Cherry) H.B. 72

2847 (F) the individual has not been convicted of a misdemeanor or felony drug distribution 2848 offense under either state or federal law, unless the individual completed any imposed sentence 2849 six months or more before the day on which the individual applies for a medical cannabis 2850 guardian card. 2851 (ii) The department shall notify the Department of Public Safety of each individual that 2852 the department registers for a medical cannabis guardian card. 2853 (c) (i) A minor is eligible for a provisional patient card if: 2854 (A) the minor has a qualifying condition: 2855 (B) the minor's qualified medical provider recommends a medical cannabis treatment 2856 to address the minor's qualifying condition; 2857 (C) one of the minor's parents or legal guardians petitions the Compassionate Use 2858 Board under Section 26-61a-105, and the Compassionate Use Board recommends department 2859 approval of the petition; and 2860 (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card 2861 under Subsection (2)(b) or designates a caregiver under Subsection (2)(d) who is eligible for a 2862 medical cannabis caregiver card under Section 26-61a-202. 2863 (ii) The department shall automatically issue a provisional patient card to the minor 2864 described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis 2865 guardian card to the minor's parent or legal guardian. 2866 (d) Beginning on the earlier of September 1, 2021, or the date on which the electronic verification system is functionally capable of servicing the designation, if the parent or legal 2867 2868 guardian of a minor described in Subsections (2)(c)(i)(A) through (C) does not qualify for a 2869 medical cannabis guardian card under Subsection (2)(b), the parent or legal guardian may 2870 designate up to two caregivers in accordance with Subsection 26-61a-202(1)(c) to ensure that 2871 the minor has adequate and safe access to the recommended medical cannabis treatment. 2872 (3) (a) An individual who is eligible for a medical cannabis card described in 2873 Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the 2874 department: 2875 (i) through an electronic application connected to the state electronic verification 2876 system; 2877 (ii) with the recommending medical provider; and

02-10-23 4:58 PM

2878 (iii) with information including: 2879 (A) the applicant's name, gender, age, and address; 2880 (B) the number of the applicant's valid form of photo identification: 2881 (C) for a medical cannabis guardian card, the name, gender, and age of the minor 2882 receiving a medical cannabis treatment under the cardholder's medical cannabis guardian card; 2883 and 2884 (D) for a provisional patient card, the name of the minor's parent or legal guardian who 2885 holds the associated medical cannabis guardian card. 2886 (b) The department shall ensure that a medical cannabis card the department issues under this section contains the information described in Subsection (3)(a)(iii). 2887 2888 (c) (i) If a recommending medical provider determines that, because of age, illness, or 2889 disability, a medical cannabis patient cardholder requires assistance in administering the 2890 medical cannabis treatment that the recommending medical provider recommends, the recommending medical provider may indicate the cardholder's need in the state electronic 2891 2892 verification system, either directly or, for a limited medical provider, through the order 2893 described in Subsections 26-61a-106(1)(c) and (d). 2894 (ii) If a recommending medical provider makes the indication described in Subsection 2895 (3)(c)(i):2896 (A) the department shall add a label to the relevant medical cannabis patient card 2897 indicating the cardholder's need for assistance; 2898 (B) any adult who is 18 years old or older and who is physically present with the 2899 cardholder at the time the cardholder needs to use the recommended medical cannabis 2900 treatment may handle the medical cannabis treatment and any associated medical cannabis 2901 device as needed to assist the cardholder in administering the recommended medical cannabis 2902 treatment; and 2903 (C) an individual of any age who is physically present with the cardholder in the event 2904 of an emergency medical condition, as that term is defined in Section 31A-1-301, may handle 2905 the medical cannabis treatment and any associated medical cannabis device as needed to assist 2906 the cardholder in administering the recommended medical cannabis treatment.

2907 2908 (iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may not:(A) ingest or inhale medical cannabis;

3rd Sub. (Cherry) H.B. 72

2909 (B) possess, transport, or handle medical cannabis or a medical cannabis device outside 2910 of the immediate area where the cardholder is present or with an intent other than to provide 2911 assistance to the cardholder; or 2912 (C) possess, transport, or handle medical cannabis or a medical cannabis device when 2913 the cardholder is not in the process of being dosed with medical cannabis. 2914 (4) To recommend a medical cannabis treatment to a patient or to renew a 2915 recommendation, a recommending medical provider shall: 2916 (a) before recommending or renewing a recommendation for medical cannabis in a 2917 medicinal dosage form or a cannabis product in a medicinal dosage form: 2918 (i) verify the patient's and, for a minor patient, the minor patient's parent or legal 2919 guardian's valid form of identification described in Subsection (3)(a); 2920 (ii) review any record related to the patient and, for a minor patient, the patient's parent 2921 or legal guardian in: 2922 (A) for a qualified medical provider, the state electronic verification system; and 2923 (B) the controlled substance database created in Section 58-37f-201; and 2924 (iii) consider the recommendation in light of the patient's qualifying condition, history 2925 of substance use or opioid use disorder, and history of medical cannabis and controlled 2926 substance use during an initial face-to-face visit with the patient: and 2927 (b) state in the recommending medical provider's recommendation that the patient: 2928 (i) suffers from a qualifying condition, including the type of qualifying condition; and 2929 (ii) may benefit from treatment with cannabis in a medicinal dosage form or a cannabis 2930 product in a medicinal dosage form. 2931 (5) (a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the 2932 department issues under this section is valid for the lesser of: 2933 (i) an amount of time that the recommending medical provider determines; or 2934 (ii) (A) six months for the first issuance, and, except as provided in Subsection 2935 (5)(a)(ii)(B), for a renewal; or 2936 (B) for a renewal, one year if, after at least one year following the issuance of the 2937 original medical cannabis card, the recommending medical provider determines that the patient 2938 has been stabilized on the medical cannabis treatment and a one-year renewal period is 2939 justified.

2940	(b) (i) A medical cannabis card that the department issues in relation to a terminal
2941	illness described in Section 26-61a-104 expires after one year.
2942	(ii) The recommending medical provider may revoke a recommendation that the
2943	provider made in relation to a terminal illness described in Section 26-61a-104 if the medical
2944	cannabis cardholder no longer has the terminal illness.
2945	(c) A medical cannabis card that the department issues in relation to acute pain as
2946	described in Section 26-61a-104 expires 30 days after the day on which the department first
2947	issues a conditional or full medical cannabis card.
2948	(6) (a) A medical cannabis patient card or a medical cannabis guardian card is
2949	renewable if:
2950	(i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or
2951	(b); or
2952	(ii) the cardholder received the medical cannabis card through the recommendation of
2953	the Compassionate Use Board under Section 26-61a-105.
2954	(b) The recommending medical provider who made the underlying recommendation
2955	for the card of a cardholder described in Subsection (6)(a) may renew the cardholder's card
2956	through phone or video conference with the cardholder, at the recommending medical
2957	provider's discretion.
2958	(c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b)
2959	shall pay to the department a renewal fee in an amount that:
2960	(i) subject to Subsection 26-61a-109(5), the department sets in accordance with Section
2961	63J-1-504; and
2962	(ii) may not exceed the cost of the relatively lower administrative burden of renewal in
2963	comparison to the original application process.
2964	(d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
2965	patient card renews automatically at the time the minor's parent or legal guardian renews the
2966	parent or legal guardian's associated medical cannabis guardian card.
2967	(7) (a) A cardholder under this section shall carry the cardholder's valid medical
2968	cannabis card with the patient's name.
2969	(b) (i) A medical cannabis patient cardholder or a provisional patient cardholder may
2970	purchase, in accordance with this chapter and the recommendation underlying the card,

2971	cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a
2972	medical cannabis device.
2973	(ii) A cardholder under this section may possess or transport, in accordance with this
2974	chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a
2975	cannabis product in a medicinal dosage form, or a medical cannabis device.
2976	(iii) To address the qualifying condition underlying the medical cannabis treatment
2977	recommendation:
2978	(A) a medical cannabis patient cardholder or a provisional patient cardholder may use
2979	cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form,
2980	or a medical cannabis device; and
2981	(B) a medical cannabis guardian cardholder may assist the associated provisional
2982	patient cardholder with the use of cannabis in a medicinal dosage form, a medical cannabis
2983	product in a medicinal dosage form, or a medical cannabis device.
2984	(8) The department may revoke a medical cannabis card that the department issues
2985	under this section if the cardholder:
2986	(a) violates this chapter; or
2987	(b) is convicted under state or federal law of, after March 17, 2021, a drug distribution
2988	offense.
2989	(9) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
2990	Utah Administrative Rulemaking Act, a process to provide information regarding the following
2991	to an individual receiving a medical cannabis card:
2992	(a) risks associated with medical cannabis treatment;
2993	(b) the fact that a condition's listing as a qualifying condition does not suggest that
2994	medical cannabis treatment is an effective treatment or cure for that condition, as described in
2995	Subsection 26-61a-104(1); and
2996	(c) other relevant warnings and safety information that the department determines.
2997	(10) The department may establish procedures by rule, in accordance with Title 63G,
2998	Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance
2999	provisions of this section.
3000	(11) (a) On or before September 1, 2021, the department shall establish by rule, in
3001	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to allow

3rd Sub. (Cherry) H.B. 72

3002 an individual from another state to register with the department in order to purchase medical 3003 cannabis or a medical cannabis device from a medical cannabis pharmacy while the individual 3004 is visiting the state. 3005 (b) The department may only provide the registration process described in Subsection 3006 (11)(a): 3007 (i) to a nonresident patient; and 3008 (ii) for no more than two visitation periods per calendar year of up to 21 calendar days 3009 per visitation period. 3010 (12) (a) A person may submit to the department a request to conduct a research study 3011 using medical cannabis cardholder data that the state electronic verification system contains. 3012 (b) The department shall review a request described in Subsection (12)(a) to determine 3013 whether an institutional review board, as that term is defined in Section 26-61-102, could 3014 approve the research study. 3015 (c) At the time an individual applies for a medical cannabis card, the department shall 3016 notify the individual: 3017 (i) of how the individual's information will be used as a cardholder; 3018 (ii) that by applying for a medical cannabis card, unless the individual withdraws 3019 consent under Subsection (12)(d), the individual consents to the use of the individual's 3020 information for external research; and 3021 (iii) that the individual may withdraw consent for the use of the individual's 3022 information for external research at any time, including at the time of application. 3023 (d) An applicant may, through the medical cannabis card application, and a medical 3024 cannabis cardholder may, through the state central patient portal, withdraw the applicant's or 3025 cardholder's consent to participate in external research at any time. 3026 (e) The department may release, for the purposes of a study described in this Subsection (12), information about a cardholder under this section who consents to participate 3027 3028 under Subsection (12)(c). 3029 (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of 3030 consent: 3031 (i) applies to external research that is initiated after the withdrawal of consent; and 3032 (ii) does not apply to research that was initiated before the withdrawal of consent.

3033	(g) The department may establish standards for a medical research study's validity, by
3034	rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
3035	(13) The department shall record the issuance or revocation of a medical cannabis card
3036	under this section in the controlled substance database.
3037	Section 37. Section 26-61a-206 is enacted to read:
3038	<u>26-61a-206.</u> Purchasing and use limitations.
3039	An individual with a medical cannabis card:
3040	(1) may purchase, in any one 28-day period, up to the legal dosage limit of:
3041	(a) unprocessed cannabis in a medicinal dosage form; and
3042	(b) a cannabis product in a medicinal dosage form;
3043	(2) may not purchase:
3044	(a) more medical cannabis than described in Subsection (1)(a); or
3045	(b) if the relevant recommending medical provider did not recommend directions of
3046	use and dosing guidelines, until the individual consults with the pharmacy medical provider in
3047	accordance with Subsection 26-61a-404(5), any medical cannabis; and
3048	(3) may not use a route of administration that the relevant recommending medical
3049	provider or the pharmacy medical provider, in accordance with Subsection 26-61a-404(5), has
3050	not recommended.
3051	Section 38. Section 26-61a-403 is amended to read:
3052	Part 4. Pharmacy Medical Providers
3053	26-61a-403. Pharmacy medical providers Registration Continuing education.
3054	(1) (a) A medical cannabis pharmacy:
3055	(i) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy
3056	Practice Act, as a pharmacy medical provider;
3057	(ii) may employ a physician who has the authority to write a prescription and is
3058	licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah
3059	Osteopathic Medical Practice Act, as a pharmacy medical provider;
3060	(iii) shall ensure that a pharmacy medical provider described in Subsection (1)(a)(i)
3061	works onsite during all business hours; and
3062	(iv) shall designate one pharmacy medical provider described in Subsection (1)(a)(i) as
3063	the pharmacist-in-charge to oversee the operation of and generally supervise the medical

02-10-23 4:58 PM

3064 cannabis pharmacy. 3065 (b) An individual may not serve as a pharmacy medical provider unless the department registers the individual as a pharmacy medical provider in accordance with Subsection (2). 3066 3067 (2) (a) The department shall, within 15 days after the day on which the department 3068 receives an application from a medical cannabis pharmacy on behalf of a prospective pharmacy 3069 medical provider, register and issue a pharmacy medical provider registration card to the 3070 prospective pharmacy medical provider if the medical cannabis pharmacy: 3071 (i) provides to the department: (A) the prospective pharmacy medical provider's name and address; 3072 3073 (B) the name and location of the licensed medical cannabis pharmacy where the 3074 prospective pharmacy medical provider seeks to act as a pharmacy medical provider; 3075 (C) a report detailing the completion of the continuing education requirement described 3076 in Subsection (3); and 3077 (D) evidence that the prospective pharmacy medical provider is a pharmacist who is 3078 licensed under Title 58, Chapter 17b, Pharmacy Practice Act, or a physician who has the 3079 authority to write a prescription and is licensed under Title 58, Chapter 67, Utah Medical 3080 Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and 3081 (ii) pays a fee to the department in an amount that, subject to Subsection 3082 26-61a-109(5), the department sets in accordance with Section 63J-1-504. 3083 (b) The department may not register a recommending medical provider or a state 3084 central patient portal medical provider as a pharmacy medical provider. 3085 (3) (a) A pharmacy medical provider shall complete the continuing education described 3086 in this Subsection (3) in the following amounts: 3087 (i) as a condition precedent to registration, four hours; and 3088 (ii) as a condition precedent to renewal of the registration, four hours every two years. 3089 (b) In accordance with Subsection (3)(a), the pharmacy medical provider shall: 3090 (i) complete continuing education: 3091 (A) regarding the topics described in Subsection (3)(d); and 3092 (B) offered by the department under Subsection (3)(c) or an accredited or approved 3093 continuing education provider that the department recognizes as offering continuing education 3094 appropriate for the medical cannabis pharmacy practice; and

3095	(ii) make a continuing education report to the department in accordance with a process
3096	that the department establishes by rule, in accordance with Title 63G, Chapter 3, Utah
3097	Administrative Rulemaking Act, and in collaboration with the Division of Professional
3098	Licensing and:
3099	(A) for a pharmacy medical provider who is licensed under Title 58, Chapter 17b,
3100	Pharmacy Practice Act, the Board of Pharmacy;
3101	(B) for a pharmacy medical provider licensed under Title 58, Chapter 67, Utah Medical
3102	Practice Act, the Physicians Licensing Board; and
3103	(C) for a pharmacy medical provider licensed under Title 58, Chapter 68, Utah
3104	Osteopathic Medical Practice Act, the Osteopathic Physician and Surgeon's Licensing Board.
3105	(c) The department may, in consultation with the Division of Professional Licensing,
3106	develop the continuing education described in this Subsection (3).
3107	(d) The continuing education described in this Subsection (3) may discuss:
3108	(i) the provisions of this chapter;
3109	(ii) general information about medical cannabis under federal and state law;
3110	(iii) the latest scientific research on the endocannabinoid system and medical cannabis,
3111	including risks and benefits;
3112	(iv) recommendations for medical cannabis as it relates to the continuing care of a
3113	patient in pain management, risk management, potential addiction, and palliative care; or
3114	(v) best practices for recommending the form and dosage of a medical cannabis
3115	product based on the qualifying condition underlying a medical cannabis recommendation.
3116	(4) (a) A pharmacy medical provider registration card expires two years after the day
3117	on which the department issues or renews the card.
3118	(b) A pharmacy medical provider may renew the provider's registration card if the
3119	provider:
3120	(i) is eligible for a pharmacy medical provider registration card under this section;
3121	(ii) certifies to the department in a renewal application that the information in
3122	Subsection (2)(a) is accurate or updates the information;
3123	(iii) submits a report detailing the completion of the continuing education requirement
3124	described in Subsection (3); and
3125	(iv) pays to the department a renewal fee in an amount that:

3126	(A) subject to Subsection $26-61a-109(5)$, the department sets in accordance with
3127	Section 63J-1-504; and
3128	(B) may not exceed the cost of the relatively lower administrative burden of renewal in
3129	comparison to the original application process.
3130	(5) (a) Except as provided in Subsection (5)(b), a person may not advertise that the
3131	person or another person dispenses medical cannabis.
3132	(b) Notwithstanding Subsection (5)(a) and [subject to] Section [26-61a-116]
3133	4-41a-109, a registered pharmacy medical provider may advertise the following:
3134	(i) a green cross;
3135	(ii) that the person is registered as a pharmacy medical provider and dispenses medical
3136	cannabis; or
3137	(iii) a scientific study regarding medical cannabis use.
3138	(6) (a) The department may revoke a pharmacy medical provider's registration for a
3139	violation of this chapter.
3140	(b) The department may inspect patient records held by a medical cannabis pharmacy
3141	to ensure a pharmacy medical provider is practicing in accordance with this chapter and
3142	applicable rules.
3143	Section 39. Section 26-61a-404, which is renumbered from Section 26-61a-503 is
3144	renumbered and amended to read:
3145	[26-61a-503]. <u>26-61a-404.</u> Partial filling Pharmacy medical provider
3146	directions of use.
3147	(1) As used in this section, "partially fill" means to provide less than the full amount of
3148	cannabis or cannabis product that the recommending medical provider recommends, if the
3149	recommending medical provider recommended specific dosing parameters.
3150	(2) A pharmacy medical provider may partially fill a recommendation for a medical
3151	cannabis treatment at the request of the recommending medical provider who issued the
3152	medical cannabis treatment recommendation or the medical cannabis cardholder.
3153	(3) The department shall make rules, in collaboration with the Division of Professional
3154	Licensing and the Board of Pharmacy and in accordance with Title 63G, Chapter 3, Utah
3155	Administrative Rulemaking Act, specifying how to record the date, quantity supplied, and
3156	quantity remaining of a partially filled medical cannabis treatment recommendation.

3157	(4) A pharmacy medical provider who is a pharmacist may, upon the request of a
3158	medical cannabis cardholder, determine different dosing parameters, subject to the dosing
3159	limits in Subsection [26-61a-502(2)] 4-41a-1102(2), to fill the quantity remaining of a partially
3160	filled medical cannabis treatment recommendation if:
3161	(a) the pharmacy medical provider determined dosing parameters for the partial fill
3162	under Subsection $\left[\frac{26-61a-502(4) \text{ or } (5)}{4-41a-1102(5) \text{ or } (6)}\right]$; and
3163	(b) the medical cannabis cardholder reports that:
3164	(i) the partial fill did not substantially affect the qualifying condition underlying the
3165	medical cannabis recommendation; or
3166	(ii) the patient experienced an adverse reaction to the partial fill or was otherwise
3167	unable to successfully use the partial fill.
3168	(5) If a recommending medical provider recommends treatment with medical cannabis
3169	but wishes for the pharmacy medical provider to determine directions of use and dosing
3170	guidelines:
3171	(a) the recommending medical provider shall provide to the pharmacy medical
3172	provider, either through the state electronic verification system or through a medical cannabis
3173	pharmacy's recording of a recommendation under the order of a limited medical provider, any
3174	of the following information that the recommending medical provider feels would be needed to
3175	provide appropriate directions of use and dosing guidelines:
3176	(i) information regarding the qualifying condition underlying the recommendation;
3177	(ii) information regarding prior treatment attempts with medical cannabis; and
3178	(iii) portions of the patient's current medication list; and
3179	(b) before the relevant medical cannabis cardholder may obtain medical cannabis, the
3180	pharmacy medical provider shall:
3181	(i) review pertinent medical records, including the recommending medical provider
3182	documentation described in Subsection (5)(a); and
3183	(ii) unless the pertinent medical records show directions of use and dosing guidelines
3184	from a state central patient portal medical provider in accordance with Subsection (6), after
3185	completing the review described in Subsection (5)(b)(i) and consulting with the recommending
3186	medical provider as needed, determine the best course of treatment through consultation with
3187	the cardholder regarding:

3188	(A) the patient's qualifying condition underlying the recommendation from the
3189	recommending medical provider;
3190	(B) indications for available treatments;
3191	(C) directions of use and dosing guidelines; and
3192	(D) potential adverse reactions.
3193	Section 40. Section 26-61a-601 is amended to read:
3194	26-61a-601. State central patient portal Department duties.
3195	(1) [On or before July 1, 2020, the] The department shall establish or contract to
3196	establish, in accordance with Title 63G, Chapter 6a, Utah Procurement Code, a state central
3197	patient portal as described in this section.
3198	(2) The state central patient portal shall:
3199	(a) authenticate each user to ensure the user is a valid medical cannabis patient
3200	cardholder;
3201	(b) allow a medical cannabis patient cardholder to:
3202	(i) obtain and download the cardholder's medical cannabis card;
3203	(ii) review the cardholder's medical cannabis purchase history; and
3204	(iii) manage the cardholder's personal information, including withdrawing consent for
3205	the use of the cardholder's information for a study described in Subsection 26-61a-201(12);
3206	(c) if the cardholder's recommending medical provider recommended the use of
3207	medical cannabis without providing directions of use and dosing guidelines and the cardholder
3208	has not yet received the counseling or consultation required in Subsection 26-61a-502(4):
3209	(i) alert the cardholder of the outstanding need for consultation; and
3210	(ii) provide the cardholder with access to the contact information for each state central
3211	patient portal medical provider and each pharmacy medical provider;
3212	(d) except as provided in Subsection (2)(e), facilitate an electronic medical cannabis
3213	order:
3214	(i) to a home delivery medical cannabis pharmacy for a medical cannabis shipment; or
3215	(ii) to a medical cannabis pharmacy for a medical cannabis cardholder to obtain in
3216	person from the pharmacy;
3217	(e) prohibit a patient from completing an electronic medical cannabis order described
3218	in Subsection (2)(d) if the purchase would exceed the limitations described in Subsection

3219	[26-61a-502(2)(a) or (b)] <u>4-41a-1102(2)(a) or (b);</u>
3220	(f) provide educational information to medical cannabis patient cardholders regarding
3221	the state's medical cannabis laws and regulatory programs and other relevant information
3222	regarding medical cannabis; and
3223	(g) allow the patient to designate up to two caregivers who may receive a medical
3224	cannabis caregiver card to purchase and transport medical cannabis on behalf of the patient in
3225	accordance with this chapter.
3226	(3) The department may make rules in accordance with Title 63G, Chapter 3, Utah
3227	Administrative Rulemaking Act, to implement the state central patient portal.
3228	Section 41. Section 26-61a-701 is amended to read:
3229	26-61a-701. Enforcement Misdemeanor.
3230	(1) Except as provided in Title 4, Chapter 41a, Cannabis Production Establishments[,
3231	and Sections 26-61a-502, 26-61a-605, and 26-61a-607] and Pharmacies, it is unlawful for a
3232	medical cannabis cardholder to sell or otherwise give to another medical cannabis cardholder
3233	cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, a medical
3234	cannabis device, or any cannabis residue remaining in or from a medical cannabis device.
3235	(2) (a) Except as provided in Subsection (2)(b), a medical cannabis cardholder who
3236	violates Subsection (1) is:
3237	(i) guilty of a class B misdemeanor; and
3238	(ii) subject to a \$1,000 fine.
3239	(b) An individual is not guilty under Subsection (2)(a) if the individual:
3240	(i) (A) is a designated caregiver; and
3241	(B) gives the product described in Subsection (1) to the medical cannabis cardholder
3242	who designated the individual as a designated caregiver; or
3243	(ii) (A) is a medical cannabis guardian cardholder; and
3244	(B) gives the product described in Subsection (1) to the relevant provisional patient
3245	cardholder.
3246	(c) An individual who is guilty of a violation described in Subsection (2)(a) is not
3247	guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct
3248	underlying the violation described in Subsection (2)(a).
3249	Section 42. Section 26-61a-703 is amended to read:

3250	26-61a-703. Report.
3251	(1) By the November interim meeting each year beginning in 2020, the department
3252	shall report to the Health and Human Services Interim Committee on:
3253	(a) the number of applications and renewal applications filed for medical cannabis
3254	cards;
3255	(b) the number of qualifying patients and designated caregivers;
3256	(c) the nature of the debilitating medical conditions of the qualifying patients;
3257	(d) the age and county of residence of cardholders;
3258	(e) the number of medical cannabis cards revoked;
3259	(f) the number of practitioners providing recommendations for qualifying patients;
3260	(g) the number of license applications and renewal license applications received;
3261	(h) the number of licenses the department has issued in each county;
3262	(i) the number of licenses the department has revoked;
3263	(j) the quantity of medical cannabis shipments that the state central patient portal
3264	facilitates;
3265	(k) the number of overall purchases of medical cannabis and medical cannabis products
3266	from each medical cannabis pharmacy;
3267	(1) the expenses incurred and revenues generated from the medical cannabis program;
3268	and
3269	(m) an analysis of product availability in medical cannabis pharmacies in consultation
3270	with the Department of Agriculture and Food.
3271	(2) The department may not include personally identifying information in the report
3272	described in this section.
3273	(3) [During the 2022 legislative interim, the] The department shall report to the
3274	working group described in Section 36-12-8.2 as requested by the working group.
3275	Section 43. Section 26-61a-801 is enacted to read:
3276	Part 8. Medical Cannabis Policy Advisory Board
3277	<u>26-61a-801.</u> Advisory board creation Membership.
3278	(1) There is created within the department the Medical Cannabis Policy Advisory
3279	Board.
3280	(2) (a) The advisory board shall consist of the following members:

3281	(i) appointed by the executive director:
3282	(A) a qualified medical provider who has at least 100 patients who have a medical
3283	cannabis patient card at the time of appointment;
3284	(B) a medical research professional;
3285	(C) a mental health specialist;
3286	(D) an individual who represents an organization that advocates for medical cannabis
3287	patients;
3288	(E) an individual who holds a medical cannabis patient card; and
3289	(F) a member of the general public who does not hold a medical cannabis card; and
3290	(ii) appointed by the commissioner of the Department of Agriculture and Food:
3291	(A) an individual who owns or operates a licensed cannabis cultivation facility;
3292	(B) an individual who owns or operates a licensed medical cannabis pharmacy; and
3293	(C) a law enforcement officer.
3294	(b) The commissioner of the Department of Agriculture and Food shall ensure that at
3295	least one individual appointed under Subsection (2)(a)(ii)(A) or (B) also owns or operates a
3296	licensed cannabis processing facility.
3297	(3) (a) Subject to Subsection (3)(b), a member of the advisory board shall serve for a
3298	four year term.
3299	(b) When appointing the initial membership of the advisory board, the executive
3300	director and the commissioner of the Department of Agriculture and Food shall coordinate to
3301	appoint four advisory board members to serve a term of two years to ensure that approximately
3302	half of the board is appointed every two years.
3303	(4) (a) If an advisory board member is no longer able to serve as a member, a new
3304	member shall be appointed in the same manner as the original appointment.
3305	(b) A member appointed in accordance with Subsection (4)(a) shall serve for the
3306	remainder of the unexpired term of the original appointment.
3307	(5) (a) A majority of the advisory board members constitutes a quorum.
3308	(b) The action of a majority of a quorum constitutes an action of the advisory board.
3309	(c) The advisory board shall annually designate one of the advisory board's members to
3310	serve as chair for a one-year period.
3311	(6) An advisory board member may not receive compensation or benefits for the

3312	member's service on the advisory board but may receive per diem and reimbursement for travel
3313	expenses incurred as an advisory board member in accordance with:
3314	(a) Sections 63A-3-106 and 63A-3-107; and
3315	(b) rules made by the Division of Finance pursuant to Sections 63A-3-106 and
3316	<u>63A-3-107.</u>
3317	(7) The department shall:
3318	(a) provide staff support for the advisory board; and
3319	(b) assist the advisory board in conducting meetings.
3320	Section 44. Section 26-61a-802 is enacted to read:
3321	<u>26-61a-802.</u> Advisory board duties.
3322	(1) The advisory board may recommend:
3323	(a) to the department or the Department of Agriculture and Food changes to current or
3324	proposed medical cannabis rules or statutes;
3325	(b) to the appropriate legislative committee whether the advisory board supports a
3326	change to medical cannabis statutes.
3327	(2) The advisory board shall:
3328	(a) review any draft rule that is authorized under this chapter or Title 4, Chapter 41a,
3329	Cannabis Production Establishments and Pharmacies;
3330	(b) consult with the Department of Agriculture and Food regarding the issuance of an
3331	additional:
3332	(i) cultivation facility license under Section 4-41a-205; or
3333	(ii) pharmacy license under Section 4-41a-1005;
3334	(c) consult with the department regarding cannabis patient education;
3335	(d) consult regarding the reasonableness of any fees set by the department or the Utah
3336	Department of Agriculture and Food that pertain to the medical cannabis program; and
3337	(e) consult regarding any issue pertaining to medical cannabis when asked by the
3338	department or the Utah Department of Agriculture and Food.
3339	Section 45. Section 26-61a-803 is enacted to read:
3340	<u>26-61a-803.</u> Department coordination.
3341	The department shall:
3342	(1) provide draft rules made under this chapter to the advisory board for the advisory

3343	board's review;
3344	(2) consult with the advisory board regarding:
3345	(a) patient education; and
3346	(b) fees set by the department that pertain to the medical cannabis program; and
3347	(3) when appropriate, consult with the advisory board regarding issues that arise in the
3348	medical cannabis program.
3349	Section 46. Section 36-12-8.2 is amended to read:
3350	36-12-8.2. Medical cannabis governance structure working group.
3351	[During the 2022 legislative interim, the]
3352	(1) The Legislative Management Committee shall establish a medical cannabis
3353	governance structure working group composed of [three members of the Health and Human
3354	Services Interim Committee and three members of the Natural Resources, Agriculture, and
3355	Environment Interim Committee to:] six members of the Legislature.
3356	(2) The working group may:
3357	[(1)] (a) work with industry, patients, medical providers, and others [to conduct a] to
3358	review [of] the state's governance structure over medical cannabis;
3359	[(2)] (b) study various regulatory structures throughout the nation regarding state
3360	agency regulation of medical cannabis; and
3361	(c) make recommendations to the Health and Human Services Interim Committee or
3362	the Natural Resources, Agriculture, and Environment Interim Committee regarding medical
3363	cannabis governance before or at the October interim meeting.
3364	[(3) at or before the October 2022 interim meeting, make recommendations to the
3365	Health and Human Services Interim Committee and the Natural Resources, Agriculture, and
3366	Environment Interim Committee on whether a committee should recommend committee
3367	legislation to vertically integrate licenses, streamline regulations, and reduce costs for patients
3368	by unifying the efforts of the Department of Health and Human Services and the Department of
3369	Agriculture and Food under a single state authority over medical cannabis.]
3370	Section 47. Section 58-17b-302 is amended to read:
3371	58-17b-302. License required License classifications for pharmacy facilities.
3372	(1) A license is required to act as a pharmacy, except:
3373	(a) as specifically exempted from licensure under Section 58-1-307;

3374	(b) for the operation of a medical cannabis pharmacy under [Title 26, Chapter 61a,
3375	Utah Medical Cannabis Act] Title 4, Chapter 41a, Cannabis Production Establishments and
3376	Pharmacies; and
3377	(c) to operate a licensed dispensing practice under Chapter 88, Part 2, Dispensing
3378	Practice.
3379	(2) The division shall issue a pharmacy license to a facility that qualifies under this
3380	chapter in the classification of a:
3381	(a) class A pharmacy;
3382	(b) class B pharmacy;
3383	(c) class C pharmacy;
3384	(d) class D pharmacy;
3385	(e) class E pharmacy; or
3386	(f) dispensing medical practitioner clinic pharmacy.
3387	(3) (a) Each place of business shall require a separate license.
3388	(b) If multiple pharmacies exist at the same address, a separate license shall be required
3389	for each pharmacy.
3390	(4) (a) The division may further define or supplement the classifications of pharmacies.
3391	(b) The division may impose restrictions upon classifications to protect the public
3392	health, safety, and welfare.
3393	(5) Each pharmacy shall have a pharmacist-in-charge, except as otherwise provided by
3394	rule.
3395	(6) Whenever an applicable statute or rule requires or prohibits action by a pharmacy,
3396	the pharmacist-in-charge and the owner of the pharmacy shall be responsible for all activities
3397	of the pharmacy, regardless of the form of the business organization.
3398	Section 48. Section 58-17b-502 is amended to read:
3399	58-17b-502. Unprofessional conduct.
3400	(1) "Unprofessional conduct" includes:
3401	(a) willfully deceiving or attempting to deceive the division, the board, or their agents
3402	as to any relevant matter regarding compliance under this chapter;
3403	(b) except as provided in Subsection (2):
3404	(i) paying or offering rebates to practitioners or any other health care providers, or

3405	receiving or soliciting rebates from practitioners or any other health care provider; or
3406	(ii) paying, offering, receiving, or soliciting compensation in the form of a commission,
3407	bonus, rebate, kickback, or split fee arrangement with practitioners or any other health care
3408	provider, for the purpose of obtaining referrals;
3409	(c) misbranding or adulteration of any drug or device or the sale, distribution, or
3410	dispensing of any outdated, misbranded, or adulterated drug or device;
3411	(d) engaging in the sale or purchase of drugs or devices that are samples or packages
3412	bearing the inscription "sample" or "not for resale" or similar words or phrases;
3413	(e) except as provided in Section 58-17b-503, accepting back and redistributing any
3414	unused drug, or a part of it, after it has left the premises of a pharmacy;
3415	(f) an act in violation of this chapter committed by a person for any form of
3416	compensation if the act is incidental to the person's professional activities, including the
3417	activities of a pharmacist, pharmacy intern, or pharmacy technician;
3418	(g) violating:
3419	(i) the federal Controlled Substances Act, Title II, P.L. 91-513;
3420	(ii) Title 58, Chapter 37, Utah Controlled Substances Act; or
3421	(iii) rules or regulations adopted under either act;
3422	(h) requiring or permitting pharmacy interns or technicians to engage in activities
3423	outside the scope of practice for their respective license classifications, as defined in this
3424	chapter and division rules made in collaboration with the board, or beyond their scope of
3425	training and ability;
3426	(i) administering:
3427	(i) without appropriate training, as defined by rule;
3428	(ii) without a physician's order, when one is required by law; and
3429	(iii) in conflict with a practitioner's written guidelines or written protocol for
3430	administering;
3431	(j) disclosing confidential patient information in violation of the provisions of the
3432	Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat.
3433	1936, as amended, or other applicable law;
3434	(k) engaging in the practice of pharmacy without a licensed pharmacist designated as
3435	the pharmacist-in-charge;

3436	(1) failing to report to the division any adverse action taken by another licensing
3437	jurisdiction, government agency, law enforcement agency, or court for conduct that in
3438	substance would be considered unprofessional conduct under this section;
3439	(m) as a pharmacist or pharmacy intern, compounding a prescription drug in a dosage
3440	form which is regularly and commonly available from a manufacturer in quantities and
3441	strengths prescribed by a practitioner;
3442	(n) failing to act in accordance with Title 26, Chapter 64, Family Planning Access Act,
3443	when dispensing a self-administered hormonal contraceptive under a standing order;
3444	(o) violating the requirements of <u>Title 4, Chapter 41a, Cannabis Production</u>
3445	Establishments and Pharmacies, or Title 26, Chapter 61a, Utah Medical Cannabis Act; or
3446	(p) falsely making an entry in, or altering, a medical record with the intent to conceal:
3447	(i) a wrongful or negligent act or omission of an individual licensed under this chapter
3448	or an individual under the direction or control of an individual licensed under this chapter; or
3449	(ii) conduct described in Subsections (1)(a) through (o) or Subsection 58-1-501(1).
3450	(2) Subsection (1)(b) does not apply to:
3451	(a) giving or receiving a price discount based on purchase volume;
3452	(b) passing along a pharmaceutical manufacturer's rebate; or
3453	(c) providing compensation for services to a veterinarian.
3454	(3) "Unprofessional conduct" does not include, in accordance with Title 26, Chapter
3455	61a, Utah Medical Cannabis Act:
3456	(a) when registered as a pharmacy medical provider, as that term is defined in Section
3457	26-61a-102, providing pharmacy medical provider services in a medical cannabis pharmacy; or
3458	(b) when acting as a state central patient portal medical provider, as that term is defined
3459	in Section 26-61a-102, providing state central patient portal medical provider services.
3460	(4) Notwithstanding Subsection (3), the division, in consultation with the board and in
3461	accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, shall define
3462	unprofessional conduct for a pharmacist described in Subsections (3)(a) and (b).
3463	Section 49. Section 58-37-3.8 is amended to read:
3464	58-37-3.8. Enforcement.
3465	(1) A law enforcement officer, as that term is defined in Section $53-13-103$, except for
3466	an officially designated drug enforcement task force regarding conduct that is not in accordance

3467	with Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies, or Title 26,
3468	Chapter 61a, Utah Medical Cannabis Act, may not expend any state or local resources,
3469	including the officer's time, to:
3470	(a) effect any arrest or seizure of cannabis, as that term is defined in Section
3471	26-61a-102, or conduct any investigation, on the sole basis of activity the officer believes to
3472	constitute a violation of federal law if the officer has reason to believe that the activity is in
3473	compliance with the state medical cannabis laws;
3474	(b) enforce a law that restricts an individual's right to acquire, own, or possess a
3475	firearm based solely on the individual's possession or use of cannabis in accordance with state
3476	medical cannabis laws; or
3477	(c) provide any information or logistical support related to an activity described in
3478	Subsection (1)(a) to any federal law enforcement authority or prosecuting entity.
3479	(2) An agency or political subdivision of the state may not take an adverse action
3480	against a person for providing a professional service to a medical cannabis pharmacy, as that
3481	term is defined in Section 26-61a-102, the state central patient portal, as that term is defined in
3482	Section 26-61a-102, or a cannabis production establishment, as that term is defined in Section
3483	4-41a-102, on the sole basis that the service is a violation of federal law.
3484	Section 50. Section 63I-2-204 is amended to read:
3485	63I-2-204. Repeal dates: Title 4.
3486	(1) Title 4, Chapter 2, Part 6, Local Food Advisory Council, is repealed November 30,
3487	2027.
3488	(2) Section 4-41a-102.1 is repealed January 1, 2024.
3489	[(2)] <u>(3)</u> Section 4-46-104, Transition, is repealed July 1, 2024.
3490	Section 51. Section 63I-2-236 is amended to read:
3491	63I-2-236. Repeal dates: Title 36.
3492	(1) Section 36-12-8.2 is repealed July 1, [2023] <u>2024</u> .
3493	(2) Section 36-29-107.5 is repealed on November 30, 2023.
3494	(3) Section 36-29-109 is repealed on November 30, 2027.
3495	(4) Section 36-29-110 is repealed on November 30, 2024.
3496	(5) Section 36-29-111 is repealed April 30, 2023.
3497	(6) The following sections regarding the State Flag Task Force are repealed on January

3498	1, 2024:
3499	(a) Section 36-29-201;
3500	(b) Section 36-29-202; and
3501	(c) Section 36-29-203.
3502	(7) Title 36, Chapter 29, Part 3, Mental Illness Psychotherapy Drug Task Force, is
3503	repealed December 31, 2023.
3504	Section 52. Section 78A-2-231 is amended to read:
3505	78A-2-231. Consideration of lawful use or possession of medical cannabis.
3506	(1) As used in this section:
3507	(a) "Cannabis product" means the same as that term is defined in Section 26-61a-102.
3508	(b) "Directions of use" means the same as that term is defined in Section 26-61a-102.
3509	(c) "Dosing guidelines" means the same as that term is defined in Section 26-61a-102.
3510	(d) "Medical cannabis" means the same as that term is defined in Section 26-61a-102.
3511	(e) "Medical cannabis card" means the same as that term is defined in Section
3512	26-61a-102.
3513	(f) "Medical cannabis device" means the same as that term is defined in Section
3514	26-61a-102.
3515	(g) "Recommending medical provider" means the same as that term is defined in
3516	Section 26-61a-102.
3517	(2) In any judicial proceeding in which a judge, panel, jury, or court commissioner
3518	makes a finding, determination, or otherwise considers an individual's medical cannabis card,
3519	medical cannabis recommendation from a recommending medical provider, or possession or
3520	use of medical cannabis, a cannabis product, or a medical cannabis device, the judge, panel,
3521	jury, or court commissioner may not consider or treat the individual's card, recommendation,
3522	possession, or use any differently than the lawful possession or use of any prescribed controlled
3523	substance if:
3524	(a) the individual's possession complies with Title 4, Chapter 41a, Cannabis Production
3525	Establishments and Pharmacies;
3526	(b) the individual's possession or use complies with Subsection 58-37-3.7(2) or (3); or
3527	(c) (i) the individual's possession or use complies with Title 26, Chapter 61a, Utah
3528	Medical Cannabis Act; and

(ii) the individual reasonably complies with the directions of use and dosing guidelines
determined by the individual's recommending medical provider or through a consultation
described in Subsection [26-61a-502(4) or (5)] <u>26-61a-404(5)</u> .
(3) Notwithstanding Sections 77-18-105 and 77-2a-3, for probation, release, a plea in
abeyance agreement, a diversion agreement, or a tendered admission under Utah Rules of
Juvenile Procedure, Rule 25, a term or condition may not require that an individual abstain
from the use or possession of medical cannabis, a cannabis product, or a medical cannabis
device, either directly or through a general prohibition on violating federal law, without an
exception related to medical cannabis use, if the individual's use or possession complies with:
(a) Title 26, Chapter 61a, Utah Medical Cannabis Act; or
(b) Subsection 58-37-3.7(2) or (3).
Section 53. Section 80-3-110 is amended to read:
80-3-110. Consideration of cannabis during proceedings Drug testing.
(1) As used in this section:
(a) "Cannabis" means the same as that term is defined in Section 26-61a-102.
(b) "Cannabis product" means the same as that term is defined in Section 26-61a-102.
(c) (i) "Chronic" means repeated or patterned.
(ii) "Chronic" does not mean an isolated incident.
(d) "Directions of use" means the same as that term is defined in Section 26-61a-102.
(e) "Dosing guidelines" means the same as that term is defined in Section 26-61a-102.
(f) "Medical cannabis" means the same as that term is defined in Section 26-61a-102.
(g) "Medical cannabis cardholder" means the same as that term is defined in Section
26-61a-102.
(h) "Recommending medical provider" means the same as that term is defined in
Section 26-61a-102.
(2) In a proceeding under this chapter, in which the juvenile court makes a finding,
determination, or otherwise considers an individual's medical cannabis card, medical cannabis
recommendation from a recommending medical provider, or possession or use of medical
cannabis, a cannabis product, or a medical cannabis device, the juvenile court may not consider
or treat the individual's medical cannabis card, recommendation, possession, or use any
differently than the lawful possession or use of any prescribed controlled substance if:

3560	(a) the individual's possession or use complies with Title 4, Chapter 41a, Cannabis
3561	Production Establishments and Pharmacies;
3562	(b) the individual's possession or use complies with Subsection 58-37-3.7(2) or (3); or
3563	(c) (i) the individual's possession or use complies with Title 26, Chapter 61a, Utah
3564	Medical Cannabis Act; and
3565	(ii) the individual reasonably complies with the directions of use and dosing guidelines
3566	determined by the individual's recommending medical provider or through a consultation
3567	described in Subsection [26-61a-502(4) or (5).] <u>26-61a-404(5).</u>
3568	(3) In a proceeding under this chapter, a child's parent's or guardian's use of cannabis or
3569	a cannabis product is not abuse or neglect of the child unless there is evidence showing that:
3570	(a) the child is harmed because of the child's inhalation or ingestion of cannabis, or
3571	because of cannabis being introduced to the child's body in another manner; or
3572	(b) the child is at an unreasonable risk of harm because of chronic inhalation or
3573	ingestion of cannabis or chronic introduction of cannabis to the child's body in another manner.
3574	(4) Unless there is harm or an unreasonable risk of harm to the child as described in
3575	Subsection (3), in a child welfare proceeding under this chapter, a child's parent's or guardian's
3576	use of medical cannabis or a cannabis product is not contrary to the best interests of the child
3577	if:
3578	(a) for a medical cannabis cardholder after January 1, 2021, the parent's or guardian's
3579	possession or use complies with Title 26, Chapter 61a, Utah Medical Cannabis Act, and there
3580	is no evidence that the parent's or guardian's use of medical cannabis unreasonably deviates
3581	from the directions of use and dosing guidelines determined by the parent's or guardian's
3582	recommending medical provider or through a consultation described in Subsection
3583	$\left[\frac{26-61a-502(4) \text{ or } (5)}{26-61a-404(5)}\right]$; or
3584	(b) before January 1, 2021, the parent's or guardian's possession or use complies with
3585	Subsection 58-37-3.7(2) or (3).
3586	(5) Subsection (3) does not prohibit a finding of abuse or neglect of a child, and
3587	Subsection (3) does not prohibit a finding that a parent's or guardian's use of medical cannabis
3588	or a cannabis product is contrary to the best interests of a child, if there is evidence showing a
3589	nexus between the parent's or guardian's use of cannabis or a cannabis product and behavior

that would separately constitute abuse or neglect of the child.

3591	(6) If an individual, who is party to a proceeding under this chapter, is ordered by the
3592	juvenile court to submit to drug testing, or is referred by the division or a guardian ad litem for
3593	drug testing, the individual may not be ordered or referred for drug testing by means of a hair
3594	or fingernail test that is administered to detect the presence of drugs.
3595	Section 54. Section 80-4-109 is amended to read:
3596	80-4-109. Consideration of cannabis during proceedings.
3597	(1) As used in this section:
3598	(a) "Cannabis" means the same as that term is defined in Section 26-61a-102.
3599	(b) "Cannabis product" means the same as that term is defined in Section 26-61a-102.
3600	(c) (i) "Chronic" means repeated or patterned.
3601	(ii) "Chronic" does not mean an isolated incident.
3602	(d) "Directions of use" means the same as that term is defined in Section 26-61a-102.
3603	(e) "Dosing guidelines" means the same as that term is defined in Section 26-61a-102.
3604	(f) "Medical cannabis" means the same as that term is defined in Section 26-61a-102.
3605	(g) "Medical cannabis cardholder" means the same as that term is defined in Section
3606	26-61a-102.
3607	(h) "Qualified medical provider" means the same as that term is defined in Section
3608	26-61a-102.
3609	(2) In a proceeding under this chapter in which the juvenile court makes a finding,
3610	determination, or otherwise considers an individual's possession or use of medical cannabis, a
3611	cannabis product, or a medical cannabis device, the juvenile court may not consider or treat the
3612	individual's possession or use any differently than the lawful possession or use of any
3613	prescribed controlled substance if:
3614	(a) the individual's possession or use complies with Title 4, Chapter 41a, Cannabis
3615	Production Establishments and Pharmacies;
3616	(b) the individual's possession or use complies with Subsection $58-37-3.7(2)$ or (3); or
3617	(c) (i) the individual's possession or use complies with Title 26, Chapter 61a, Utah
3618	Medical Cannabis Act; and
3619	(ii) the individual reasonably complies with the directions of use and dosing guidelines
3620	determined by the individual's qualified medical provider or through a consultation described
3621	in Subsection [26-61a-502(4) or (5).] <u>26-61a-404(5).</u>

3622	(3) In a proceeding under this chapter, a parent's or guardian's use of cannabis or a
3623	cannabis product is not abuse or neglect of a child unless there is evidence showing that:
3624	(a) the child is harmed because of the child's inhalation or ingestion of cannabis, or
3625	because of cannabis being introduced to the child's body in another manner; or
3626	(b) the child is at an unreasonable risk of harm because of chronic inhalation or
3627	ingestion of cannabis or chronic introduction of cannabis to the child's body in another manner.
3628	(4) Unless there is harm or an unreasonable risk of harm to the child as described in
3629	Subsection (3), a parent's or guardian's use of medical cannabis or a cannabis product is not
3630	contrary to the best interests of a child if:
3631	(a) for a medical cannabis cardholder after January 1, 2021, the parent's or guardian's
3632	possession or use complies with Title 26, Chapter 61a, Utah Medical Cannabis Act, and there
3633	is no evidence that the parent's or guardian's use of medical cannabis unreasonably deviates
3634	from the directions of use and dosing guidelines determined by the parent's or guardian's
3635	qualified medical provider or through a consultation described in Subsection [26-61a-502(4) or
3636	(5)] <u>26-61a-404(5);</u> or
3637	(b) before January 1, 2021, the parent's or guardian's possession or use complies with
3638	Subsection 58-37-3.7(2) or (3).
3639	(5) Subsection (3) does not prohibit a finding of abuse or neglect of a child and
3640	Subsection (3) does not prohibit a finding that a parent's or guardian's use of medical cannabis
3641	or a cannabis product is contrary to the best interests of a child, if there is evidence showing a
3642	nexus between the parent's or guardian's use of cannabis or a cannabis product and behavior
3643	that would separately constitute abuse or neglect of the child.
3644	Section 55. Repealer.
3645	This bill repeals:
3646	Section 26-61a-108, Agreement with a tribe.
3647	Section 26-61a-506, Medical cannabis transportation.
3648	Section 56. Effective date.
3649	(1) Except as provided in Subsection (2), this bill takes effect on July 1, 2023.
3650	(2) The actions affecting the following sections take effect on May 3, 2023:
3651	(a) Section 4-41a-102;

3652 (b) Section <u>4-41a-110;</u>

- 3653 (c) Section <u>4-41a-802;</u>
- 3654 (d) Section 26-61-202;
- 3655 (e) Section <u>26-61a-102;</u>
- 3656 (f) Section <u>26-61a-105;</u>
- 3657 (g) Section <u>26-61a-801;</u>
- 3658 (h) Section <u>26-61a-802;</u>
- 3659 <u>(i) Section 26-61a-803;</u>
- 3660 (j) Section <u>36-12-8.2</u>; and
- 3661 <u>(k) Section 63I-2-236.</u>